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Summary 
 
Using an IBV reverse genetics system a series of recombinant viruses were 
generated to investigate the potential for utilizing IBV as a vaccine vector. Through 
the replacement of non-essential regions of the IBV genome, with eGFP or hRluc, 
factors influencing the stability of recombinant viruses expressing heterologous 
genes were determined. Expression of heterologous proteins was possible from a 
variety of virus constructs. The stability of recombinant viruses varied depending on 
the genome location of the heterologous gene, with replacement of Gene 5 proving 
to be most stable following passage in cell culture. Stability was strongly influenced 
by the MOI at which viruses were passaged, with low MOIs resulting in increased 
stability. The replacement of Gene 5 with a heterologous virus gene may be a 
suitable target for development of a bivalent vaccine capable of protecting against 
IBV and a second avian viral disease. 
 
Analysis of recombinant IBV mRNA expression profiles led to an investigation into 
an uncharacterized RNA species, and its link to the IBV intergenic region. A novel 
subgenomic mRNA was identified associated with the intergenic region that was 
shown to be transcribed via a non-canonical transcription regulatory sequence. In 
contradiction to the current model of coronavirus transcription this mRNA has a 
transcription regulatory sequence derived mainly from the leader, and not the body, 
transcription regulatory sequence. The non-canonical sequence was shown to be 
responsible for reduced transcription levels of the intergenic region mRNA. This 
project proposes the presence of an additional IBV subgenomic mRNA, transcribed 
via a non-canonical mechanism, and encoding a novel 5
th
 accessory protein of IBV 
and closely related gammacoronaviruses. 
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Chapter 1: Introduction 
 
1.1 Infectious bronchitis virus 
 
The avian coronavirus infectious bronchitis virus (IBV) is a highly pathogenic and 
contagious virus of domestic fowl that causes disease in chickens of all ages. First 
described in the United States in the 1930’s, infectious bronchitis is now prevalent 
everywhere there is poultry farming and can be considered a global endemic disease. 
Primarily causing a respiratory disease, IBV initially infects tissues of the upper 
respiratory tract although the virus is able to replicate within, and cause disease in, 
other tissues such as the kidney, oviduct and testes and many parts of the alimentary 
tract (reviewed in (Cavanagh 2007, Raj and Jones 1997)). Uncomplicated infections 
in juvenile and mature birds have low mortality rates but other effects of infection, 
such as growth retardation, are observed. In egg laying birds infection can result in 
diminished egg production and egg quality (Crinion 1972). There is evidence to 
suggest that IBV infection can lead to reduced fertility in roosters resulting in 
reduced breeding capabilities (Boltz, et al. 2007, Boltz, et al. 2004). As a result of 
these effects IBV is responsible for huge economic loss within the global poultry 
industry. 
 
Control of IBV by vaccination, using both live attenuated and inactivated vaccines, 
has been employed for many years in both commercial and smallholding settings. 
However, IBV is highly antigenically variable with over twenty different serotypes 
currently circulating worldwide and low levels of cross-protection between 
serotypes. Current vaccine strategy for egg laying birds is two, or more, vaccinations 
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with live vaccine starting at 2-3 weeks of age, followed by vaccination with 
inactivated vaccine shortly before birds come into lay. Broilers, those birds utilized 
for meat production, are typically vaccinated at one day of age with live vaccines, 
and as required subsequently if new serotypes are in circulation, or a threat to a flock 
(Cavanagh 2007). Production of a protective immune response varies depending on 
the similarity of the vaccine serotype to that of the challenge serotype and often no 
protective effect is seen from existing commercially available vaccines against new 
serotypes. In order to achieve control of the virus, vaccines must therefore be 
continually developed based on currently circulating strains (Ladman, et al. 2002, 
Lin, et al. 2005, Liu, et al. 2009). 
 
Infectious bronchitis virus is classified in the genus gammacoronavirus within the 
family Coronaviridae, a member of the order Nidovirales (Table 1.1). Infectious 
bronchitis virus particles contain positive-sense, single stranded RNA genomes of 
approximately 27.6Kb (Lai and Holmes 2001) that are both 5' capped and 3' 
polyadenylated. Coronaviruses are unique amongst the positive-sense RNA viruses 
in that they have helical nucleocapsids, formed by the association of the genome 
with the nucleocapsid (N) protein. These helical nucleocapsids are enclosed within a 
lipid envelope consisting of the spike (S), membrane (M) and envelope (E) proteins, 
giving rise to pleiomorphic particles approximately 120nm in diameter with petal-
shaped spikes projecting from the surface (Fig. 1.1). 
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TABLE 1.1: Classification of the Coronaviridae 
Genus Species* 
Alphacoronavirus 
Alphacoronavirus 1 
Feline coronavirus (FCoV) 
Porcine transmissible gastroenteritis 
virus (TGEV) 
Human coronavirus 229E (HCoV-229E) 
Human coronavirus NL63 (HCoV-NL63) 
Miniopterus bat coronavirus 1 
Miniopterus bat coronavirus HKU8 
Porcine epidemic diarrhoea virus (PEDV) 
Rhinolophus bat coronavirus HKU2 
Scotophilus bat coronavirus 512 
Betacoronavirus 
Betacoronavirus 1 
Bovine coronavirus (BCoV) 
Human coronavirus OC43 (HCoV-
OC43) 
Human enteric coronavirus (HECoV) 
Porcine haemagglutinating 
encephalomyelitis virus (HEV) 
Equine coronavirus 
Human coronavirus HKU1 (HCoV-HKU1) 
Murine coronavirus 
Murine hepatitis virus (MHV) 
Puffinosis coronavirus 
Rat coronavirus (RtCoV) 
Pipistrellus bat coronavirus HKU5 
Rousettus bat coronavirus HKU9 
Severe acute respiratory syndrome-related coronavirus 
(SARS-CoV) 
Tylonycteris bat coronavirus HKU4 
Gammacoronavirus 
Avian coronavirus 
Infectious bronchitis virus (IBV) 
Turkey coronavirus (TCoV) 
Pheasant coronavirus (PhCoV) 
Goose coronavirus 
Pigeon coronavirus 
Duck coronavirus 
Beluga whale coronavirus SW1 (BeCoV) 
Deltacoronavirus 
Bulbul coronavirus HKU11 (BuCoV) 
Munia coronavirus HKU13 (MunCoV) 
Thrush coronavirus HKU 12(ThCoV) 
* The coronavirus species are listed as according to the International Committee on 
Taxonomy of Viruses – 2011 Release, for family Coronaviridae. 
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Fig. 1.1. Infectious bronchitis virus particles. (A) Schematic representation of a 
coronavirus particle identifying locations of the structural proteins (Stadler, et al. 
2003). (B) Electron micrograph of IBV particles (sourced from www.infectious-
bronchitis.com). 
 
 
1.2 Genome organisation and replication 
 
The IBV genome contains multiple open reading frames (ORFs) as shown in Fig. 
1.2. The 5'-most two-thirds of the genome encodes the non-structural proteins 
involved in virus transcription and replication while the structural proteins S, E, M 
and N, are encoded within the 3'-most third of the genome, along with the group-
specific accessory proteins 3a/3b and 5a/5b. At the very 5'-end of the genome is a 
~60 nucleotide (nt) region known as the Leader, a feature common to all 
coronaviruses that will be discussed in the context of subgenomic (sg) mRNA 
transcription. 
  
A B
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Fig. 1.2. Schematic of IBV genome. The replicase gene is shown at the 5'-end of 
the genome and the junction at which the ribosome frameshift occurs is highlighted 
(RFS). Structural and accessory proteins are shown at the 3'-end. Leader sequence 
(L) is shown upstream of ORF1a and uncharacterized intergenic region (IR) is 
located between the M gene and Gene 5. 
 
 
1.2.1 Attachment and entry 
The life cycle of IBV is similar to all other coronaviruses and is shown schematically 
in Fig. 1.3. Infectious bronchitis virus initially infects cells of the upper respiratory 
tract and can subsequently spread to other tissues. However, the cellular receptor to 
which IBV binds has not yet been identified; although there is evidence to suggest 
that sialic acid, specifically α2,3-linked sialic acid, plays an important role in 
infection (Winter, et al. 2008, Winter, et al. 2006). Binding to this receptor alone 
does not explain the tissue tropism of different IBV strains however, and it is likely 
that another receptor or protein is also involved in initiating infection. 
 
The S protein mediates attachment to the host cell and entry has been demonstrated 
to involve a low-pH-dependent fusion activation event (Chu, et al. 2006). The exact 
process of virus entry is currently unclear but results in the release of the 
nucleocapsid into the cytoplasm, where host cell ribosomes translate genomic RNAs 
to produce the non-structural proteins (nsps), encoded in Gene 1, necessary for 
replication of the viral genome. 
Replicase ORF1a S
N
RFS
5'
Replicase ORF1b 3a 3b
5a 5bIR
M
E
3'
L
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Fig. 1.3. Schematic representation of the coronavirus life cycle. The main steps of 
the coronavirus life cycle are shown. Attachment of the virus particle to the host cell 
is mediated by the virus spike protein. The virus entry pathway, which may involve a 
process of endocytosis or direct membrane fusion, has not been fully elucidated but 
results in the genomic RNA being deposited into the cytoplasm. Translation of 
ORF1a and ORF1b yields the nsps that form the replication transcription complex 
and genome replication and sg mRNA synthesis proceeds. Progeny virus particles 
are assembled at the ER-Golgi Intermediate Compartment (ERGIC) and are released 
from the cell via exocytosis. 
 
 
1.2.2 The non-structural proteins 
Gene 1 consists of two ORFs designated 1a and 1b. ORF1a and ORF1b briefly 
overlap and it is at this junction that a -1 ribosomal frameshift event occurs resulting 
in production of the replicase polyproteins pp1a and pp1ab (Brierley, et al. 1987). 
Virus-encoded proteases are responsible for the cleavage of the 15 nsps (nsps 2-16) 
5'
5'
5'
5'
5'
5'
5'3'
3'
3'
3'
3'
3'
3'
(-ve)
(+ve)
S
3/E
M
5
N
Replication 
transcription 
complex
Rough ER
ERGIC
Golgi
Vesicle
EXOCYTOSIS
TRANSCRIPTION 
+ REPLICATION
TRANSLATION ORF1a + 1b
5' 3'
5' 3'
Genomic RNA
ASSEMBLY
UNCOATING
ATTACHMENT 
+ ENTRY
VIRUS 
RELEASE
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encoded for by the IBV replicase polyproteins (Fig. 1.4). The number of nsps of IBV 
differs from the majority of other coronaviruses, which encode 16 nsps. The nsps 
encoded by ORF1b are produced 60-80% less than proteins of ORF1a indicating the 
frameshift event to be a method of regulating protein production.  
 
 
 
Fig. 1.4. Domain organisation of IBV pp1a and pp1ab. Non-structural proteins 
are numbered from 2 to 16 with known functions labelled. Nsp1 is not present in 
IBV. The coding sequence of nsp11 overlaps with elements involved in ribosomal 
frameshifting and is therefore not shown in pp1ab. Cleavage sites for PL2
pro
 and 
M
pro
 are indicated by black and grey arrowheads respectively. The PL1
pro
 domain is 
proteolytically inactive in IBV. 
 
 
As indicated in Fig. 1.4 the nsps have been shown to play a number of roles in virus 
replication and transcription, although not all have been fully characterized. One 
major difference is observed between the gammacoronaviruses and other 
coronavirus genera and relates to nsp1 and the PL1
pro
 domain of nsp3. The nsp1 
ORF, suggested to be involved in controlling host mRNA synthesis (Huang, et al. 
2011, Tanaka, et al. 2012) is not present in IBV. Additionally, the PL1
pro
 domain of 
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nsp3, responsible for nsp1/nsp2 cleavage and missing in SARS-CoV (Rota, et al. 
2003), is considered proteolytically inactive due to the absence of some sequences 
essential for proteolytic activity. It is possible that this is a result of co-evolution; the 
lack of nsp1 in IBV means that PL1
pro
 is dispensable, as the main substrate of PL1
pro
, 
the nsp1/nsp2 cleavage site, does not exist. 
 
As well as the papain-like proteases nsp3 contains an ADP-ribose-1"-
monophosphatase (ADRP) domain that dephosphorylates ADP-ribose-1"-
monophosphate, a side product of cellular tRNA splicing, to ADP-ribose (Putics, et 
al. 2005). This may function to control the cellular concentrations of certain 
intracellular metabolites and thereby regulate cell metabolism during infection. The 
presence of the transmembrane (TM) domains of nsp3, 4 and 6 suggests a role for 
these proteins in determining membrane rearrangements, an essential function of 
replication for not only coronaviruses but also many other positive-sense RNA 
viruses (Baliji, et al. 2009, Kanjanahaluethai, et al. 2007, Oostra, et al. 2007). 
 
While nsp12 was identified as the main viral primer-dependent RNA-dependent 
RNA polymerase (RdRp) in early studies of IBV (Gorbalenya, et al. 1989), nsp8 has 
more recently been proposed as a primase with RdRp activity capable of de novo 
initiation and primer extension. Interestingly nsp8 has only ever been crystallized in 
a complex with nsp7; while for SARS-CoV a hexadecameric structure consisting of 
8 copies of each nsp was demonstrated, for FCoV a heterotrimer of 2 copies of nsp7 
and 1 copy of nsp8 was observed, and the precise nature of this relationship is 
therefore still unclear (te Velthuis, et al. 2012, Xiao, et al. 2012). The function of 
nsp9 is unclear but has been shown to have RNA binding properties and is known to 
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form a dimer that is essential to virus replication (Miknis, et al. 2009, Sutton, et al. 
2004). Studies of the SARS-CoV nsp13 helicase demonstrated both RNA and DNA 
duplex unwinding activities, (deoxy) nucleoside triphosphatase (dNTPase) activity 
and a RNA 5'-triphosphatase activity that might play a role in the formation of the 5' 
cap structure of viral RNAs (Ivanov, et al. 2004). 
 
The finding that nsp14 includes 3'- to 5'-exonuclease (ExoN) motifs suggested a 
proofreading mechanism for coronaviruses that may help explain how the large RNA 
genomes maintain fidelity during replication (reviewed in (Denison, et al. 2011)). It 
has been shown that interaction of nsp14 with nsp10 forms a complex that is 
involved in 3'-end mismatch excision and results in a >35-fold more potent 
exoribonuclease (Bouvet, et al. 2012). Additionally, nsp14 has been characterized as 
a novel guanine-N7-methyltransferase (N7-MTase) involved in the capping of viral 
mRNAs (Chen, et al. 2009). The nsp15 is highly conserved across the Nidovirales 
and has been demonstrated in a number of coronaviruses, including IBV, to be a 
manganese-dependent endoribonuclease (termed NendoU) that can cleave both 
single- and double-stranded RNA and may play a role in cellular RNA processing 
during infection (Bhardwaj, et al. 2004). Finally, nsp16 has been demonstrated to be 
a 2'O-methyltransferase that binds capped RNAs carrying a methyl group at the N7 
position of the guanosine cap, thus functioning in conjunction with nsp14 as part of 
the coronavirus RNA capping mechanism (Decroly, et al. 2008). 
 
Once all of the replicase proteins have been produced, virus replication continues 
with the transcription of negative-sense copies of the genomic RNA that are 
subsequently used as templates for transcription of positive-sense copies of the virus 
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genome. Additionally, a nested set of mRNAs is produced for the structural and 
group-specific genes via a process of discontinuous transcription as described below. 
 
1.2.3 Subgenomic mRNA synthesis 
During the coronavirus replication cycle only the nsps from Gene 1 are translated 
directly from the genomic RNA, with all other proteins expressed from a 3'- and 5'-
co-terminal nested set of sg mRNAs. A model proposed by Sawicki and Sawicki 
(Sawicki and Sawicki 1995) has led to the general acceptance that these sg mRNAs 
are synthesised via a process of discontinuous transcription during negative-strand 
synthesis (Fig. 1.5). 
 
Located at the distal end of the 5' Leader sequence, all coronaviruses have a 
conserved sequence known as a transcription regulatory sequence (TRS). This short 
AU rich sequence, approximately 5 to 8 nucleotides in length depending on the 
coronavirus, is an important aspect of sg mRNA transcription. An exact copy of the 
Leader TRS (TRS-L), or a highly similar sequence, is also located upstream of each 
structural and group-specific gene of the virus and is referred to as a body TRS 
(TRS-B). For IBV the TRS is recognized to be the highly conserved sequence 
CUUAACAA. However, there are exceptions to this such as the S and Gene 3 TRSs 
of Beaudette strains, which have the sequence CUGAACAA, and the S and Gene 5 
TRSs of the M41 strain, which have the sequences CUGAACAA and CUUAAUAA 
respectively. This demonstrates that there is some flexibility in the TRS-B 
requirements for different genes although all are still easily recognisable as the TRS 
for the associated gene. 
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Fig. 1.5. Schematic representation of IBV sg mRNA synthesis. Following entry 
ORF1a/b is translated to yield the replicase proteins. These replicase proteins use the 
genome as a template to generate full-length negative-sense RNAs that are then used 
as templates to generate new genomes. A process of discontinuous transcription 
yields each of the structural and accessory proteins as a nested set of sg RNAs. 
Transcription is initiated at the 3'-end of the genome and continues until a 
transcriptional regulatory sequence is reached. The nascent minus-strand is then 
translocated to the now complementary 5' TRS-L where it hybridizes and 
transcription continues to the 5'-end of the genome. Each sg RNA then acts as a 
template for sg mRNA synthesis. 
 
 
Synthesis of negative-sense sg RNAs is initiated at the 3'-end of the genome and 
proceeds until a TRS-B is encountered. The TRS-B is proposed to act as a pause/stop 
signal for the replication transcription complex (RTC) and once copied one of two 
possible outcomes will arise; either transcription will continue to the next TRS-B or, 
the now complementary TRS-B of the nascent negative-strand RNA will hybridize 
to the TRS-L and transcription will continue to the very 5'-end of the genome, 
adding the Leader sequence to each sg RNA. The negative-sense sg RNAs, with co-
terminal 5'- and 3'-ends, are then transcribed into a nested set of sg mRNAs. 
 
Transfer of  nascent minus 
strands and hybridisation to 
Leader-TRS
5' 3'
Leader TRS-L TRS-B
Genome
Replicase Spike 3 M IR 5 N
Transcription 
continues to 5' end
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The precise mechanisms of sg mRNA synthesis are unknown, and while the TRS is 
known to be important (Pasternak, et al. 2001, Pasternak, et al. 2003, van Marle, et 
al. 1999, Zuniga, et al. 2004), there is increasing evidence to suggest a number of 
additional factors might also be involved. These may include specific sequence 
elements and RNA-RNA interactions (Mateos-Gomez, et al. 2011, Moreno, et al. 
2008), the formation of secondary RNA structures such as stem-loops (Dufour, et al. 
2011, Ozdarendeli, et al. 2001, Yang, et al. 2011) or RNA-protein interactions 
(Baric, et al. 1988, Keane, et al. 2012, Sola, et al. 2011, Zhang and Lai 1995, 
Zuniga, et al. 2010). 
 
Once synthesised the sg mRNAs are translated by host cell ribosomes to produce the 
structural and group-specific accessory proteins. With the exception of the smallest 
sg mRNA (N), all other sg mRNAs contain two or more ORFs however, generally 
only the 5'-most ORF is subsequently translated to yield the associated protein. 
 
1.2.4 Structural proteins 
Infectious bronchitis virus encodes four structural proteins, S, E, M and N, as shown 
in Fig. 1.1. The largest of these, S, is a multifunctional type 1 glycoprotein involved 
in binding to the host cell receptor and mediating virus-cell and cell-cell fusion. 
Mature S proteins assemble into a trimer to form the spikes seen on the surface of 
the virus (Delmas and Laude 1990) and are incorporated into virus particles at the 
ER-Golgi Intermediate Compartment (ERGIC), the site of coronavirus budding 
(Klumperman, et al. 1994). The S1 subunit of the protein mediates receptor binding 
and a conformational change in the protein is triggered. The S2 subunit, containing 
two heptad repeat regions, is responsible for the class I virus fusion protein activity 
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of the spike (Bosch, et al. 2003, Yamada, et al. 2009) and is therefore thought to be 
involved in initial fusion of virus to the cell membrane following attachment, as well 
as playing a role in cell-cell spread. 
 
As well as a role in attachment the S1 subunit is involved in the induction of a 
protective immune response (Cavanagh, et al. 1986, Ignjatovic and Galli 1994). 
However, S1 sequences are highly variable and this has led to extensive variation. 
As a result numerous serotypes exist in the field which are generally poorly cross-
protective (Cavanagh, et al. 1997). 
 
The coronavirus E protein is a small integral membrane protein (76-109 amino 
acids) and, in the case of IBV, is translated from the third ORF (ORF 3c) of a tri-
cistronic Gene 3 sg mRNA via an internal ribosome entry site (IRES) (Liu and Inglis 
1992). Although a minor structural component of the viral envelope, the E protein is 
thought to play a role in inducing membrane curvature and, if co-expressed with the 
M protein leads to the formation of virus-like particles (VLPs) (Baudoux, et al. 
1998, Corse and Machamer 2000, Raamsman, et al. 2000). The requirement for E in 
a productive infection appears to vary amongst coronaviruses; proving essential for 
the production of recombinant infectious TGEV virions (Curtis, et al. 2002), while 
for both MHV and SARS-CoV recombinant viruses lacking E were shown to 
replicate in cell culture, albeit to reduced levels compared to recombinant wild type 
viruses (DeDiego, et al. 2007, Kuo and Masters 2003). There is also evidence that 
the E protein has ion channel activity, although the exact role of this activity during 
infection is currently unclear (Wilson, et al. 2006). 
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The M protein, a type III membrane protein, is the most abundant protein in the viral 
envelope, estimated to account for ~40% of the mass of IBV particles (de Haan, et 
al. 1998, Stern, et al. 1982) and plays a major role in virus assembly and budding. 
As mentioned above, M interacts with E leading to the formation of VLPs with all 
domains of M shown to be important for VLP formation (Corse and Machamer 
2003, de Haan, et al. 1998). Additionally, M-M interactions, particularly at TM 
domains, have been shown to be essential for envelope formation (de Haan, et al. 
2000). Studies carried out with MHV have also shown that the M protein interacts 
with the N protein, in conjunction with genome length RNAs, suggesting a 
mechanism by which genomes are specifically packaged into virus particles during 
infection (Narayanan, et al. 2000). 
 
The nucleocapsid protein, N, is a multifunctional phosphoprotein (Calvo, et al. 2005) 
involved in packaging the genomic RNA into a helical ribonucleoprotein, a unique 
occurrence amongst positive-strand RNA viruses. A number of additional roles of 
the N protein have also been demonstrated including regulation of viral RNA 
synthesis (Baric, et al. 1988, Grossoehme, et al. 2009, Keane, et al. 2012, Nelson, et 
al. 2000), likely mediated by the known RNA-binding domains of the protein 
(Chang, et al. 2006). The importance of the N protein was highlighted with the 
development of reverse genetics systems for coronaviruses when it was 
demonstrated that the N protein was either essential for the recovery of infectious 
virions, as in the case of IBV (Casais, et al. 2001), or resulted in substantially 
enhanced recovery of infectious virions (Almazan, et al. 2004, Yount, et al. 2000, 
Yount, et al. 2003). 
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1.2.5 The group-specific accessory proteins 
In addition to genes for the structural proteins, all coronaviruses possess a varying 
number of group-specific genes at the 3'-end of the genomic RNA, interspersed 
between the structural genes. These group-specific genes encode a variety of 
proteins generally referred to as accessory proteins due to the fact that they can be 
deleted with limited effects observed on virus replication in cell culture (Casais, et 
al. 2005, de Haan, et al. 2002, Frieman, et al. 2006, Hodgson, et al. 2006, Ortego, et 
al. 2003, Youn, et al. 2005, Yount, et al. 2005). Although relatively few coronavirus 
accessory proteins have been characterized to date, the evidence suggests that these 
proteins have immunomodulatory roles thereby influencing virus pathogenicity and 
virulence (Cruz, et al. 2011, de Haan, et al. 2002, Freundt, et al. 2010, Frieman, et 
al. 2007, Koetzner, et al. 2010, Varshney, et al. 2012). 
 
Infectious bronchitis virus possesses two group-specific genes, Gene 3 and Gene 5, 
each of which encode two accessory proteins designated 3a and 3b, and 5a and 5b 
respectively (Liu, et al. 1991, Liu and Inglis 1992). At present no functions have 
been determined for any of the four IBV accessory proteins although all have been 
shown to be dispensable for virus replication in cell culture (Casais, et al. 2005, 
Hodgson, et al. 2006, Youn, et al. 2005). 
 
1.2.6 The intergenic region 
In addition to the structural and group-specific genes IBV, and closely related 
gammacoronaviruses such as turkey coronavirus (TCoV), also contain an 
uncharacterized region located between the M gene and Gene 5, referred to variably 
as the IR, ORF4b, or ORF X (Armesto, et al. 2009, Cao, et al. 2008, Gomaa, et al. 
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2008, Hewson, et al. 2011). With the exception of some vaccine and attenuated 
laboratory strains of IBV this region, of ~350nts, contains a putative ORF with the 
potential to code for a protein of 94 amino acids. The AUG initiation codon of this 
potential protein is located directly downstream of the M gene stop codon. 
 
The chick kidney (CK) cell adapted IBV strain, Beau-CK, from which the Beau-R 
cDNA clone used in the Coronavirus Group at the Institute of Animal Health (IAH) 
was derived, contains a large deletion of ~40 amino acids from the 3'-end of the 
potential coding sequence. Smaller truncations are observed for some other strains of 
IBV making it likely that any potential protein from this ORF is inactive in these 
strains (Fig. 1.6). Such deletions and truncations also indirectly demonstrate that the 
IR is dispensable for virus replication. 
 
 
 
                      10        20        30        40        50        60        70        80        90 
             ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|.... 
D1466        MCVCREYLKLFFNSASILRARKSICFEDININPLCFVLSLQELLFKQQFFLSFVWKKVVVNGVEFQVENGKVHYEGNPIF..............  
H120-A       MCVCREYLKLFFNSASILRARKSICFEDININPLCFVLSLQELLFKQQFFLSFVWKKVVVNGVEFQVENGKVHYEGNPIF..............  
TCoV-NC95    MCVCREYLKLFFNSASILSARKSIWFEDININPLCFVLSLQELLFKQQFFLSFVWKKVVVNGVEFQVENGKVHYEGNPIFQKGCCRLWSHYKRD  
Ark-DPI      MCVCREYLRLFFNSASILRAHTSIYFEDININPLWFILSFQELLFKKQFFHSFVPKTIVVNGVTFQVDNGKVYYEGTPVFQKGCCRMWSNYKKD  
Connecticut  MCVCREYLRLFFNSASILRAHKSIYFEDININPLCFILSFQELLFKKQFFHSFVPKTIVVNGVTFQVDNGKVYYEGTPVFQKGCCRMWSNYKKD  
4-91         MCVCKEYLKLFFDSASILRAWKSIIFEDININPLCFILSFQELLFKKQFFHSFVPKTVCVNGVSFQVDNGKVYYEGKPIFQKGCCRLWSSYKKD  
M41-CK       MCVCREYLKLFFNSASILRAHNSIIFEDININPLCFILSFQELLFKKQFFHSFVPKTIVVNGVTFQVDNGKVYYEGKPIFQKGCCRLWLSYKKD  
Beau-CK      MCVCREYLKLFFNSASVLRAHKSIYFEDTNINPLCFILSFQELLTVLPFK............................................ 
 
Fig. 1.6. Amino acid alignments of gammacoronavirus IR ORF. The amino acid 
alignments are shown for the putative 94 amino acid protein coding sequence of the 
IR. A selection of strains including Beau-CK and M41-CK, as used in the 
Coronavirus Group at the IAH, are shown to demonstrate the deletions and 
truncations present in some strains. 
 
 
Despite the presence of the IR ORF the function of this region has always been 
debated due to the lack of identification of a TRS upstream of the IR. The presence 
of a TRS is believed to be a fundamental requirement for the expression of sg 
mRNAs and therefore subsequent protein expression. For IBV the TRS-Bs of the 
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known genes are located ~20-100nts upstream of the AUG for the gene and despite 
extensive scans of the IBV genome no sequence closely matching the required 
CUUAACAA TRS has been identified upstream of the IR. The identification of the 
IR in TCoV (as ORF X) was accompanied by a proposed TRS-B of GUCAACAA 
located 288nts upstream of the initiation codon (Gomaa, et al. 2008). However, there 
was no experimental data to back-up this proposal and the sequence mis-matches 
and distance from the AUG make it an unlikely target. The function of this region 
therefore remains unclear. 
 
1.2.7 Virus assembly and release 
Coronaviruses, as with many positive strand RNA viruses, are known to induce a 
variety of membrane rearrangements to support virus replication complexes 
including double-membrane vesicles and convoluted membranes (Knoops, et al. 
2008, Ulasli, et al. 2010). As well as providing a scaffold for replication these 
membrane rearrangements may offer a mechanism by which the replicating viruses 
can evade host immune responses by shielding immunogenic molecules, such as 
double-stranded RNA, from the host immune system. The association of replication 
with membranes may also be beneficial for assembly as all the components of 
progeny virions are concentrated together ready for incorporation into new virions, 
although it is not clear how each of the structural proteins are associated with the 
membranes. 
 
Assembly begins with the encapsidation of newly synthesised genomes, by 
numerous copies of the N protein, to form helical nucleocapsids. Interactions 
between N, M and the genomic RNA, as previously described, at the endoplasmic 
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reticulum and Golgi body mediate the selective packaging of new genomes into 
virions. The final stages of assembly and budding of new virions has been 
demonstrated to occur at cytoplasmic surfaces of the ERGIC (Klumperman, et al. 
1994) with virions subsequently transported in membrane-bound vesicles to the 
plasma membrane where they are released from the cell by a process of exocytosis 
(Tooze, et al. 1987). 
 
1.3 Viral-vector vaccines 
 
For many years viruses, particularly members of the Adenoviridae, Poxviridae and 
Retroviridae families, have been studied for their potential to be utilized as gene 
delivery systems, for example in the treatment of certain types of cancer, or as viral-
vector vaccines for protection against human and veterinary infectious diseases 
(reviewed in (Draper and Heeney 2010)). As well as mammalian viruses, some avian 
viruses such as the paramyxovirus newcastle disease virus (NDV) and the 
avipoxvirus fowlpox virus (FPV) have been evaluated for use as vectors, not only as 
vaccines for veterinary use (Ge, et al. 2011, Shi, et al. 2011) but also for vaccine and 
gene therapy use in humans ((DiNapoli, et al. 2007, Nakaya, et al. 2001, Tsang, et 
al. 2005) and reviewed in (Skinner, et al. 2005, Weli and Tryland 2011)). 
 
Often the virus backbone simply provides a delivery mechanism for the gene of 
interest. However, particularly in veterinary situations, the desire is to generate a 
viral-vector vaccine that is bi- or polyvalent and can be used to vaccinate against two 
or more diseases at the same time. This desire is particularly true in the field of avian 
diseases and commercial poultry enterprises. Birds in commercial flocks may require 
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vaccination against up to 6 or 7 different viral diseases, often with multiple doses 
required, and any ability to reduce this number through combining vaccines will 
have enormous benefits for both animal welfare and commercial interests. There has 
already been success in this field with the production of several vector vaccines 
including Merial’s VAXXITEK® HVT+IBD vaccine, which vaccinates against both 
Mareks disease virus (MDV) and infectious bursal disease virus, and the 
Vectormune® HVT-NDV vaccine from Ceva, which protects against both MDV and 
NDV. The MDV HVT vaccine offers many possibilities for use as a vector to also 
immunize against additional avian diseases and research is ongoing in this area 
(Iqbal 2012). 
 
1.3.1 Reporter genes 
To be successful, viral-vector vaccines must be capable of stably expressing foreign 
genes and this ability can be investigated by using recombinant viruses expressing 
reporter genes. When expressed from an organism a reporter gene allows for a 
measurable output of gene expression, with a wide variety available to suit different 
needs. A number of bacterial genes such as the E. coli enzyme beta-glucoronidase 
(GUS), the chloramphenicol resistance gene chloramphenicol acetyltransferase 
(CAT) and the E. coli lacZ gene were developed into successful reporter gene 
systems. However, these systems have been overshadowed in the study of viral 
vectors by the popularity of fluorescent and luminescent proteins. 
 
The fluorescent protein green fluorescent protein (GFP), first isolated in 1962 from 
the jellyfish Aequorea victoria (Shimomura, et al. 1962), has become one of the 
most widely used markers for gene expression. The A. victoria GFP is a 27kDa 
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protein of 238 amino acids that absorbs blue light (maximally at 395nm) and emits 
green light with a peak emission of 509nm (Prasher, et al. 1992). This process can be 
reproduced experimentally by exposure to a source of UV light, such as from a 
fluorescence microscope. One of the advantages of GFP is that to achieve 
fluorescence no additional substrates or cofactors are required, thus allowing 
detection of expression in living cells and tissues. However, GFP is also species 
specific and it was not until the development of ‘humanised’ and ‘enhanced’ GFPs 
(hGFP and eGFP), which were modified for increased translation in mammalian 
cells, that GFP could be fully exploited (Zhang, et al. 1996, Zolotukhin, et al. 1996). 
 
Luminescent proteins are enzymes, referred to as a luciferase, which catalyse a light-
emitting reaction of its associated substrate, known as luciferin. Isolated from the sea 
pansy Renilla reniformis, the Renilla luciferase is a protein of 311 amino acids that 
catalyses the oxidation of coelenterazine to yield blue light of 480nm, which can 
then be detected using a luminometer (Lorenz, et al. 1991). Renilla luciferase, with a 
molecular weight of 37kDa, originally showed some limitation in use compared to 
other luciferases, such as the larger (~60kDa) firefly luciferase (fLuc), due to low 
levels of autoluminescence, which reduced assay sensitivity. However, as with GFP, 
Renilla luciferase has also been modified for improved expression in mammalian 
cells in an effort to increase the reliability as a genetic reporter and reduce levels of 
autoluminescence. This was achieved by redesigning the gene sequence using 
preferred mammalian codons and generating a synthetic Renilla gene, hRluc 
(Zhuang, et al. 2001). There have also been improvements to substrates for Renilla 
luciferase allowing it to also be used in living cells and tissues. 
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1.4 Coronaviruses and the expression of heterologous genes 
 
The large size of coronavirus genomes, combined with the possibility of expressing 
heterologous genes via the generation of novel sg mRNAs, has meant that 
coronaviruses have long been attractive targets for use as viral-vector vaccines. 
However, the expression of heterologous genes requires considerable manipulation 
of the virus genome and thus requires the development of a reverse genetics system 
for the virus. Initially the development of coronavirus reverse genetics systems were 
hampered; partly due to the large size of coronavirus genomes but also because of 
the instability of certain regions of the replicase gene when expressed from bacteria. 
In the absence of reverse genetics systems expression of heterologous genes from 
coronaviruses was limited to artificial constructs such as defective RNAs (D-RNAs) 
(Stirrups, et al. 2000), replicon particles (Curtis, et al. 2002) or expression vectors 
(Thiel, et al. 2003), which although useful as tools to study aspects of the 
coronavirus life cycle, were not always suitable for use as vaccine vectors. 
 
In recent years the problems associated with coronavirus reverse genetics systems 
have been overcome and a number of strategies have been successfully developed to 
produce full-length cDNAs from several coronaviruses including TGEV, human 
coronavirus 229E, SARS-CoV and human coronavirus NL63 (Almazan, et al. 2000, 
Donaldson, et al. 2008, Thiel, et al. 2001, Yount, et al. 2000, Yount, et al. 2003). A 
reverse genetics system for IBV, utilizing vaccinia virus, has also been established 
and so made it possible to investigate the use of recombinant IBVs (rIBVs) for 
vaccine development (Casais, et al. 2001). Using vaccinia virus as a vector for IBV 
cDNA it is possible to make large-, or small-scale modifications to the IBV cDNA 
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directly by utilizing the natural ability of vaccinia virus to undergo homologous 
recombination (see Chapter 2 section 2.10 for more details) (Britton, et al. 2005). 
These advances in reverse genetics have made it possible to realize the potential of 
using coronaviruses as vaccine vectors, as well as gaining the ability to generate 
recombinant viruses that can be used as tools to study various aspects of the 
coronavirus life cycle through the expression of reporter genes. 
 
To investigate the potential use of coronaviruses as vaccine vectors, and as tools to 
investigate virus replication, studies have often focussed on how to generate 
recombinant viruses that can stably express heterologous genes. Utilizing reporter 
genes such as GFP/eGFP, fLuc or hRluc allows for visual analysis and determination 
of the factors that influence the stability of recombinant viruses. Of particular 
interest is the position at which heterologous genes are inserted into the virus 
genome. Due to the nature of coronavirus sg mRNA transcription two possibilities 
present themselves for the expression of heterologous genes: (1) expression from an 
additional, newly synthesised sg mRNA or, (2) expression from an existing sg 
mRNA via insertion of a gene cassette, replacement of existing genes or fusion to 
existing genes. 
 
Expression of heterologous genes via the synthesis of additional sg mRNAs was 
demonstrated with the use of expression systems such as minigenomes and D-RNAs 
(Alonso, et al. 2002, Stirrups, et al. 2000). However, when using recombinant 
viruses consisting of full-length virus genomes stability was often greatest following 
the replacement of the non-essential accessory genes (de Haan, et al. 2003, Shen, et 
al. 2009, Tekes, et al. 2008, Youn, et al. 2005). Alterations to coronavirus structural 
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genes appear to be less well tolerated with reduced stability, or an inability to rescue 
infectious virus (Bosch, et al. 2004, Shen, et al. 2009). Differences in recombinant 
virus stability have also been identified depending on the particular coronavirus 
genomic background, as well as the type of heterologous gene being inserted (de 
Haan, et al. 2005). 
 
In the case of the closely related arteriviruses the genomes do not contain genes that 
are dispensable for virus replication, as with the coronaviruses, and therefore gene 
replacement has not been a viable option for the expression of heterologous genes. 
However, the successful rescue of infectious recombinant viruses expressing 
heterologous genes has been achieved for the arterivirus equine arteritis virus (EAV) 
by synthesis of novel sg mRNAs inserted within the structural genes (de Vries, et al. 
2001), or the replicase gene (van den Born, et al. 2007), with the latter proving to be 
the more stable construct. 
 
Few studies have analysed the potential of coronavirus vectors beyond aspects of 
stability, although the generation of antigen-specific immune responses has been 
demonstrated, thus providing further evidence that coronaviruses have the potential 
to be utilized as vaccine vectors (Cervantes-Barragan, et al. 2010, Sola, et al. 2003). 
Taking the concept of coronavirus vaccine vectors one step further the generation of 
a TGEV-based vector expressing the rotavirus VP7 protein resulted in detection of 
rotavirus-specific antibodies, as well as demonstrating partial protection against 
rotavirus-induced disease when used to immunize mice against rotavirus challenge 
(Ribes, et al. 2011). One previous report also suggested the possibility of utilizing 
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the human coronavirus 229E as a multigene vaccine for HIV although the outcomes 
of this proposed work are unknown (Eriksson, et al. 2006). 
 
1.5 Aims 
 
The use of viral-vector vaccines in the poultry industry has already proved to be a 
possibility with successful vaccines from veterinary pharmaceutical companies on 
the market. However, the number of diseases for which poultry require vaccination 
against warrants the research and development of more bivalent, or polyvalent, viral-
vector vaccines. Coronaviruses have been suggested as good candidates for the 
generation of vectors for the expression of heterologous genes. The avian 
coronavirus IBV may be suitable for the generation of viral-vector vaccines to 
protect against not only IBV but also additional avian diseases based on the 
heterologous genes expressed. The initial aim of this thesis therefore, was to 
investigate the potential for using IBV as a vector for the expression of heterologous 
genes. This was to be achieved through the generation of a series of recombinant 
viruses, expressing reporter genes, which could be used to test the following four 
hypotheses: 
1) Expression of heterologous genes from different locations within the IBV 
genome would result in recombinant viruses with varying degrees of genome 
stability. 
2) Expression of heterologous genes of different sizes, and with different 
characteristics, would alter the stability of the resultant recombinant viruses. 
3) Codon optimization of the heterologous gene sequence would improve the 
stability of the recombinant viruses. 
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4) Fusion of the heterologous gene to an existing virus gene would result in 
improved stability of recombinant viruses. 
Due to observations made during the analysis of rIBVs for the vaccine vector 
project, relating to the uncharacterized intergenic region of IBV, a second project 
was initiated to investigate the findings. This led to additional aims being defined for 
this thesis: 
1) To confirm that a novel sg mRNA corresponding to the IBV intergenic 
region is synthesised during infection. 
2) To determine the transcription mechanism for this novel sg mRNA. 
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Chapter 2: Materials and Methods 
 
2.1 Cells 
 
All cell cultures were prepared, and stocks maintained, by the Microbiological 
Services department of the Institute for Animal Health, Compton. Cell cultures were 
maintained at 37°C, 5% CO2. 
 
CK cells: Chick kidney (CK) cells are a primary cell line generated by the removal 
and trypsinization of kidneys from 2- to 3-week old specific-pathogen-free (SPF) 
Rhode Island Red chickens. 
Vero cells: Vero cells are a continuous cell line originally derived from kidney 
epithelial cells of the African Green Monkey. 
BHK-21 cells: Baby hamster kidney cells (BHK-21) cells are a continuous cell line 
originally derived from the kidneys of 5 1-day old Syrian golden hamsters. 
CEF cells: Chicken embryo fibroblasts (CEF) are a primary cell line prepared from 
9-day old embryonated eggs from SPF Rhode Island Red chickens. Embryos are 
decapitated, eviscerated and washed in PBS. Individual cells are generated using 
0.25% trypsin in PBS. Cells are spun and resuspended in growth medium.  
 
2.2 Cell culture media 
A variety of cell media were used for maintenance of different cell lines and plaque 
assays as listed in Tables 2.1 – 2.4. All recipes are made to 100mL final volume with 
sterile water. 
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TABLE 2.1: 1X BES CK cell maintenance medium 
                    2X BES IBV plaque assay medium 
Ingredient Volume (mL) 
(1X/2X) 
10X EMEM (Sigma) 10/20 
Tryptose Phosphate Broth  10/20 
10% BSA (Sigma) 2/4 
1M N,N-bis[2-hydroxethyl]-2-
Aminoethanesulfonic acid (BES) (Sigma)  
2/4 
7.5% Sodium bicarbonate  2.8/5.6 
L-glutamine (100X) (Life Technologies)  1/2 
Nystatin (100,000 U/mL) (Sigma)  0.25/0.5 
Penicillin/Streptomycin (100,000 U/mL) (Sigma) 0.1/0.2 
 
TABLE 2.2: 2X EMEM vaccinia virus plaque assay medium 
Ingredient Volume 
(mL) 
10X EMEM (Sigma) 20 
FCS (Sigma) 10 
7.5% Sodium bicarbonate  4.6 
L-glutamine (100X)  (Life Technologies)  2 
Nystatin (100,000 U/ml) (Sigma)  0.5 
Penicillin/Streptomycin (100,000 U/mL) (Sigma) 0.2 
 
TABLE 2.3: 1X GMEM BHK-21 maintenance medium 
Ingredient Volume 
(mL) 
G-MEM 88.4 
FCS (Sigma) 1 
Tryptose Phosphate Broth 10 
Nystatin (100,000 U/mL) (Sigma) 0.5 
Penicillin/Streptomycin (100,000 U/mL) (Sigma) 0.1 
 
TABLE 2.4: 1X 199 CEF maintenance medium 
Ingredient Volume 
(mL) 
10X 199 (Sigma) 10 
Tryptose Phosphate Broth 10 
7.5% Sodium bicarbonate  3 
L-glutamine (100X)  (Life Technologies)  1 
Nystatin (100,000 U/mL) (Sigma) 2.5 
Penicillin/Streptomycin (100,000 U/mL) (Sigma) 0.1 
NBCS (New born calf serum) (Sigma) 2 
 
 
Chapter Two 
28 
 
2.3 Viruses 
 
Beau-R: Beau-R is a molecular clone of Beaudette-CK (Beau-CK); a CK cell-
adapted strain of Beaudette generated by multiple passages in embryonated hens’ 
eggs and CK cells. Compared to Beau-CK, Beau-R contains two nucleotide 
substitutions: (1) C19666U in the replicase, resulting in a Ser to Leu change and (2) 
A27087G in the N gene, a silent mutation. Beau-R stocks were grown on CK cells, 
harvested 24 hours post-infection (hpi) and titrated on CK cells. 
M41-CK: M41-CK is a pathogenic strain of IBV that has been adapted for growth 
on CK cells. Stocks were grown in 10-day old embryonated SPF Rhode Island Red 
hens’ eggs and titrated on CK cells. 
BeauRΔIR: BeauRΔIR is a recombinant of Beau-R in which the intergenic region 
has been deleted between nucleotides 25191 and 25450 inclusively. BeauRΔIR 
stocks were grown on CK cells, harvested 24 hpi and titrated on CK cells. 
BeauR 5ab: BeauR 5ab is a recombinant of Beau-R in which all of ORF 5a and 
the first seven amino acids of ORF 5b has been deleted (nucleotides 25488-25702 
inclusive). BeauRΔ5ab stocks were grown on CK cells, harvested 24 hpi and titrated 
on CK cells. 
BeauR 3ab: BeauR 3ab is a recombinant of Beau-R in which all of ORF 3a, and 
all except the final 17 nucleotides of ORF 3b has been deleted (nucleotides 23857-
24203 inclusive). BeauRΔ3ab stocks were grown on CK cells, harvested 24 hpi and 
titrated on CK cells. 
Additional IBV field and vaccine strains: Field strains D1466, Italy-02 and QX, 
and vaccine strains CR88 and H120 were obtained from Prof. Richard Jones, 
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University of Liverpool for an unrelated project. Stocks were grown in 10-day old 
embryonated SPF Rhode Island Red hens’ eggs. 
vNotI/IBVFL: vNotI/IBVFL is a recombinant vaccinia virus containing a full length 
cDNA clone of IBV Beau-R (Fig. 2.1). Stocks of vNotI/IBVFL were grown on BHK-
21 cells and harvested 4 days post-infection. 
rFPV-T7: rFPV-T7 is a recombinant fowlpox virus expressing the T7 bacteriophage 
RNA polymerase under the control of the vaccinia virus P7.5 promoter. Stocks were 
grown on CEF cells, harvested 4 days post-infection and titrated on CEF cells. 
 
 
 
 
Fig. 2.1. Schematic of vNotI/IBVFL. The IBV Beau-R genome is shown in a 3' to 5' 
orientation within the vaccinia virus genome. The IBV genes within the cDNA are 
shown. T7-Promoter, HδR and T7-T refer to the positions of the T7 promoter, 
hepatitis delta antigenome ribozyme and T7 terminator sequences respectively. 
 
 
2.4 IBV plaque assay 
 
Virus was 10-fold serially diluted in 1X BES medium and used to infect duplicate 
wells of 6-well plates of confluent CK cells. After 1 h incubation inoculum was 
removed and cells washed once with PBS. Cells were overlayed with a mixture of 
50% 2X BES medium, 50% 2%-agar and incubated for a further 72 h. Cells were 
VV-TK (Fragment)
T7-Promoter
ReplicaseS3M5N
HδR
T7-T
VV DNA
SalI AscI
VV DNA
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fixed by the addition of 1mL/well of 10% formaldehyde in PBS for 1 h. Agar plugs 
were removed and cells stained with 0.1% (w/v) crystal violet solution for 20 min to 
visualize plaques. 
 
2.5 Vaccinia virus plaque assay 
 
Vaccinia virus plaque assays were carried out as part of the IBV reverse genetics 
system to generate rVVs (see section 2.10). Vaccinia viruses were subjected to three 
cycles of freeze-thawing, sonicated and 10-fold serially diluted in serum-free EMEM 
from 10
-1
 – 10-3 and used to infect duplicate wells of six-well plates of confluent 
Vero cells at 500μL/well. After 1 h incubation inoculum was removed and cells 
washed once with PBS. Cells were overlayed with a mixture of 50% 2X EMEM, 
50% 2%-agar, with or without selection components as described in section 2.10, 
and incubated for a further 72 h. Cells were stained overnight by the addition of a 
further 2mL overlay medium containing 0.01% (w/v) neutral red. Well-isolated 
plaques were picked for each recombinant and placed in 400μL of serum-free 
EMEM. 
 
2.6 Growth curves 
 
Individual wells of 6-well plates of confluent CK cells were infected with 1x10
5
 pfu 
of virus and incubated for 1 h after which cells were washed twice with PBS and 
2mL of fresh 1X BES medium added. Extracellular virus was harvested at 1, 8, 12, 
24, 48 and 72 hpi and subsequently analysed in triplicate by plaque assay on CK 
cells for progeny virus. 
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2.7 Bacteriological methods 
 
2.7.1 Transformation of TOP10 cells 
All transformations were carried out using One Shot® TOP10 chemically competent 
E. coli (Life Technologies) according to manufacturer’s instructions. Transformation 
reactions were plated out onto LB plus ampicillin (100 g/mL) agar plates and placed 
at 37°C overnight. SOC medium and LB plates were produced by the IAH 
Microbiological Services department. 
 
2.7.2 Bacterial cultures 
Transformed E. coli cells were cultured for mini- or maxi-prep of plasmid DNA in 
LB plus ampicillin (100 g/mL) in 5mL (mini-prep) or 100mL (maxi-prep) volumes 
overnight at 37°C, 1600 rpm. 
 
2.8 RNA methods 
 
2.8.1 RNA extraction 
 Viral RNA was extracted from extracellular virus samples using the RNeasy 
Mini Kit (Qiagen) following the protocol for RNA Cleanup as per 
manufacturer’s instructions. 
 Total RNA was extracted from CK cells using the RNeasy Mini Kit (Qiagen) 
following the protocol for Animal Cells as per manufacturer’s instructions with 
homogenization using the TissueLyser II (Qiagen) for 30 s at 25hz. 
 Total RNA was extracted from excised chicken tracheas using the RNeasy Mini 
Kit (Qiagen) following the protocol for Animal Tissues as per manufacturer’s 
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instructions with homogenization using the TissueLyser II (Qiagen) for 2 x 1 min 
at 30hz. 
 
2.8.2 Reverse transcription 
Viral RNA was reverse transcribed using SuperScript III (Life Technologies) with 
random primer (5'-GTTTCCCAGTCACGATCNNNNNNNNNNNNNNN-3') as 
follows: 
RNA template 5 L  
65°C – 5 min 
 
dTNP mix (10mM each dNTP) 1 L 
Random primer (40 M) 1 L 
Water 6 L 
 
Incubate on ice for  1 min and add 7 L of SuperScript III mix: 
5x first strand buffer 4.5 L 25°C – 5 min 
50°C – 60 min 
70°C – 10 min 
0.1M DTT 1 L 
RNase OUT (Life Technologies) 1 L 
SuperScript III 0.5 L 
 
 
2.8.3 Northern blot analysis 
Messenger RNA was purified from total RNA samples using the Poly(A)Purist
TM
 
MAG Kit (Ambion), as per manufacturer’s instructions. Northern blot analysis was 
carried out with the NorthernMax®-Gly Kit (Ambion) with the following conditions. 
Briefly, viral mRNA transcripts were denatured in glyoxal load dye at 50°C for 30 
min followed by separation on a 0.8% LE-agarose gel. RNA was transferred to 
BrightStar®-Plus positively charged nylon membrane (Ambion) using capillary 
action for 2 h, cross-linked by treatment with UV light using the auto-crosslink 
function on a Stratalinker UV Crosslinker (Stratagene) and prehybridised for 30 min 
with ULTRAhyb® buffer at 42°C. Blots were probed with a DNA probe specific to 
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the 3'-end of IBV (forward primer 5'-CAACAGCGCCCAAAGAAG-3' and reverse 
primer 5'-GCTCTAACTCTATACTAGCCT-3') that was labelled using the 
BrightStar® Psoralen-Biotin Nonisotopic Labeling Kit (Ambion). Blots were 
hybridised overnight at 42 C followed by washing and development with the 
BrightStar® BioDetect
TM
 Kit (Ambion). 
 
2.9 DNA methods 
 
2.9.1 Plasmid mini-prep 
Plasmid DNA was prepared from 5mL cultures of transformed E. coli using the 
QIAprep Spin Miniprep Kit (Qiagen) as per manufacturer’s instructions. Plasmid 
DNA was eluted in 30 L water and quantified on a Nanodrop ND-1000 (Thermo 
Scientific). 
 
2.9.2 Plasmid maxi-prep 
Plasmid DNA was prepared from 100mL cultures of transformed E. coli using the 
QIAfilter Plasmid Maxi Kit (Qiagen) as per manufacturer’s instructions. Plasmid 
DNA was eluted in 100 L water, quantified on a Nanodrop ND-1000 (Thermo 
Scientific) and diluted to a final concentration of 1 g/ L in water. 
 
2.9.3 PCR 
All reactions were carried out using an Applied Biosystems 2720 Thermal Cycler. 
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Overlapping PCR 
All PCR reactions were carried out using Pfu Ultra II fusion hotstart DNA 
polymerase (Agilent Technologies) with the following reaction mix and cycle 
parameters: 
Primer 1 (10 M)  1 L  
95°C – 2 min 
95°C – 30 sec 
55°C – 30 sec        x 25 
72°C – 30 sec 
72°C – 5 min 
 
Primer 2 (10 M)  1 L 
dNTP mix (10mM each dNTP)  1 L 
10x Pfu Ultra II reaction buffer  5 L 
Pfu Ultra II polymerase  1 L 
DNA template (100ng/ L)  1 L 
Water 40 L 
 
rVV and rIBV rescue confirmation PCR 
All PCRs were carried out with Taq polymerase (Life Technologies) using the 
following reaction mix and cycle parameters: 
Primer 1 (10 M)  1 L  
94°C – 2 min 
94°C – 30 sec 
50°C – 30 sec        x 25 
72°C – 30 sec 
72°C – 2 min 
Primer 2 (10 M)  1 L 
dNTP mix (10mM each dNTP)  1 L 
MgCl2 (50mM) 2 L 
10x Reaction buffer  5 L 
Taq polymerase 0.5 L 
cDNA template 2 L 
Water 37.5 L 
 
Leader-body junction PCR 
All PCRs were carried out with Taq polymerase (Life Technologies) using the 
following reaction mix and cycle parameters (see Fig. 6.2 for additional details): 
Primer 1 (10 M)  1 L  
94°C – 2 min 
94°C – 30 sec 
50°C – 30 sec        x 25 
72°C – 30 sec 
72°C – 2 min 
Primer 2 (10 M)  1 L 
dNTP mix (10mM each dNTP)  1 L 
MgCl2 (50mM) 4 L 
10x Reaction buffer  5 L 
Taq polymerase 1 L 
cDNA template 2 L 
Water 35 L 
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Site-directed mutagenesis PCR 
The PCR mutagenesis was carried out using PFU Turbo high fidelity polymerase 
(Agilent Technologies) with the following reaction mix and cycle parameters: 
 
Primer 1 (10mM) 0.5 L  
 
95°C – 30 sec 
95°C – 30 sec 
45°C – 45 sec        x 16 
72°C – 15 min 
 
Primer 2 (10mM) 0.5 L 
dNTP mix (10mM each dNTP) 0.4 L 
10X PFU reaction buffer 2 L 
PFU Turbo polymerase 0.5 L 
Water 15.1 L 
pGPT-Vaccinia/IBV DNA (300ng/ L) 1 L 
 
 
2.9.4 PCR cloning 
PCR products amplified using Taq polymerase were cloned using the TOPO TA 
Cloning® Kit for Sequencing (Life Technologies) as per manufacturer’s instructions 
with 4 L of PCR product per reaction. Cloning reactions were used to transform 
chemically competent TOP10 cells as in section 2.7. 
 
2.9.5 DNA gel electrophoresis 
DNA products were visualized on 1% agarose gels (0.5g agarose, 50mL 1X TBE 
buffer, 1 L ethidium bromide (10mg/mL)). Electrophoresis was carried out at 150V 
until products had run sufficiently far. Samples were run with loading buffer (70% 
water, 30% glycerol, 3.5% (w/v) bromophenol blue). Size marker for all gels was 
1Kb plus ladder (Life Technologies) prepared in loading buffer. 
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2.9.6 PCR purification 
PCR products were purified using the QIAquick PCR Purification Kit (Qiagen) as 
per manufacturer’s instructions. Purified products were eluted in 30 L water. 
 
2.9.7 Nucleotide removal 
Digested DNA products were purified, and unwanted digested fragments removed, 
using the QIAquick Nucleotide Removal Kit (Qiagen) as per manufacturer’s 
instructions. DNA was eluted in 50 L water. 
 
2.9.8 Gel extraction 
DNA products were extracted from agarose gels using the QIAquick Gel Extraction 
Kit (Qiagen) as per manufacturer’s instructions. DNA was eluted in 30- or 50 L 
water depending on concentration of starting material. 
 
2.9.9 Ligation 
All ligations were carried out using the Quick Ligation
TM
 Kit (NEB) as per 
manufacturer’s instructions. 
 
2.9.10 Sequence analysis 
All sequencing reactions were performed by DNA Sequencing and Services, an 
MRC unit at the University of Dundee. DNA templates were supplied ready mixed 
with appropriate primers at the requested concentrations depending on the source 
material to be sequenced. A complete list of primers is given in Table A1.5. 
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2.10 IBV reverse genetics and rescue of recombinant viruses 
 
All rIBVs used in these studies were generated using the IBV reverse genetics 
system developed in the Coronavirus Group at IAH (Britton, et al. 2005, Casais, et 
al. 2001). The following sections describe the different stages, and the methods used, 
to generate rIBVs. 
 
2.10.1 Generation of recombinant vaccinia virus by homologous recombination 
The reverse genetics system for generating rIBVs is based on a process of transient 
dominant selection (TDS) (Falkner and Moss 1990). The initial stage involves a 
recombination event between an IBV cDNA clone in a recombinant vaccinia virus 
(rVV) and a plasmid containing a modified stretch of IBV genome. Each individual 
rIBV requires an appropriately modified region of the IBV cDNA genome inserted 
into selection plasmid pGPTNEB193 (Appendix 2), a modified version of pNEB193 
that also contains the E. coli Ecogpt gene (GPT) that codes for guanine-xanthine 
phosphoribosyltransferase. Details are given in individual results chapters as to how 
the modified genome regions and GPT plasmids were constructed for each rIBV. 
 
Each modified pGPT plasmid was used to generate a rVV containing a correctly 
modified IBV cDNA. Vero cells grown to 70% confluency in 6-well culture plates 
were infected with vNotI/IBVFL at an MOI equivalent to 0.2 pfu per cell and 
incubated for 2 h. Culture medium was removed and cells transfected with 5 g of 
GPT plasmid DNA using 12 L Lipofectin® (Life Technologies) as per 
manufacturer’s instructions, in a final volume of 3mL OPTI-MEM (Life 
Technologies). Transfection medium was replaced after 1 h with 3mL of 1X BES 
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medium and incubated for a further 24 h to allow for the occurrence of a 
recombination event between the IBV cDNA clone in vNotI/IBVFL and the modified 
IBV genome region in the GPT selection plasmid. A successful recombination event 
results in the production of an unstable virus intermediate containing the modified 
IBV sequence and the GPT gene (Fig. 2.2). 
 
2.10.2 Transient dominant selection 
The unstable virus intermediate was maintained by the addition of GPT selection 
components at 24 h consisting of 25 g/mL mycophenolic acid (MPA), 250 g/mL 
xanthine and 15 g/mL hypoxanthine. As MPA is an inhibitor of purine biosynthesis 
replication of vaccinia virus is blocked in its presence. The presence of the GPT gene 
provides an alternative pathway for purine biosynthesis when xanthine and 
hypoxanthine are also supplied. 
 
Following a 48 h incubation in the presence of selection components cell-associated 
virus was harvested by centrifugation at 13K rpm, 4°C for 3 min (Biofuge fresco, 
Heraeus) and cell pellets resuspended in 500 L of EMEM. Recombinant vaccinia 
viruses expressing GPT were selected for by three rounds of plaque purification on 
Vero cells in the presence of selection components (see 2.5). This was followed by 
three rounds of plaque purification in the absence of selection components, which 
results in the rapid loss of GPT and one of two possible virus outcomes depending 
on a second recombination event (Fig. 2.2). Around 50% of viruses revert to the 
original virus while the other 50% will contain the desired modification to the IBV 
cDNA. Plaque purified rVVs were screened by sequence analysis to identify those 
rVVs containing the correct modification to the IBV cDNA, and were GPT-negative. 
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Fig. 2.2. Schematic of transient dominant selection. The schematic shows the four 
stages of the TDS process. (1) Recombination event between the modified genome 
fragment of the GPT selection plasmid and the IBV cDNA in vNotI/IBVFL. (2) 
Maintenance of an unstable intermediate during plaque purification under positive 
selection. (3) Second recombination event following plaque purification in the 
absence of selection components. (4) The possible outcomes of the second 
recombination; reversion to wild type or incorporation of the genome modification. 
 
 
2.10.3 Isolation of rVV DNA 
Individual rVVs were grown in 11 T150 flasks of BHK-21 cells until cytopathic 
effect (CPE) was observed. Infected cells were harvested and resuspended in Tris-
EDTA (TE) buffer, pH9 at a volume of 1mL/T150 flask of cells. Cells were lysed by 
three cycles of freeze-thawing, sonicated and cell nuclei pelleted by centrifugation at 
1200 rpm, 4°C for 10 min (ALC, PK121R). Supernatant was transferred to a clean 
50mL tube and volume adjusted to 13mL with TE buffer, pH9. Virus particles were 
partially purified by centrifugation through a 30% sucrose cushion at 14K rpm, 4°C 
4) Return to original
4) Modified vNotI/IBVFL containing eGFP in place of 5a/5b
2) Unstable Intermediate
1) First recombination event
3) Second recombination event
M 5bIR eGFP N
GPT
vv
M 5bIR 5a N3SpikeReplicase
vv
GPTM 5bIR eGFP N
vv vv
M 5bIR 5a N3SpikeReplicase
M 5bIR eGFP N3SpikeReplicase
vv vv
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for 1 h (Sorvall WX Ultra-80, Surespin 630 Sorvall Rotor (Thermo Scientific)) and 
resuspended in 5mL of TE buffer, pH9. 
 
Partially purified virus was incubated in an equal volume of 2X proteinase K buffer 
(400mM NaCl, 200mM Tris/HCl pH 7.5, 10mM EDTA, 0.4% SDS),  containing 
200 g/mL proteinase K for 2.5 h at 50°C. DNA was extracted by 2 x phenol-
chloroform and 1 x chloroform extraction and DNA ethanol precipitated. DNA 
pellets were re-dissolved by the addition of 100 L water and incubation at 4°C 
overnight. 
 
2.10.4 Pulsed field gel electrophoresis 
Vaccinia virus DNA was examined by pulsed field electrophoresis. One g of rVV 
DNA was restriction digested with SalI for 3 h at 37°C in a 20 L final volume 
reaction. Loading buffer was added to DNA samples and heated for 10 min at 65°C. 
DNA was separated on a 0.8% agarose gel (Pulsed Field Certified Agarose, Bio-Rad 
Laboratories) prepared in 0.5X TBE buffer using a pulsed field gel electrophoresis 
tank. DNA samples were run against CHEF DNA Size Standards 8-48 Kb (Bio-Rad 
Laboratories). Conditions for running the gel were; initial pulse time of 0.1 sec, final 
pulse time of 1.0 sec, 6.0 V/cm for 12 h. The gel was stained in MQ water containing 
0.1 g/mL ethidium bromide for 30 min. Visualization of a DNA product at 33.5Kb, 
corresponding to the IBV cDNA, was required to confirm that the rVV DNA was 
intact and suitable for rescue of rIBVs (Fig. 2.3). 
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Fig. 2.3. Pulsed field gel analysis of rVV. (A) Pulsed field gel analysis comparing 
SalI digested vNotI/tk (without IBV cDNA) and vNotI/IBVFL (with IBV cDNA) 
(Casais, et al. 2001). (B) Example of pulsed field analysis of generated recombinant 
viruses rVVBeauR-hRluc 5ab and rVVBeauR-eGFP IR. 
 
 
2.10.5 Rescue of recombinant IBVs 
Recombinant IBVs were rescued on primary CK cells cultured in 6-well tissue 
culture plates. Synthesis of infectious IBV RNA, that is equivalent to genomic RNA, 
is driven by T7 polymerase expressed from recombinant fowlpox rFPV-T7. The 
infectious IBV RNAs are subsequently used as templates for further rounds of 
replication of the virus. 
 
Confluent monolayers of CK cells were infected with rFPV-T7 at an MOI of 10 and 
incubated for 1 h. Virus inoculum was removed and cells washed once with OPTI-
MEM (Life Technologies). Cells were transfected with 10 g of rVV DNA plus 5 g 
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of pCi-Nuc, a plasmid expressing the IBV N protein and essential for rescue, in a 
total volume of 3mL of OPTI-MEM containing 30 L Lipofectin (Life 
Technologies). Cells were incubated overnight, transfection medium removed and 
5mL of 1X BES added. Following a 48 h incubation the cell supernatant was 
harvested and passed through 0.22 m filters to remove any fowlpox virus. Cell 
supernatants containing any potential rescued rIBVs were subsequently passaged on 
CK cells. One mL of supernatant was used to inoculate 1x T25 flask of confluent CK 
cells and following a 1 h incubation inoculum was removed and 3mL of 1X BES 
medium added to flask. Cells were incubated for 3-4 days, or until IBV-induced CPE 
was observed, and supernatants harvested. Supernatants were passaged a total of 3 
times on CK cells before further analysis. 
 
2.11 Protein methods 
 
2.11.1 Western blot analysis 
Confluent monolayers of CK cells were infected with 1x10
5
 pfu virus. At 20 hpi 
cells were washed twice with PBS and lysed with 20mM Tris, 150mM NaCl, 5mM 
EDTA, 0.3% Triton X100 and 1X protease inhibitor cocktail (Sigma) for 15 min on 
ice, and clarified by centrifugation for 5 min at 4°C (Biofuge fresco, Heraeus). Cell 
lysates in 13 L sample volumes were heated at 70°C for 10 min with 5 L NuPage 
Sample Buffer (Life Technologies) and 2 L 25% -mercaptoethanol and separated 
on 10% Bis-Tris precast gels (Life Technologies). Samples were transferred to 
nitrocellulose membrane (Amersham Hybond ECL nitrocellulose membrane) and 
probed with antibody. Primary antibodies were diluted in PBS containing 10% 
Tween 20; (1) anti-IBV polyclonal antibody (non-commercial) at a dilution of 
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1/2500, (2) anti-beta Actin polyclonal antibody (Abcam) at a dilution of 1/500, (3) 
anti-GFP polyclonal antibody (Abcam) at a dilution of 1/1000, (4) anti-Renilla 
Luciferase polyclonal antibody (MBL International) at a dilution of 1/1000. Bound 
antibody was visualized using an enhanced-chemiluminescence detection system 
(ECL) (Millipore). 
 
2.11.2 Luciferase assay 
Cell lysates were prepared from IBV-infected CK cells and 20 L samples analysed 
for luminescence using the Renilla Luciferase Assay System (Promega) as per 
manufacturer’s instructions. Luminescence values were obtained using a GloMax® 
20/20 luminometer (Promega) with integration over 10-seconds with a 2-second 
delay. 
 
2.11.3 BCA protein assay 
Protein concentrations were calculated from cell lysates generated for Renilla 
luciferase assays using a BCA protein assay (Pearce). Due to incompatibilities with 
the Renilla Luciferase Assay System lysis buffer, samples were first acetone 
precipitated to remove traces of buffer. Cell lysates were clarified by centrifugation 
and to each sample was added 4 volumes of -20°C acetone. Samples were incubated 
at -20°C for 1 h followed by centrifugation for 10 min at 13K rpm (Biofuge Pico, 
Heraeus). Supernatants were removed and protein pellets left to air dry before being 
resuspended in a volume of sterile water equal to the original sample volume. 
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BCA assays were carried out using the protocol for microtitre well plates as per 
manufacturer’s instructions, with protein samples diluted 1/10 in sterile water and 
readings taken at 540nm. 
 
2.12 Bright field and fluorescence microscopy 
 
All bright field images were captured on an EVOS xl digital inverted microscope. 
All fluorescence images were captured on a Leica DM IRB inverted microscope 
attached to a camera. 
 
2.13 Confocal microscopy 
 
Monolayers of Vero cells at 70% confluency and grown on coverslips in 24-well 
tissue culture plates were infected with 1x10
5
 pfu of rIBV. At 18 hpi cells were 
washed twice with PBS and fixed with 4% paraformaldehyde for 10 min. Cells were 
washed once with PBS and permeabilised with PBS containing 0.5% Triton X100 
for 15 min with shaking. Cells were blocked with PBS containing 0.5% BSA for 1 h 
with shaking. Primary antibodies were prepared in PBS containing 0.5% BSA and 
added for 1 h with shaking: (1) anti-IBV polyclonal antibody (non-commercial) at a 
dilution of 1/1000, (2) anti-Renilla Luciferase polyclonal antibody (MBL 
International) at a dilution of 1/500. Cells were washed 3 x 5 min with PBS. 
Secondary antibodies were prepared in PBS containing 0.5% BSA and added at a 
1/200 dilution for 1 h with shaking: (1) Alexa-Fluor 568-goat anti-rabbit for 
detection of anti-IBV binding (Life Technologies), (2) Alexa-Fluor 488-goat anti-
rabbit for detection of anti-Renilla Luciferase binding (Life Technologies). Cells 
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were washed 3 x 5 min in PBS. DAPI stain (Life Technologies) was added at 
1/20,000 dilution in water for 10 min with shaking. DAPI stain was removed and 
coverslips mounted on slides. All images were taken using a Leica TCS 
SP5DM6000 confocal microscope and analysed using Leica Microsystems LAS AF 
software. 
 
2.14 Quantitative PCR 
 
Confluent monolayers of CK cells were infected with 1x10
5
 pfu of Beau-R, BeauR-
L-CTGAACAA, BeauR-L-CTTAACAT or BeauR-IR-CTGAACAA and 
intracellular RNA harvested at 18 hpi. From each infection the IR and Gene 3 
mRNAs were amplified for analysis along with 28S rRNA to act as a housekeeping 
gene. 
 
Reverse transcription 
RNA was reverse transcribed using TaqMan® Reverse Transcription Reagents as 
supplied (Applied Biosystems). To ensure only mRNAs, and not negative sense 
RNAs, were reverse transcribed only reverse primers were used for the generation of 
cDNA (Table 2.5): 
 
10x Reaction buffer 1 L  
 
 
48°C – 30 min 
95°C – 5 min 
MgCl2 2.2 L 
dNTP 2 L 
Reverse Primer (2 M) 1 L 
RNAsin 0.2 L 
Reverse Transcriptase (RT) 0.25 L 
RNAse free water 1.35 L 
RNA (250ng/ L) 2 L 
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For each cDNA generated a no-RT reaction was included to control against non-
target amplification during the PCR. 
 
Standard curves 
To quantify the mRNA levels for each virus standard curves were generated for each 
of the three genes to be amplified. The 28S standard curve was generated using 
Beau-R cDNA that was 10-fold serially diluted and PCRs run on 10
-1–10-8 samples. 
For the Gene 3 and IR standard curves the relevant sequences were amplified by 
PCR and cloned into pcDNA3.12(-) (Life Technologies) using restriction sites 5'-
XhoI and 3'-HindIII (Table 2.5). Plasmid DNA was 10-fold serially diluted from a 
starting concentration of 100pg/ L. 
 
qPCR 
The synthesised cDNAs were subsequently used as templates for specific PCR 
amplification. Trial experiments demonstrated that all test cDNAs be diluted 10
-4
 to 
give Ct values that fit to the relevant standard curve. All primer and probe sequences 
are shown in Table 2.5. Samples were run using Applied Biosystems TaqMan Fast 
Universal PCR Master Mix and the following conditions: 
 
TaqMan Fast Universal PCR Master Mix (2x) 5 L  
 
95°C – 20 sec 
95°C – 3 sec 
60°C – 30 sec        
Probe (5 M) 0.25 L 
Primers (F and R) (Final 1 M) 0.2 L 
Water  2.05 L 
cDNA 2.5 L 
 
 
For each sample a no-template control containing water instead of cDNA was 
included to control against sample contamination. 
x 40 
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Data analysis 
Amplification plots were analysed using Applied Biosystems Sequence Detection 
Software version 1.3.1.21 and the average Ct values for each sample calculated. 
Standard curves were generated using all points falling within the linear range from 
the relevant dilution series, and these were then used to calculate the amount of DNA 
in each sample based on the Ct value. All Ct values were normalized to 28S to 
standardize each sample. The IR values were additionally normalized against the 
Gene 3 Ct values for each virus to account for any differences between virus 
replication rates of the different rIBVs. Finally IR mRNA levels of each rIBV were 
calculated as a fold-change compared to wild type Beau-R levels. 
 
 
TABLE 2.5: qRT-PCR Primer and Probe Sequences 
Primer/Probe Sequence  
Primer qPCR Cloning (F) ATCGCTCGAGCTAGCCTTGCGCTAGATTTT
TAAC 
IR Cloning (R) GCATAAGCTTGCATAGACAAACGTAGCAA
ACCTTT 
Gene 3 Cloning (R) GCATAAGCTTCGTGGGACTTTGGATCATC
AAAC 
28S (F) GGGGAAGCCAGAGGAAACT 
28S (R) GACGACCGATTTGCACGTC 
IBV (F) CTAGCCTTGCGCTAGATTTTTAACT 
Gene 3 (R) TGGGACTTTGGATCATCAAACA 
IR (R) GCATAGACAAACGTAGCAAACCTTT 
Probe 28S 6FAM-AGGACCGCTACGGACCTCCACCA-
TAM 
Gene 3 6FAM-CAATACAGACCTAAAAAGT-MGB 
IR 6FAM-ACAAAGCGGAAATAA-MGB 
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Chapter 3: Generation of recombinant IBVs to investigate 
the potential of IBV as a vaccine vector 
 
3.1 Introduction 
 
The initial aim of this project was to investigate the potential for using IBV as a 
vaccine vector. This was achieved through the generation of a series of rIBVs, 
expressing a heterologous protein, and the subsequent analysis of these 
recombinants. The use of coronaviruses as vaccine vectors has been investigated 
with a number of different viruses. These studies showed that the expression of 
heterologous proteins is dependent on a number of factors, as outlined by de Haan et 
al. (de Haan, et al. 2005, de Haan, et al. 2003). These factors include the genetic 
background of the virus, the location at which the heterologous gene is inserted and, 
if replacing genes, how essential these genes are to the replication of the coronavirus. 
 
Using these criteria as a guideline this project aimed to identify the best rIBV 
construct for use as a vaccine vector. Recombinant viruses were designed with the 
aim of answering four fundamental questions regarding the expression of 
heterologous genes and the stability of the resultant rIBVs. 
 
1. Does the position of the heterologous gene within the IBV genome affect gene 
expression and virus stability? 
 
Previous work by the IAH Coronavirus group showed that the group-specific genes 
encoding accessory proteins 3a/3b and 5a/5b could be deleted, or expression 
Chapter Three 
49 
 
prevented, without affecting replication of the virus in cell culture (Casais, et al. 
2005, Hodgson, et al. 2006). Additionally, the region referred to as the IR, located 
between the M gene and Gene 5, had also been shown to be dispensable for virus 
replication in cell culture (unpublished observations). Recombinant viruses were 
designed to express heterologous genes, individually from each of the three 
locations, and to subsequently identify the best location in terms of heterologous 
gene expression and virus stability. 
 
2. Does the size, or type, of heterologous protein inserted affect gene expression or 
stability? 
 
For each location of the genome to be replaced two rIBVs were designed with the 
insertion of one of two possible reporter genes, eGFP and hRluc. By generating 
isogenic pairs of rIBVs, where only the heterologous gene is altered, it is possible to 
identify any differences in protein expression or virus stability that are influenced by 
the protein itself. The decision to use reporter genes eGFP and hRluc was based on 
the ability to have a visual output of gene expression in the form of fluorescing 
(eGFP), or light emitting (hRluc) cells, thus aiding in analysis of protein expression. 
Additionally, these proteins differ in size by approximately 200bp thus allowing a 
limited investigation into whether virus stability is affected by the size of the gene 
inserted. The fLuc gene would have allowed for a greater comparison of gene sizes 
than hRluc, as it is over twice the size of eGFP. However, previous attempts to use 
fLuc in IBV D-RNA constructs did not lead to stable D-RNA production (Stirrups, 
et al. 2000). Therefore, hRluc was chosen over fLuc to maximise the chances of 
producing viable rIBVs. 
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3. Does codon optimization of the heterologous gene affect virus stability? 
 
Both reporter genes to be used in this study have been optimized for expression in 
mammalian systems through manipulation of the amino acid, and nucleotide, 
sequence of the gene (Zhang, et al. 1996, Zhuang, et al. 2001). It was hypothesised 
that altering the nucleotide sequence of each gene, so that codon usage better 
represents that utilized by IBV and avian cells, virus stability would be improved. To 
limit the number of rIBVs to be made, comparison of optimized and non-optimized 
genes was planned with rIBVs replacing Gene 5 only. 
 
4. Is recombinant virus stability improved by fusion of the heterologous protein to 
an existing virus protein? 
 
It was hypothesised that by coupling expression of the heterologous protein to 
expression of an existing virus protein the resulting recombinant virus would be 
more stable. Due to the overlapping nature of many of the IBV genes there were 
limited options to test this hypothesis, with the most suitable being the fusion of the 
reporter gene to the C-terminus of accessory protein 5a. Only eGFP was tested in 
this construct to keep the fusion protein as small as possible and again, limit the 
number of rIBVs that needed to be made. 
 
Based on the questions outlined above the generation of nine rIBVs was planned to 
investigate the potential for using IBV as a vaccine vector (Fig. 3.1). This chapter 
details the construction of each of these recombinants while Chapters 4 and 5 discuss 
the subsequent analysis of the rIBVs in terms of growth and protein expression 
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(Chapter 4) and virus stability (Chapter 5). Due to the inter-linked nature of the three 
chapters all of the data will be discussed together at the end of Chapter 5. 
 
 
 
Fig. 3.1. Schematic of recombinant IBVs. The genome of wild type Beau-R is 
shown with each of the recombinant virus genomes below. Each rIBV genome 
shows the replacement of a particular genome region with either eGFP or hRluc. 
 
 
3.2 Generation of heterologous gene constructs 
 
The first step of the IBV reverse genetics system (described in full in section 2.10) 
was the generation of a modified IBV genome fragment, containing the desired 
changes to the IBV genome for each different rIBV, and subsequent cloning of this 
fragment into plasmid pGPTNEB193. These modified plasmids were then used in 
the transient dominant selection stage of the reverse genetics system. Different 
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strategies were used to generate appropriate plasmids for each of the different 
recombinant viruses. 
 
3.2.1 Generation of pGPT-eGFP 5ab and pGPT-hRluc 5ab 
 
Generation of plasmids for recombinant viruses BeauR-eGFP 5ab and BeauR-
hRluc 5ab utilized a series of overlapping PCRs to obtain genome fragments, 
containing reporter genes, that could subsequently be cloned into plasmid 
pGPTNEB193. The sequence of Beau-R Gene 5 to be replaced by the reporter genes 
was determined by the previously successful deletion of Gene 5 between nucleotides 
25488 and 25702 inclusive (unpublished data from IAH Coronavirus group), which 
resulted in the entire deletion of ORF 5a and deletion of the first 7 amino acids of 
ORF 5b. It had not been possible in this construct to delete the entire of ORF 5b as 
this ORF overlaps with the N gene ORF at the 3'-end and additionally contains the N 
gene TRS required for transcription. As the N protein is essential to replication the 
majority of the ORF 5b sequence therefore needed to be retained. Genome fragments 
were designed with approximately 400bp of IBV sequence either side of the reporter 
gene to allow for homologous recombination events in the vaccinia clone. Genome 
fragment sequences can be found in Appendix 3. 
 
Genome fragments were split into three sections (A, B and C) and PCR primers 
designed to amplify each of the sections with an approximate 20bp overhang of the 
neighbouring section (Table A1.1; Fig. 3.2,). IBV sequences were amplified from 
vNotI/IBVFL while eGFP and hRluc were amplified from plasmids pEGFP-C1 
(Clontech) and pGL4.75hRluc/CMV (Promega) respectively. To facilitate cloning of 
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the completed fragment, restriction sites were added to the 5'-end of section A (AscI) 
and to the 3'-end of section C (PacI). 
 
 
 
Fig. 3.2. Schematic of overlapping PCR. Sections A, B and C were amplified by 
PCR from IBV or plasmid templates. The three sections were joined by further 
rounds of PCR to generate the modified genome fragment. 
 
 
Modified genome fragments were amplified by PCR (see section 2.9) and cloned 
into plasmid pGPTNEB193, as outlined in Fig. 3.3, to yield plasmids pGPT-
eGFP 5ab and pGPT-hRluc 5ab (Fig. 3.4). 
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Fig. 3.3. Overlapping PCR process. Flowchart outlining the steps taken to generate 
plasmids pGPT-eGFP 5ab and pGPT-hRluc 5ab by overlapping PCR. 
 
 
A            B 
  
 
Fig. 3.4. Plasmid maps ∆5ab constructs. Plasmid maps for (A) BeauR-eGFP 5ab 
and (B) BeauR-hRluc 5ab showing the modified IBV genome fragment within 
plasmid pGPTNEB193. 
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3.2.2 Generation of pGPT-eGFP IR and pGPT-hRluc IR 
 
To generate plasmids pGPT-eGFP IR and pGPT-hRluc IR, plasmid pGPT IR 
previously made in the IAH Coronavirus group was utilized. This plasmid contains a 
268bp deletion in the Beau-R intergenic region (nucleotides 25192 to 25459 
inclusive) and an inserted multiple cloning site adapter (see Appendix 2 for plasmid 
map).  Restriction sites NheI and XmaI were added by PCR to the 5'- and 3'-end of 
each reporter gene respectively, using overlapping PCR cycle parameters. Primer 
sequences can be found in Table A1.2. Amplified reporter gene sequences were NheI 
and XmaI digested, processed through a nucleotide removal column and 
subsequently ligated into plasmid pGPT IR to generate plasmids pGPT-eGFP IR 
and pGPT-hRluc IR with a complete genome fragment encompassing ORF 3c to the 
N gene (Fig. 3.5) (see Appendix 3 for sequences). 
 
A            B 
  
Fig. 3.5. Plasmid maps ∆IR constructs. Plasmid maps for (A) BeauR-eGFP IR 
and (B) BeauR-hRluc IR showing the modified IBV genome fragment within 
plasmid pGPT IR. 
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3.2.3 Generation of pGPT-IBVeGFP 5ab and pGPT-IBVhRluc 5ab 
 
The first stage in generation of plasmids pGPT-IBVeGFP 5ab and pGPT-
IBVhRluc 5ab was codon optimization of reporter genes eGFP and hRluc to be 
more IBV-like. An IBV codon usage table was generated using the Codon Usage 
Database program hosted at www.kazusa.or.jp/codon/ (Table 3.1). 
 
 
TABLE 3.1: IBV Codon Usage 
*/Infectious bronchitis virus /[gbvrl]: 785 CDS's (286941 codons)* 
-------------------------------------------------------------------- 
        fields: [triplet] [frequency: *per thousand*] ([number]) 
-------------------------------------------------------------------- 
 
UUU 42.3(12136)  UCU 22.2(6359)  UAU 29.9( 8580)  UGU 22.3( 6395) 
UUC 10.0( 2859)  UCC  3.1( 879)  UAC 12.2( 3487)  UGC  5.8( 1653) 
UUA 18.6( 5339)  UCA 18.3(5254)  UAA  1.3(  376)  UGA  1.0(  292) 
UUG 14.3( 4101)  UCG  3.0( 871)  UAG  0.4(  113)  UGG 14.8( 4247) 
 
CUU 24.9( 7142)  CCU 18.5(5312)  CAU  8.7( 2500)  CGU 12.2( 3501) 
CUC  5.4( 1541)  CCC  5.0(1428)  CAC  5.3( 1533)  CGC  5.6( 1612) 
CUA 11.4( 3266)  CCA 20.0(5733)  CAA 24.2( 6937)  CGA  2.5(  708) 
CUG  7.2( 2057)  CCG  4.0(1138)  CAG 18.8( 5381)  CGG  1.5(  424) 
 
AUU 27.2( 7813)  ACU 26.5(7618)  AAU 44.0(12624)  AGU 21.6( 6186) 
AUC  5.6( 1596)  ACC  4.8(1379)  AAC 12.8( 3671)  AGC  5.9( 1690) 
AUA 19.7( 5643)  ACA 20.9(6004)  AAA 31.1( 8924)  AGA 16.0( 4605) 
AUG 15.5( 4434)  ACG  4.9(1415)  AAG 30.6( 8769)  AGG  8.2( 2341) 
 
GUU 33.3( 9556)  GCU 25.7(7371)  GAU 38.3(10980)  GGU 39.4(11297) 
GUC  7.7( 2198)  GCC  8.0(2302)  GAC 15.6( 4482)  GGC  8.1( 2332) 
GUA 18.8( 5383)  GCA 27.4(7874)  GAA 26.2( 7506)  GGA 18.6( 5347) 
GUG 14.6( 4199)  GCG  6.7(1916)  GAG 17.4( 4979)  GGG  4.7( 1353) 
 
---------------------------------------------------------------------- 
Coding GC 39.32% 1st letter GC 48.54% 2nd letter GC 40.72% 3rd letter 
        GC 28.71% 
---------------------------------------------------------------------- 
 
 
The codon usage table was input, along with amino acid sequences for eGFP and 
hRluc, into the EMBOSS backtranseq application (details at http://emboss.open-
bio.org/). Nucleotide sequences were derived for both eGFP and hRluc where codon 
usage mirrored the predominant codon usage of IBV (see Appendix 4). Additionally, 
to confirm the results of the backtranseq programme the eGFP sequence was 
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manually altered and found to be identical to the computer generated sequence. The 
codon optimized sequences were placed in context of the larger genome fragment 
used for pGPT-eGFP 5ab and pGPT-hRluc 5ab to give the complete sequence for 
cloning into pGPTNEB193 (see Appendix 3). The entire sequences, with AscI and 
PacI restriction sites at the 5'- and 3'-end respectively, were sent to GeneArt® for 
gene synthesis. Once synthesised GeneArt® were additionally tasked with cloning 
the sequences into pGPTNEB193 to give plasmids pGPT-IBVeGFP 5ab and pGPT-
IBVhRluc 5ab. Plasmid maps are identical to those for pGPT-eGFP 5ab and 
pGPT-hRluc 5ab (see Fig. 3.4). 
 
3.2.4 Generation of pGPT-eGFP 3ab and pGPT-hRluc 3ab 
 
The initial step in constructing plasmids pGPT-eGFP 3ab and pGPT-hRluc 3ab 
was to determine the sequence of Gene 3 that could be deleted whilst maintaining 
the E protein (ORF 3c) that is also translated from the Gene 3 mRNA. It was also 
necessary to take into account the overlapping spike stop and ORF 3a initiation 
codons. It was therefore decided to replace the Beau-R genome from position 23857 
to 24203 inclusive, with eGFP or hRluc. In order to ensure transcription of a mRNA 
for ORF 3c a single copy of the Gene 5 TRS, along with flanking nucleotides, was 
inserted between the reporter gene stop and the E protein start codons (see Appendix 
3). Due to the complexity of the sequences, gene synthesis and cloning into 
pGPTNEB193 was again contracted to GeneArt® for construction of pGPT-
eGFP 3ab and pGPT-hRluc 3ab (Fig. 3.6). 
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A            B 
  
Fig. 3.6. Plasmid maps ∆3ab constructs. Plasmid maps for (A) BeauR-eGFP 3ab 
and (B) BeauR-hRluc 3ab showing the modified IBV genome fragment within 
plasmid pGPTNEB193. 
 
 
3.2.5 Generation of pGPT-ORF5a/eGFP 
 
Generation of plasmid pGPT-ORF5a/eGFP, for the fusion protein recombinant virus, 
also required gene synthesis and cloning by GeneArt®. To create the fusion protein, 
the eGFP sequence, minus the initiation codon, was added to the 3'-end of ORF 5a 
with the stop codon deleted. The sequence then continued with ORF 5b as for wild 
type, with the complete genome fragment consisting of the M gene to the N gene 
(see Appendix 3). The genome fragment was cloned into pGPTNEB193 using AscI 
and PacI restriction sites (Fig. 3.7). 
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Fig. 3.7. Plasmid map 5a fusion. Plasmid map for pGPT-ORF5a/eGFP showing the 
modified IBV genome fragment within plasmid pGPTNEB193. 
 
 
3.3 Generation of recombinant IBVs expressing heterologous genes 
 
The successful rescue of recombinant viruses was initially characterized by progress 
through four main steps: 
1. Generation of a pGPT plasmid containing the correctly modified IBV 
genome sequence as confirmed by sequence analysis. 
2. Generation of two recombinant vaccinia viruses containing the correctly 
modified full-length IBV cDNA clone. Vaccinia viruses were taken from as 
distinct plaque lineages as possible and confirmed by sequence analysis of 
the modified region. 
3. Rescue of rIBV from vaccinia viruses as confirmed by observation of CPE in 
CK cells by passage (P) 3. 
4. Confirmation of presence of reporter gene, by RT-PCR, in two replicates (R1 
and R2) of rIBV. 
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The PCR process used to amplify virus regions for sequence analysis of the modified 
IBV cDNA clones (step 2), and the RT-PCR process used to confirm the successful 
rescue of each rIBV (step 4), used specific primer pairs (Table A1.4) to amplify a 
region of the IBV genome containing the inserted reporter gene. PCR products were 
subsequently analysed by gel electrophoresis. The expected PCR products for each 
recombinant are listed in Table 3.2. 
 
 
TABLE 3.2: Confirmation PCR Products 
Virus Primer Set PCR 
Product (bp) 
BeauR-eGFP 5ab/ 
BeauR-IBVeGFP 5ab 
5abS + BG147 963 
BeauR-hRluc 5ab/  
BeauR-IBVhRluc 5ab 
5abS + BG147 1179 
BeauR-eGFP IR BG52 + BG146 1087 
BeauR-hRluc IR BG52 + BG146 1303 
BeauR-eGFP 3ab BG49 + BG144 1700 
BeauR-hRluc 3ab BG49 + BG144 1916 
BeauR-5a/eGFP 5abS + BG148 1475 
 
 
The success, or failure, of each rescue is summarized in Table 3.3. As shown three of 
the planned viruses, BeauR-IBVeGFP 5ab, BeauR-eGFP 3ab and BeauR-5a/eGFP, 
did not result in a rescued rIBV. For all other viruses two replicates of each were 
successfully rescued, as determined by RT-PCR analysis described above, and were 
taken forward for further analysis (see Chapters 4 and 5). 
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TABLE 3.3: Rescue of Recombinant IBVs 
Virus pGPT 
Plasmid 
rVV 
Clones 
rIBV 
CPE 
rIBV 
PCR 
BeauR-eGFP 5ab     
BeauR-hRluc 5ab     
BeauR-IBVeGFP 5ab  N/A N/A N/A 
BeauR-IBVhRluc 5ab     
BeauR-eGFP IR     
BeauR-hRluc IR     
BeauR-eGFP 3ab    N/A 
BeauR-hRluc 3ab     
BeauR-5a/eGFP     
 
The three viruses that were not rescued each failed at different stages of the reverse 
genetics process as described below. 
 
3.3.1 Investigation of BeauR-IBVeGFP 5ab 
 
Attempts to generate a recombinant virus containing a codon optimized version of 
eGFP in place of Gene 5 did not go beyond initial attempts to clone the modified 
genome fragment into plasmid pGPTNEB193. The genome fragment was correctly 
synthesised by GeneArt®, as confirmed by sequence analysis, however they were 
unable to clone the fragment into plasmid pGPTNEB193. Analysis of the genome 
fragment revealed no obvious reasons for the failure, i.e. toxic sequences, and 
several competent cell lines were tried without success (personal communication 
from GeneArt®). The synthesised genome fragment was provided in the form of a 
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PCR product. Several further attempts were made by myself to clone this fragment 
though none were successful and therefore this construct was taken no further. 
 
3.3.2 Investigation of BeauR-eGFP 3ab 
 
Two correctly sequenced vaccinia viruses were obtained for BeauR-eGFP 3ab 
however, no rIBVs could be rescued from these viruses. The rescue process in CK 
cells was carried out a total of three times using fresh preparations of vaccinia virus 
DNA each time. At each attempt no CPE could be seen in any cells up to, and 
including, P3 of the virus. To confirm that the lack of CPE was due to a lack of virus 
and not due to potentially altered growth characteristics, RT-PCRs were carried out 
at P3 of each attempt to look for virus RNA. This RT-PCR was carried out using 
primers BG56 and 93/100, which cover the 3' UTR of the virus. As an essential 
region of the virus a positive RT-PCR result would demonstrate that the virus is 
present in some form. All RT-PCRs showed negative results confirming that this 
virus did not rescue in CK cells. 
 
Previously in the IAH Coronavirus group some rIBVs had been shown to rescue 
only when passaged in embryonated eggs, believed to be a consequence of the 
increased efficiency of virus replication in eggs. An attempt was therefore made to 
rescue BeauR-eGFP 3ab by passage in embryonated hens’ eggs. Passage 0 was 
carried out in CK cells as normal but any potential virus harvested in the cell culture 
medium was immediately inoculated into 10-day old Rhode Island Red embryonated 
hens’ eggs for P1. Allantoic fluid harvested from these eggs, at 20 h post inoculation, 
was subsequently passaged twice more in eggs and then screened by RT-PCR as 
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above to check for the presence of virus. Again, all RT-PCRs were negative 
confirming that this virus could not be rescued. The lack of rescued virus meant that 
this construct could also not be studied any further. 
 
3.3.3 Investigation of BeauR-5a/eGFP 
 
Recombinant virus BeauR-5a/eGFP was identified as a successful rescue as defined 
by the observation of CPE by P3 in CK cells. However, when RT-PCRs were carried 
out to confirm the presence of eGFP unexpected results were observed. Using 
primers 5abS and BG148, which flank the modified region, a PCR product of 
1475bp was expected, but instead a product of between 650bp and 850bp was 
observed (Fig. 3.8). 
 
 
Fig. 3.8. RT-PCR confirmation of BeauR-5a/eGFP rescue. Presence of eGFP was 
investigated by RT-PCR of P3 rescued virus. Two rescued replicates (A and B) from 
each vaccinia virus lineage were tested and a PCR product of between 650bp and 
850bp was confirmed in all four viruses. Lane L; DNA marker. 
 
The size of the PCR product observed is between 625bp and 825bp smaller than that 
expected and suggests the deletion of the eGFP gene, the size of which falls into this 
range. To confirm if this was the case each rescued virus replicate was sequenced 
from the IR to the end of ORF 5b to capture any deletion (Fig. 3.9). 
AA
Lineage 1 Lineage 2
L B B
850 –
650 –
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Fig. 3.9. BeauR-5a/eGFP sequence alignment. Each replicate of BeauR-5a/eGFP 
rescued was analysed by RT-PCR with primers 5abS and BG148. Shown are partial 
alignments of each rescue with the wild type sequence. The complete eGFP 
sequence was found to be deleted in all four replicates. The starts of eGFP and 5b are 
highlighted green, the ends of 5a and eGFP are highlighted red.  
  
 
                                                                                                                                                                                                                                     5a End/eGFP Start 
BeauR-5a/eGFP: ACTTAGAGTGTTAGATAGGTTAATTTTAGATCACGGACTACTACGCGTTTTAACGTGTAGTAGGCGCGTGCTTTTAGTTCAATTAGATTTAGTTTATAGGTTGGCGTATACGCCCACCCAATCGCTGGCAGTGAGCAAGGGCGAGGAGCT 
1-A          : ACTTAGAGTGTTAGATAGGTTAATTTTAGATCACGGACTACTACGCGTTTTAACGTGTAGTAGGCGCGTGCTTTTAGTTCAATTAGATTTAGTTTATAGGTTGGCGTATACGCCCACCCAATCGCTGGC--------------------- 
1-B          : ACTTAGAGTGTTAGATAGGTTAATTTTAGATCACGGACTACTACGCGTTTTAACGTGTAGTAGGCGCGTGCTTTTAGTTCAATTAGATTTAGTTTATAGGTTGGCGTATACGCCCACCCAATCGCTGGC--------------------- 
2-A          : ACTTAGAGTGTTAGATAGGTTAATTTTAGATCACGGACTACTACGCGTTTTAACGTGTAGTAGGCGCGTGCTTTTAGTTCAATTAGATTTAGTTTATAGGTTGGCGTATACGCCCACCCAATCGCTGGC--------------------- 
2-B          : ACTTAGAGTGTTAGATAGGTTAATTTTAGATCACGGACTACTACGCGTTTTAACGTGTAGTAGGCGCGTGCTTTTAGTTCAATTAGATTTAGTTTATAGGTTGGCGTATACGCCCACCCAATCGCTGGC--------------------- 
 
 
BeauR-5a/eGFP: GTTCACCGGGGTGGTGCCCATCCTGGTCGAGCTGGACGGCGACGTAAACGGCCACAAGTTCAGCGTGTCCGGCGAGGGCGAGGGCGATGCCACCTACGGCAAGCTGACCCTGAAGTTCATCTGCACCACCGGCAAGCTGCCCGTGCCCTG 
1-A          : ------------------------------------------------------------------------------------------------------------------------------------------------------ 
1-B          : ------------------------------------------------------------------------------------------------------------------------------------------------------ 
2-A          : ------------------------------------------------------------------------------------------------------------------------------------------------------ 
2-B          : ------------------------------------------------------------------------------------------------------------------------------------------------------ 
 
 
BeauR-5a/eGFP: GCCCACCCTCGTGACCACCCTGACCTACGGCGTGCAGTGCTTCAGCCGCTACCCCGACCACATGAAGCAGCACGACTTCTTCAAGTCCGCCATGCCCGAAGGCTACGTCCAGGAGCGCACCATCTTCTTCAAGGACGACGGCAACTACAA 
1-A          : ------------------------------------------------------------------------------------------------------------------------------------------------------ 
1-B          : ------------------------------------------------------------------------------------------------------------------------------------------------------ 
2-A          : ------------------------------------------------------------------------------------------------------------------------------------------------------ 
2-B          : ------------------------------------------------------------------------------------------------------------------------------------------------------ 
 
 
BeauR-5a/eGFP: GACCCGCGCCGAGGTGAAGTTCGAGGGCGACACCCTGGTGAACCGCATCGAGCTGAAGGGCATCGACTTCAAGGAGGACGGCAACATCCTGGGGCACAAGCTGGAGTACAACTACAACAGCCACAACGTCTATATCATGGCCGACAAGCA 
1-A          : ------------------------------------------------------------------------------------------------------------------------------------------------------ 
1-B          : ------------------------------------------------------------------------------------------------------------------------------------------------------ 
2-A          : ------------------------------------------------------------------------------------------------------------------------------------------------------ 
2-B          : ------------------------------------------------------------------------------------------------------------------------------------------------------ 
 
 
BeauR-5a/eGFP: GAAGAACGGCATCAAGGTGAACTTCAAGATCCGCCACAACATCGAGGACGGCAGCGTGCAGCTCGCCGACCACTACCAGCAGAACACCCCCATCGGCGACGGCCCCGTGCTGCTGCCCGACAACCACTACCTGAGCACCCAGTCCGCCCT 
1-A          : ------------------------------------------------------------------------------------------------------------------------------------------------------ 
1-B          : ------------------------------------------------------------------------------------------------------------------------------------------------------ 
2-A          : ------------------------------------------------------------------------------------------------------------------------------------------------------ 
2-B          : ------------------------------------------------------------------------------------------------------------------------------------------------------ 
 
 eGFP Stop/5b Start 
BeauR-5a/eGFP: GAGCAAAGACCCCAACGAGAAGCGCGATCACATGGTCCTGCTGGAGTTCGTGACCGCCGCCGGGATCACTCTCGGCATGGACGAGCTGTACAAGTAATAAATGAATAATAGTAAAGATAATCCTTTTCGCGGAGCAATAGCAAGAAAAGC 
1-A          : ----------------------------------------------------------------------------------------------------ATGAATAATAGTAAAGATAATCCTTTTCGCGGAGCAATAGCAAGAAAAGC 
1-B          : ----------------------------------------------------------------------------------------------------ATGAATAATAGTAAAGATAATCCTTTTCGCGGAGCAATAGCAAGAAAAGC 
2-A          : ----------------------------------------------------------------------------------------------------ATGAATAATAGTAAAGATAATCCTTTTCGCGGAGCAATAGCAAGAAAAGC 
2-B          : ----------------------------------------------------------------------------------------------------ATGAATAATAGTAAAGATAATCCTTTTCGCGGAGCAATAGCAAGAAAAGC 
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The sequence alignment shows the precise deletion of the eGFP sequence from each 
virus replicate. As the recombinant vaccinia viruses from which the rIBVs were 
rescued had been shown by sequence analysis to contain the correctly modified 
sequence it was clear that the deletion of eGFP had occurred during passage on CK 
cells as part of the rescue process. The presence of the same deletion in all four 
replicates suggests the sequence construction of this virus was not conducive to 
production of the desired fusion protein. No further analysis of this virus was carried 
out and given timescales it was not possible to alter the virus sequence and attempt a 
different construct for generating the fusion protein recombinant. 
 
3.4 Summary 
 
 Virus was successfully rescued for six of the nine planned recombinants 
based on the presence of the reporter gene by RT-PCR: BeauR-eGFP 5ab, 
BeauR-hRluc 5ab, BeauR-IBVhRluc 5ab, BeauR-eGFP IR, BeauR-
hRluc IR and BeauR-hRluc 3ab. 
 BeauR-IBVeGFP 5ab could not be rescued, as the modified genome 
fragment could not successfully be cloned into plasmid pGPTNEB193 for 
reverse genetics. 
 BeauR-eGFP 3ab failed to rescue from correctly modified vaccinia virus 
clones for unknown reasons. 
 BeauR-5a/eGFP did not successfully rescue. Although virus was rescued the 
eGFP sequence was deleted in all replicates obtained. 
Results from this chapter will be discussed in detail in an overall discussion of 
Chapters 3-5 at the end of Chapter 5. 
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Chapter 4: Analysis of rIBV growth characteristics and 
heterologous gene expression 
 
4.1 Introduction 
 
This chapter details the analyses carried out for each of the successfully rescued 
rIBVs. Each virus was assessed on a number of criteria to establish which constructs 
are the most suitable to act as vaccine vectors. Viruses were assessed for growth on 
CK cells, transcription of the reporter gene and expression of the reporter protein. In 
some of the analyses rIBVs were compared to a parental virus as well as the wild 
type Beau-R. These parental viruses, BeauR 5ab, BeauR IR and BeauR 3ab, 
contain deletions in the Beau-R genome corresponding to the regions replaced by the 
reporter genes in the rIBVs being analysed, and were used to confirm that any 
differences between rIBVs and Beau-R were not simply due to the loss of virus 
genes. All analyses were carried out using P4 stocks of rIBVs. 
 
4.2 Characterization of rIBVs 
 
All rIBVs that rescued were initially assessed for the formation of plaques on CK 
cells to highlight any differences between wild type, or parental viruses, and the 
rIBVs (Table 4.1; Fig 4.1). 
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Fig. 4.1. Plaque morphology of rIBVs. Viruses were titrated on CK cells by plaque 
assay in 6-well culture plates. Images were taken of individual wells for each virus in 
which plaques could be counted and measured. Recombinants were compared to 
wild type Beau-R and parental viruses BeauR 5ab, BeauR IR and BeauR 3ab.
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TABLE 4.1: Recombinant IBV Plaque Size 
Virus 
Plaque Size (mm)
a
 
R1 R2 
Beau-R 3.37 ± 0.43 - 
BeauRΔ5ab 1.50 ± 0.33 - 
BeauRΔIR 2.85 ± 0.47 - 
BeauRΔ3ab 2.65 ± 0.47 - 
BeauR-eGFPΔ5ab 1.22 ± 0.34 1.32 ± 0.40 
BeauR-hRlucΔ5ab 1.28 ± 0.34 1.42 ± 0.32 
BeauR-IBVhRlucΔ5ab 1.35 ± 0.35 1.15 ± 0.30 
BeauR-eGFPΔIR 1.15 ± 0.30 1.25 ± 0.34 
BeauR-hRlucΔIR 2.23 ± 0.39 2.35 ± 0.42 
BeauR-hRlucΔ3ab 2.12 ± 0.31 1.72 ± 0.41 
a
 Average of 30 plaques from triplicate titrations ± standard deviation(SD) 
 
 
All viruses were found to form plaques on CK cells as expected with similar results 
for the two replicates. However, it is clear that plaques for all rIBVs, including 
parental viruses BeauRΔ5ab, BeauR IR and BeauR 3ab were smaller than wild 
type Beau-R. Recombinant viruses in which Gene 5 was deleted, or replaced, 
displayed the smallest plaque sizes overall and were approximately 2mm smaller in 
diameter than wild type. This suggested that the loss of Gene 5 results in some form 
of growth defect for the virus, although the reason for this cannot be deduced from 
plaque data alone. 
 
Parental virus BeauR IR showed an approximate 0.5mm reduction in diameter size 
compared to wild type indicating a minimal effect on virus growth when the IR is 
deleted. Interestingly, while BeauR-hRluc IR only showed a further size reduction 
of approximately 0.5mm for both replicates, BeauR-eGFP IR showed a further 
decrease of approximately 1.5mm suggesting that eGFP is less well tolerated than 
hRluc at this position with regard to growth on CK cells. The unsuccessful rescues of 
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BeauR-IBVeGFP 5ab and BeauR-eGFP 3ab meant that it was not possible to fully 
compare eGFP constructs to see if eGFP is generally less well tolerated, or if this 
effect is only observed following replacement of the IR. 
 
The deletion of ORFs 3a and 3b (BeauR 3ab) resulted in a similar reduction in 
plaque size to the deletion of the IR, again suggesting a minimal effect on virus 
growth on CK cells. The presence of hRluc resulted in a further small decrease in 
plaque diameter similar to the effect observed with the IR recombinants. However, 
while similar sized plaques are seen between replicates for the 5ab and IR 
recombinants this is not the case for BeauR-hRluc 3ab where a mixture of plaque 
sizes is visible for R2. Varied plaque sizes are often the result of a mixed virus 
population, and suggested that BeauR-hRluc 3ab had not rescued as a single 
population of virus (discussed further in 4.3). 
 
To further investigate the growth characteristics of the rIBVs replication kinetics 
were compared to wild type and parental viruses using multistep growth curves. 
Initially growth curves were carried out to assay R1 only for each rIBV. Comparing 
the replacement of Gene 5 with eGFP, hRluc or IBVhRluc all three rIBVs replicated 
as observed for the parental virus BeauR 5ab (Fig. 4.2). However, when compared 
to Beau-R two differences in kinetics were observed. First, all 5ab rIBVs replicated 
to approximately 1-log10 lower peak titres at 24 h than wild type suggesting an 
impairment of virus growth with the deletion of Gene 5. Second, there is a delay in 
replication at 8 h compared to wild type. A 2-log10 increase in titre is noted for Beau-
R from 1 to 8 h post infection compared to a <0.5-log10 increase for the rIBVs. 
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Together with the smaller plaque sizes these results suggest that the loss of Gene 5 
has a small detrimental effect on virus replication. 
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Fig. 4.2. Replication kinetics of 5ab rIBVs. Confluent monolayers of CK cells 
were infected with 1x10
5
 pfu virus and extracellular virus harvested at various time 
points for plaque assay. Error bars represent SD of results from three independent 
experiments each assayed in triplicate. 
 
 
The replication kinetics of rIBVs replacing the IR were also investigated (Fig. 4.3). 
No difference in replication was observed between Beau-R and parental virus 
BeauR IR with only an approximate 0.5-log10 drop in peak titre of BeauR-
hRluc IR. However, a reduction in peak titre of almost 2-log10 was observed for 
BeauR-eGFP IR. 
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Fig. 4.3. Replication kinetics of IR rIBVs. Confluent monolayers of CK cells were 
infected with 1x10
5
 pfu virus and extracellular virus harvested at various time points 
for plaque assay. Error bars represent SD of results from three independent 
experiments each assayed in triplicate. 
 
 
Although this result was consistent with the plaque sizes observed for these viruses it 
was decided to sequence the IR rIBVs at this stage to ensure that no additional, 
unintentional, changes were present and to confirm that all effects observed were due 
to the presence of eGFP. Sequence analysis identified that R1 of BeauR-eGFP IR 
contained an additional change when compared to the sequences of each of the other 
IR rIBVs. This consisted of a double TA mutation, at nucleotides 25770 and 
25771, directly upstream of the N gene TRS resulting in amino acid change F30Stop 
within ORF 5b (Fig. 4.4A). Comparing this to R2 of BeauR-eGFP IR the presence 
of the same two mutations was observed, but as a minor population (Fig. 4.4B). 
Additional sequence analysis of a later passage of R2 (P7) showed the continuing 
presence of this double mutation as a minor virus population (Fig. 4.4C). Later 
passage data was not available to investigate whether these mutations would 
eventually become the dominant population in both replicates. 
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Fig. 4.4. Sequence traces of BeauR-eGFP IR 5b mutations. Viruses were 
sequenced with primer BG148 and sequence traces compared. (A) Passage 4 BeauR-
eGFP IR R1. (B) Passage 4 BeauR-eGFP IR R2. (C) Passage 7 BeauR-eGFP IR 
R2. Grey box highlights position of mutations. 
 
 
The result of this double mutation is the introduction of a premature stop codon 
within ORF 5b and therefore loss of expression of this protein. To determine 
whether the additional loss of 5b in R1 of BeauR-eGFP IR was responsible for the 
lower titres of this virus compared to BeauR IR and BeauR-hRluc IR a second 
growth curve was carried out to compare replication kinetics of the two BeauR-
eGFP IR replicates, R1 and R2 (Fig. 4.5). As the double mutation is present only as 
a minor population in R2 any additional effect of the loss of 5b should be noticeable 
between the two replicates. 
A
B
C
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Fig. 4.5. Replication kinetics of BeauR-eGFP IR replicates. Confluent 
monolayers of CK cells were infected with 1x10
5
 pfu virus and extracellular virus 
harvested at various time points for plaque assay. Error bars represent SD of results 
from three independent experiments each assayed in triplicate. 
 
 
Both R1 and R2 of BeauR-eGFP IR displayed the same replication kinetics 
indicating that the additional loss of 5b was not responsible for the decrease in 
replication fitness of R1 compared to wild type and parental virus. Growth 
differences are therefore due to the insertion of eGFP and suggest that eGFP is not as 
well tolerated as hRluc at this location. 
 
The final growth curve showed that the replication kinetics of rIBV BeauR-
hRluc 3ab were similar to those observed for parental virus BeauR 3ab, with both 
viruses reaching peak titres at 24 h that were approximately 1-log10 lower than wild 
type virus (Fig. 4.6). As with the deletion of Gene 5, the lower peak titres suggest a 
minor impact on the replication fitness of viruses lacking ORFs 3a and 3b, but no 
additional effect is observed by the insertion of hRluc. 
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Fig. 4.6. Replication kinetics of 3ab rIBVs. Confluent monolayers of CK cells 
were infected with 1x10
5
 pfu virus and extracellular virus harvested at various time 
points for plaque assay. Error bars represent SD of results from three independent 
experiments each assayed in triplicate. 
 
 
All of the recombinant viruses were able to grow on CK cells although peak titres 
were between approximately 1- and 2-log10 lower than wild type Beau-R. This was 
considered acceptable based on the modifications made to the virus and analysis was 
continued to investigate heterologous gene expression from each of the 
recombinants. 
 
4.3 Recombinant IBV subgenomic mRNA expression 
 
The mechanism of transcription for coronavirus structural and accessory genes 
yields a nested set of sg mRNAs that can be studied by northern blot analysis to 
show changes in the number, or size, of mRNAs produced as well as changes in 
mRNA expression levels as a result of alteration to the virus. A typical northern blot 
for the structural and accessory genes of Beau-R shows the presence of five mRNAs 
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plus one unidentified RNA species as originally described by Stern & Kennedy 
(Stern and Kennedy 1980) (Fig. 4.7). 
 
 
 
Fig. 4.7. Northern blot analysis of Beau-R. Intracellular RNA was harvested 24 
hpi and northern blot analysis carried out. Left hand markers denote mRNA sizes of 
Beau-R structural and accessory genes. Right hand markers denote which genes are 
encoded on each mRNA. The * represents the unidentified RNA species of IBV. 
 
 
To confirm the generation of an IBV sg mRNA capable of expressing eGFP or 
hRluc from each of the rIBVs, northern blot analyses of the rIBV sg mRNAs were 
carried out (Fig. 4.8). For each of the rIBVs the new expected sizes for each sg 
mRNA are summarized in Table 4.2. 
Chapter Four 
78 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4.8. Characterization of rIBV mRNA Expression. Northern blot analysis was 
carried out 24 hpi with (A) BeauR-eGFP 5ab, (B) BeauR-hRluc 5ab and BeauR-
IBVhRluc 5ab, (C) BeauR-eGFP IR, (D) BeauR-hRluc IR and (E) BeauR-
hRluc 3ab.  denotes wild type mRNA sizes.  denotes altered mRNA sizes in 
rIBVs. * denotes unidentified RNA. 
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TABLE 4.2: Recombinant IBV mRNA Sizes 
rIBV mRNA 
Expected 
Size (nts) 
BeauR-eGFP 5ab/ 
BeauR-IBVeGFP 5ab 
N 1924 
eGFP 2733 
M 3784 
Gene 3 4379 
Spike 7896 
BeauR-hRluc 5ab/ 
BeauR-IBVhRluc 5ab 
N 1924 
hRluc 2949 
M 4000 
Gene 3 4595 
Spike 8112 
BeauR-eGFP IR N 1924 
Gene 5 2225 
eGFP 3005 
M 3786 
Gene 3 4381 
Spike 7898 
BeauR-hRluc IR N 1924 
Gene 5 2225 
hRluc 3221 
M 4002 
Gene 3 4597 
Spike 8114 
BeauR-hRluc 3ab N 1924 
Gene 5 2225 
M 3276 
E 3512 
hRluc 4489 
Spike 8006 
 
 
The replacement of Gene 5 with eGFP or hRluc was expected to increase the size of 
the Gene 5 mRNA by 508nts or 724nts, respectively. This is shown in blots A and B, 
along with the subsequent increase in size of all upstream mRNAs as expected. Only 
the N mRNA remains unchanged for these rIBVs, as transcription of this mRNA is 
not affected by insertion of genes upstream. The increases in mRNA sizes confirmed 
the correct transcription of the reporter gene mRNAs from the Gene 5 location. 
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Recombinant viruses BeauR-eGFP IR and BeauR-hRluc IR utilized the insertion 
of a new TRS in order to obtain transcription of the reporter gene as an additional 
mRNA. Based on the insertion site of the reporter genes this new transcript was 
expected to be 3005nts for BeauR-eGFP IR and 3221nts for BeauR-hRluc IR. 
Northern blots C and D showed the presence of mRNA transcripts at the sizes 
expected for eGFP and hRluc and again the subsequent increase in size of all 
upstream mRNAs. It is interesting to note from these two blots that the band 
representing the unidentified RNA species (*) was no longer present for these rIBVs. 
Re-examination of blots A and B showed that this band also shifted in size with the 
mRNAs upstream of Gene 5 (as labelled). These observations suggested that the 
unidentified RNA species might be a mRNA linked to the IR. Investigation of these 
observations forms the work detailed in Chapters 6 and 7 of this thesis. 
 
Analysis of rIBV BeauR-hRluc 3ab is shown in blot E. The replacement of ORFs 
3a and 3b with hRluc was expected to yield a mRNA, representing the hRluc gene, 
of 4489nts. As described in section 3.2.4, when constructing this recombinant virus 
an additional TRS was inserted upstream of ORF 3c (E) to ensure transcription of a 
mRNA for the envelope protein, normally translated from the Gene 3 mRNA via an 
IRES. This was expected to generate a new mRNA transcript of 3512nts, in addition 
to the hRluc mRNA. 
 
Both replicates showed the presence of a band representing hRluc although for R2 
the mRNA appeared to be slightly smaller than for R1 suggesting a possible deletion 
in the hRluc mRNA. To investigate whether this observation was a result of a 
problem during the northern blot process or if there is a deletion in this replicate both 
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replicates were sequenced over the region of the hRluc insert. Sequence analysis 
showed that R2 contains a ~40nt region at the 3'-end of the hRluc gene (also 
covering the inserted TRS for transcription of E) that did not yield clean sequence 
traces, and showed a number of potential virus populations, as well as a potential 
deletion in the inserted E TRS (Fig. 4.9A). 
 
 
Fig. 4.9. Analysis of BeauR-hRluc 3ab. Passage 4 stocks of (A) BeauR-
hRluc 3ab R2 and (B) BeauR-hRluc 3ab R1 were sequenced with primer BG143. 
Grey box highlights sequence that should correlate to E TRS. Underlined in black 
are the hRluc stop codons. Underlined in red is the E initiation codon. 
 
 
The presence of mixed virus populations in this region may be enough to account for 
the apparent decrease in hRluc mRNA size for R2 if the majority of these 
populations contain deletions in the hRluc gene. This result could be linked back to 
the mixed plaque sizes observed for R2 in Fig. 4.1 and confirmed that the cause of 
the mixed virus populations is a region located at the 3'-end of the inserted hRluc 
gene. Furthermore, sequence analysis of R1 showed a 3nt deletion of CAA within 
the inserted TRS for E (Fig. 4.9B). A question was raised over whether transcripts 
for E were being generated by BeauR-hRluc 3ab as both replicates contained 
A
B
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sequence changes over the inserted TRS (Fig. 4.9). Close examination of the BeauR-
hRluc 3ab northern blot (Fig. 4.8E) showed the faint detection of a mRNA for R1 at 
the size expected for the E mRNA. This mRNA was not observed for R2, although 
this may have been a result of the overall lower levels of mRNA detection for R2 
due to differences in the amount of RNA loaded onto the gel for each replicate. 
 
With no definitive proof of the E mRNA for either replicate it was decided to 
investigate this further via leader-body junction PCRs carried out on intracellular 
RNA extracted from CK cells infected with either R1 or R2 of BeauR-hRluc 3ab 
(see section 2.9 and Fig. 6.2 for PCR methodology). A PCR product relating to the E 
mRNA could not be amplified for R2, possibly due to the sequencing errors 
previously identified. For R1 a PCR product relating to the E mRNA was amplified, 
cloned and two colonies sequenced. The mRNA sequence obtained confirmed that E 
was being transcribed from R1 however, the TRS of the mRNA was non-canonical 
and its entire derivation was unclear (Fig. 4.10). 
 
 
E-mRNA (1)        :ACACTAGCCTTGCGCTAGATTTTTAACTTACTTAAATACGGACGATGATGAATTT:85 
E-mRNA (2)        :ACACTAGCCTTGCGCTAGATTTTTAACTTACTTAAATACGGACGATGATGAATTT:85 
BeauR-hRlucΔ3ab R1:GTGCTGAAGAACGAGCAGTAATAAGTTTTACTTAAATACGGACGATGATGAATTT:24836 
rVVBeauR-hRlucΔ3ab:GTGCTGAAGAACGAGCAGTAATAAGTTTTACTTAACAAATACGGACGATGATGAA:24836  
 
Fig. 4.10. Messenger RNA sequence of E transcript. Two mRNAs representing 
the E ORF of BeauR-hRluc 3ab R1 were sequenced using primers Leader1 and 
BG143. rVVBeauR-hRluc∆3ab shows the presence of the complete TRS-B for ORF 
E in the vaccinia virus IBV cDNA sequence. The genome sequence of BeauR-
hRluc 3ab R1 shows the deletion in the TRS-B. The mRNA Leader sequence is 
highlighted in blue. Aligned sequences are highlighted in black with the ATG of E 
highlighted in green. Region of rVVBeauR-hRluc 3ab highlighted in grey shows 
the misalignment of genome due to the complete TRS-B. Yellow highlighted text 
represents the different E TRSs observed. Red highlighted text denotes sequence of 
the mRNA TRS from an unknown source. Genome and mRNA positions are given 
on the right. 
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The E mRNA sequences showed the presence of a shortened CTTAA TRS as 
highlighted in yellow. This TRS is derived from the altered TRS-B for E as seen in 
Fig. 4.9B. However, an additional CTTA sequence has also been added upstream of 
this TRS, with the derivation of this sequence less clear. The TTA of the additional 
sequence does align with the virus genome upstream of the CTTAA TRS-B 
suggesting transcription has continued past the standard TRS-B position to include 
additional nucleotides, possibly to compensate for the deletion at the 3'-end of the 
TRS-B. This still does not account for the addition of the C nucleotide, which may 
be a result of an aberrant hybridization event between the TR-L and the altered TRS-
B, leading to transcription of nucleotides from the TRS-L. This explanation can be 
better understood in light of findings in Chapters 6 and 7. Given the presence of this 
mRNA for R1, and the belief that E is essential to virus replication, it is likely that E 
is translated by both virus replicates, even though a corresponding mRNA was 
undetected in R2. 
 
Each of the rIBVs, with the exception of BeauR-hRluc 3ab R2, were shown to 
correctly transcribe a mRNA for the reporter gene with no apparent changes to 
mRNA expression of any other virus gene. Analysis of the rIBVs was therefore 
continued to confirm that synthesis of the modified mRNAs resulted in the correct 
translation of either eGFP or hRluc. 
 
4.4 Reporter gene protein expression 
 
To confirm translation of a functional protein from the reporter gene mRNAs protein 
expression in CK cells was first analysed by western blot (Fig. 4.11). Correct protein 
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expression of eGFP and hRluc should yield proteins of 29kDa and 37kDa, 
respectively. BeauR-eGFP 5ab showed correct eGFP expression for both replicates 
with no expression from wild type or mock infected as expected (Fig. 4.11A). The 
same was true for hRluc expression from BeauR-hRluc 5ab and BeauR-
IBVhRluc 5ab (Fig. 4.11B). Differences in the range of IBV proteins expressed (top 
panels) are due to the polyclonal nature of the anti-IBV primary antibody and 
varying sensitivities of blots from different infections. 
 
Reporter protein expression from BeauR-eGFP IR and BeauR-hRluc IR was also 
shown to be correct for both replicates (Fig. 4.11C, D). For BeauR-hRluc 3ab 
luciferase protein expression could only be detected for R1 (Fig. 4.11E). This is 
consistent with the results seen with mRNA expression and sequence analysis of 
both replicates, suggesting that the problems seen at the 3'-end of the hRluc gene in 
R2 are affecting hRluc protein expression. 
 
Protein expression was further analysed by confocal microscopy to confirm 
fluorescence from eGFP rIBVs, and to see if any differences could be observed in 
reporter protein distribution within the cell for any of the rIBVs. Confocal 
microscopy images are shown for infection of Vero cells as difficulties were 
encountered in obtaining clear images from primary CK cells due to the presence of 
high levels of cell debris. Confocal images confirmed expression of eGFP or hRluc 
in Vero cells following infection with R1 of each rIBV (Fig. 4.12). In all constructs 
proteins eGFP and hRluc were found distributed throughout the cytoplasm and 
nuclei of infected cells. 
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Fig. 4.11. Characterization of rIBV protein expression. Western blot analyses of 
rIBV infected CK cell lysates. (A) BeauR-eGFP 5ab, (B) BeauR-hRluc 5ab and 
BeauR-IBVhRluc 5ab (C) BeauR-eGFP IR (D) BeauR-hRluc IR (E) BeauR-
hRluc 3ab. Each group of cell lysates were run on three separate gels and 
corresponding blots probed with either anti-IBV (top panels), anti-actin (middle 
panels) or, anti-eGFP (A, C) or anti-hRluc (B, D, E) (bottom panels). Lanes: (A, C, 
D, E) WT, Beau-R; 1, R1; 2, R2; M, mock; (B) WT, Beau-R; 1, BeauR-hRluc 5ab 
R1; 2, BeauR-hRluc 5ab R2; 3, BeauR-IBVhRluc 5ab R1; 4, BeauR-
IBVhRluc 5ab R2; M, mock.  
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Fig. 4.12. Confocal microscopy of rIBVs. Monolayers of Vero cells at 80% 
confluency were infected with 1x10
5
 pfu of (A) eGFP rIBVs or (B) hRluc rIBVs. 
Cells were fixed 18 hpi with 4% paraformaldehyde. Cells were labelled with anti-
IBV (red). For (A) eGFP was detected by fluorescence (green). For (B) cells were 
additionally labelled with anti-hRluc (green). Nuclei were stained blue with DAPI. 
Scale bars represent 25µm. 
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4.5 Luciferase expression 
 
As luciferase expression can be quantified using a luminometer, the rIBVs 
expressing hRluc could be used as tools to investigate whether heterologous protein 
expression levels varied based on the location of the heterologous gene. Utilizing 
cell lysates harvested at the same time as extracellular virus for growth curves, 
protein expression was analysed from each of the rIBVs expressing hRluc (Fig. 
4.13). 
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Fig. 4.13. Luciferase expression. Luciferase expression was measured in cell 
lysates taken at various time points during infection and expressed as relative light 
units (RLU) per g of protein. Error bars represent SD of triplicate readings of three 
independent experiments. 
 
 
Protein expression peaked for all rIBVs at 24 h except BeauR-hRlucΔIR, which 
peaked at 48 h. This coincides with peak virus titres obtained for rIBVs, except in 
the case of BeauR-hRlucΔIR. Comparing the 24 h time point data luciferase 
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expression was found to be highest in BeauR-hRluc 5ab followed by BeauR-
hRluc 3ab and then BeauR-hRluc IR. 
 
Surprisingly, BeauR-IBVhRluc 5ab was found to have the lowest levels of 
luciferase expression with peak levels approximately 3.5-log10 lower than for 
BeauR-hRluc 5ab. Codon optimization of the heterologous gene had been 
hypothesised to improve virus stability but was not expected to decrease protein 
expression from that gene. Due to the differences observed between BeauR-
hRluc 5ab and BeauR-IBVhRluc 5ab sequence analysis of all 5ab rIBVs was 
carried out at this time to check that no errors had occurred within the modified 
regions of the rIBV genomes. 
 
Sequence analysis showed that a mutation had occurred in the hRluc gene of BeauR-
IBVhRluc 5ab R1 that was not present in either of the BeauR-hRluc 5ab replicates 
or R2 of BeauR-IBVhRluc 5ab. This mutation consisted of the insertion of two 
additional T nucleotides in a stretch of eight T nucleotides beginning at genome 
position 26267. The additional residues caused a frameshift and alteration to the 
hRluc amino acid sequence downstream of amino acid 262 (Fig. 4.14). This 
frameshift also resulted in the addition of eight amino acids to the 3'-end of the 
hRluc gene before a stop codon was reached. The modified hRluc gene generated by 
these changes was referred to as hRluc*. 
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Fig. 4.14. Amino acid alignment of codon optimized hRluc. The altered hRluc 
gene (hRluc*) of BeauR-IBVhRluc∆5ab R1 was sequenced and compared to wild 
type hRluc. Grey box highlights the amino acid positions affected by the mutations 
arising in hRluc*. 
 
 
To investigate whether the changes in the hRluc gene of BeauR-IBVhRluc 5ab R1 
were responsible for the lower than expected levels of luciferase expression the time 
course experiment was carried out for R2 (Fig. 4.15). 
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Fig. 4.15. Codon optimized luciferase expression. Luciferase expression was 
measured in cell lysates taken at various time points during infection and expressed 
as relative light units (RLU) per g of protein. Error bars represent SD of triplicate 
readings of three independent experiments. 
 
10        20        30        40        50        60        70        80               
....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|
hRluc   MASKVYDPEQRKRMITGPQWWARCKQMNVLDSFINYYDSEKHAENAVIFLHGNAASSYLWRHVVPHIEPVARCIIPDLIG
hRluc*  MASKVYDPEQRKRMITGPQWWARCKQMNVLDSFINYYDSEKHAENAVIFLHGNAASSYLWRHVVPHIEPVARCIIPDLIG
90       100       110       120       130       140       150       160        
....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|
hRluc   MGKSGKSGNGSYRLLDHYKYLTAWFELLNLPKKIIFVGHDWGACLAFHYSYEHQDKIKAIVHAESVVDVIESWDEWPDIE
hRluc*  MGKSGKSGNGSYRLLDHYKYLTAWFELLNLPKKIIFVGHDWGACLAFHYSYEHQDKIKAIVHAESVVDVIESWDEWPDIE
170       180       190       200       210       220       230       240       
....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|
hRluc   EDIALIKSEEGEKMVLENNFFVETMLPSKIMRKLEPEEFAAYLEPFKEKGEVRRPTLSWPREIPLVKGGKPDVVQIVRNY
hRluc*  EDIALIKSEEGEKMVLENNFFVETMLPSKIMRKLEPEEFAAYLEPFKEKGEVRRPTLSWPREIPLVKGGKPDVVQIVRNY
250       260       270       280       290       300       310       320       
....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|
hRluc   NAYLRASDDLPKMFIESDPGFFSNAIVEGAKKFPNTEFVKVKGLHFSQEDAPDEMGKYIKSFVERVLKNEQ*        
hRluc*  NAYLRASDDLPKMFIESDPGFFFLMQLLKVQKNFQILNLLKLKVFIFLKKMHQMKWVNILNLLLKEFLKMNNNNLFAEQ* 
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Luciferase expression for BeauR-IBVhRluc 5ab R2 was found to be greater than R1 
suggesting that the changes within the hRluc gene were likely responsible for the 
lower levels of luciferase expression. However, expression levels were diminished 
slightly by 72 h compared to BeauR-hRluc 5ab; highlighting that in this case codon 
optimization may have a small negative impact on protein expression. 
 
4.6 Utilizing eGFP rIBVs for live cell imaging studies 
 
Having obtained two recombinant viruses expressing eGFP from different regions of 
the IBV genome it was decided to try and use these viruses as tools to study aspects 
of IBV infection by live cell imaging. As no previous publications or information 
could be found describing the use of CK cells for live cell imaging it was decided to 
first optimize infection of these viruses on Vero cells, as protocols were already in 
place for this cell culture. A trial infection was carried out, and monitored by 
standard fluorescence microscopy, to obtain timeframes for live cell imaging. 
However, it was observed that BeauR-eGFP 5ab did not propagate as well on Vero 
cells when compared to BeauR-eGFP IR with very few fluorescing cells visible. 
 
To investigate this effect further, infections of BeauR-eGFP 5ab and BeauR-
eGFP IR on both CK cells and Vero cells were carried out and monitored for 72 h 
(Fig. 4.16). At 24 h both viruses on CK cells showed wide spread virus infection as 
indicated by the high number of green fluorescent cells. By 72 h the number of 
fluorescent cells had decreased rapidly due to high levels of cell death, as expected 
for CK cells, and confirmed by bright field microscopy (Fig. 4.16A, lower panels). 
In contrast, on Vero cells at 24 h very few infected cells were observed for BeauR-
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eGFP IR and only one or two infected cells observed for BeauR-eGFP 5ab (Fig. 
4.16B). 
 
At 72 h on Vero cells there was a distinct difference in the progression of virus 
infection between the two rIBVs. While BeauR-eGFP IR had spread throughout the 
cell monolayer, with large foci of infection and separate, individually infected cells 
visible, BeauR-eGFP 5ab was limited to very small, discrete foci of infection. These 
observations indicated that the loss of Gene 5 limits the ability of Beau-R to spread 
on Vero cells. Taken together with the plaque morphology data and the slight delay 
in replication kinetics observed for rIBVs lacking Gene 5 this suggested a role for 
one, or both, of the Gene 5 accessory proteins in cell-cell spread. 
 
Following these observations it was decided not to pursue the use of BeauR-
eGFP 5ab in live cell imaging as it could not be guaranteed that the effects of the 
loss of Gene 5 would not impact on the results obtained and yield inaccurate data. 
Additionally, whilst growth on Vero cells was not restricted for BeauR-eGFP IR the 
levels of fluorescence observed were considerably lower with long exposure times 
required to obtain images. Although slightly better fluorescence levels were 
observed in CK cells it was considered that the quality of images that could be 
obtained for BeauR-eGFP IR was not good enough to proceed with live cell 
imaging. For these reasons no live cell imaging experiments were carried out. 
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Fig. 4.16. Virus infection of Vero cells. Monolayers of CK (A) or Vero (B) cells at 
80% confluency were infected with 1x10
5
 pfu of BeauR-eGFP 5ab or BeauR-
eGFP IR. Images were taken at 24 h and 72 h by fluorescence microscopy (upper 
panels) at 10x magnification, or bright field microscopy (lower panels) where scale 
bars represent 400 m. 
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4.7 Summary 
 
This chapter detailed the analysis of the rescued rIBVs in terms of growth 
characteristics and protein expression. The main findings from this chapter are 
summarized below: 
 BeauR-eGFP 5ab and BeauR-hRluc 5ab replicated similarly to wild type 
but with 1-log10 lower peak titres and a delay in replication at 8 h. All virus 
replicates correctly transcribed and expressed reporter genes. 
 BeauR-IBVhRluc 5ab replicated as other 5ab rIBVs but codon 
optimization resulted in diminished hRluc expression compared to BeauR-
hRluc 5ab. 
 BeauR-eGFP IR replicated with similar kinetics to wild type but with ~2-
log10 lower titres from 24 h onwards. Replicate 1 was found to have a 
mutation leading to the additional loss of accessory protein 5b. Both virus 
replicates correctly transcribed and expressed eGFP. 
 BeauR-hRluc IR replicated as wild type and both virus replicates correctly 
transcribed and expressed hRluc. 
 BeauR-hRluc 3ab replicated to 1-log10 lower peak titres than wild type but 
both virus replicates contained sequence errors in, or around, the inserted 
hRluc gene. Replicate 2 did not express hRluc due to errors. 
 The loss of Gene 5 resulted in an inability of Beau-R to undergo cell-cell 
spread on Vero cells. 
 
As with Chapter 3, these results will be discussed in detail in an overall discussion at 
the end of Chapter 5. 
Chapter Five 
99 
 
Chapter 5: Analysis of rIBV stability in cell culture 
 
5.1 Overview 
 
This chapter details the experiments that were carried out to investigate the stability 
of the rescued rIBVs. By passaging each virus on CK cells the aim was to identify 
which rIBV constructs resulted in the expression of heterologous genes for the 
greatest number of passages. Initially both replicates of each rIBV were passaged, 
regardless of any issues identified in Chapter 4, in order to more accurately establish 
the stability of each construct. For the purposes of this chapter the rIBVs will be 
referred to as the wild type viruses with Beau-R referred to as the parental virus. 
 
5.2 Recombinant IBV passaging 
 
Initial experiments were carried out with rIBVs BeauR-eGFP 5ab, BeauR-
hRluc 5ab, BeauR-eGFP IR and BeauR-hRluc IR as the first rIBVs to have been 
rescued. Recombinant viruses BeauR-IBVhRluc∆5ab and BeauR-hRluc∆3ab were 
rescued at a later date and therefore not included in initial experiments. The P3 stock 
of each virus was taken and blind passaged a further five times on CK cells. At each 
passage virus was diluted 1:100 prior to infection, to ensure the previous passage 
stock was not depleted, but no quantification of the virus inoculum was carried out. 
 
All passaging was carried out in 6-well plates of confluent CK cells. Each rIBV was 
used to infect one well of CK cells (500 L/well). Cells were incubated for 1 h after 
which virus inoculum was removed and fresh medium added to cells. At 36 hpi 
Chapter Five 
100 
 
extracellular virus was harvested from cells and reverse transcribed for PCR 
analysis. Stability was measured by the presence or absence of the reporter gene, 
based on visualisation of PCR products as previously described in section 3.3, Table 
3.2. The expected PCR products for the rIBVs specific to this chapter are listed again 
in Table 5.1. 
 
 
TABLE 5.1: Expected PCR Products for Wild Type Virus 
Virus Primer Set PCR 
Product (bp) 
BeauR-eGFP 5ab   5abS + BG147 963 
BeauR-hRluc 5ab/ 
BeauR-IBVhRluc 5ab 
5abS + BG147 1179 
BeauR-eGFP IR BG52 + BG146 1087 
BeauR-hRluc IR BG52 + BG146 1303 
BeauR-hRluc 3ab BG49 + BG144 1916 
 
 
All RT-PCR products from P3 to P8 for BeauR-eGFP 5ab, BeauR-hRluc 5ab, 
BeauR-eGFP IR and BeauR-hRluc IR were subsequently analysed by gel 
electrophoresis at the same time to observe any changes in the detection of reporter 
gene PCR products (Fig. 5.1). A single PCR product of the expected size at each 
passage would represent a stably replicating virus. The presence of smaller PCR 
products would indicate deletions were occurring somewhere over the region of the 
PCR. The results for these rIBVs showed that even at early passages (P3-P5) a 
number of smaller PCR products could be seen for each virus, indicating the loss of 
genomic sequence over the region of the PCR. This suggested that the reporter genes 
were being rapidly deleted from the genome and that the rIBVs were unstable.  
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Fig. 5.1. Initial passaging of rIBVs. Recombinant viruses were blind passaged on 
CK cells. Confluent monolayers were infected with 500 l rIBV, extracellular virus 
was harvested 36 hpi and screened by RT-PCR. Gel electrophoresis shows PCR 
results for R1 and R2 of each virus from P3 to P8. DNA marker is shown as lane L 
with selected values identified on the left. 
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Complete loss of wild type PCR product was observed by P7 for BeauR-eGFP 5ab, 
P5 for BeauR-eGFP IR, P7 for BeauR-hRluc 5ab and P6 for BeauR-hRluc IR, 
although PCR products representing virus populations containing suspected 
deletions could be seen before said passages. Both R1 and R2 of each rIBV showed 
instability arising in the virus within one or two passages of each other, as would be 
expected for replicates of the same virus, and confirmed that both replicates are 
under the same replication pressures. 
 
Due to the nature of the passaging, at potentially high virus titres, it was initially 
hypothesised that these suspected deletions in the reporter genes might be occurring 
in conjunction with other deletions across the virus genome, and thus leading to the 
formation of D-RNAs. Defective RNAs have previously been reported to occur for 
coronaviruses, including IBV, following serial passage in cell culture (Makino, et al. 
1985, Penzes, et al. 1994). It is known that to control the generation of D-RNAs 
viruses must be passaged at a low MOI to prevent the smaller, faster replicating, 
defective genomes from being packaged and passaged on with the aid of helper, 
intact, virus genomes. Control of D-RNAs can also be achieved by simple dilution of 
virus stocks (without the need for calculation of an MOI) as this is known to reduce 
the co-infection of potential D-RNAs with helper viruses and therefore reduce, or 
abolish, subsequent passage of D-RNAs. 
 
To investigate if D-RNAs were the cause of the observed rIBV instability the rescue 
process was repeated from P1 for each rIBV to establish new virus stocks at P4. This 
time each rIBV was subject to greater dilution prior to infection of CK cells at each 
passage. Due to potentially low virus titres at P1, P2 was carried out using a dilution 
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of 1:1000, followed by P3 and P4 stocks at a dilution of 1:10,000. The expectation 
was that these new P4 stocks would be free of any D-RNAs and would give a more 
reliable estimate of the stability of each rIBV when passaged. This process was also 
carried out with the additional rIBVs, BeauR-IBVhRluc 5ab and BeauR-
hRluc 3ab, that had been subsequently rescued. 
 
To examine the effect on stability by passaging from potentially D-RNA-free stocks 
of virus the passaging was repeated for BeauR-eGFP 5ab, BeauR-hRluc 5ab, 
BeauR-eGFP IR and BeauR-hRluc IR from P4 onwards. Those viruses not 
previously passaged, BeauR-IBVhRluc 5ab and BeauR-hRluc 3ab, were also 
included and passaging of all rIBVs was extended to P12. Parental virus Beau-R was 
also passaged and screened with each primer set to confirm whether deletions were 
arising due to the insertion of heterologous genes, or if deletions occur naturally over 
these regions when Beau-R is passaged (Fig. 5.2). As previously, viruses were 
diluted 1:100 from P4 onwards to ensure the previous passage stock was not 
depleted.  
 
Passaging of Beau-R, under the conditions described, showed that deletions did not 
naturally occur within the unmodified genome regions, with the expected PCR 
products of 455bp, 623bp and 1324bp observed at all passages for the 5ab, IR and 
3ab PCRs respectively (Fig. 5.2A). The detection of the non-wild type PCR products 
from the rIBVs, and the deletion of reporter genes, is therefore a result of the 
modifications made to the virus genomes. 
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Repeat passaging of the rIBVs with potentially D-RNA-free stocks resulted in an 
overall improvement in stability for rIBVs BeauR-eGFP 5ab, BeauR-hRluc 5ab, 
BeauR-eGFP IR and BeauR-hRluc IR, as measured by the passage number at 
which the first non-wild type PCR products appeared, and at which the wild type 
product was no longer detected. Recombinant IBVs BeauR-IBVhRluc 5ab and 
BeauR-hRluc 3ab, which had not been analysed previously, also showed the 
accumulation of non-wild type PCR products over the course of passaging, 
indicating that all of the rIBVs are subject to deletion of the heterologous reporter 
gene sequences. 
 
To more easily compare the data from the first two experiments the passage number 
at which instability was first detected is summarized for each rIBV in Table 5.2, 
along with the passage numbers at which the wild type product became undetectable. 
 
 
TABLE 5.2: Recombinant IBV Stability 
Virus R1 R2 
Instability 
Arises 
Reporter 
Gene Lost 
Instability 
Arises 
Reporter 
Gene Lost 
BeauR-eGFP 5ab 
Initial Passaging 
Repeat Passaging 
 
P5 
P9 
 
P7 
P11 
 
P5 
P8 
 
P6 
P10 
BeauR-hRluc 5ab 
Initial Passaging 
Repeat Passaging 
 
P5 
P8 
 
P7 
P10 
 
P4 
P9 
 
P6 
P12 
BeauR-eGFP IR 
Initial Passaging 
Repeat Passaging 
 
P4 
P7 
 
P5 
P8 
 
P4 
P7 
 
P6 
P8 
BeauR-hRluc IR 
Initial Passaging 
Repeat Passaging 
 
P4 
P8 
 
P7 
P10 
 
P4 
P8 
 
P6 
P10 
BeauR-IBVhRluc 5ab P10 P12 P10 P12 
BeauR-hRluc 3ab P5 P12 P7 P12 
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If stability is defined by a single measurement, such as the passage number at which 
a non-wild type PCR product was first detected, then those rIBVs with reporter 
genes replacing Gene 5 are, on average, the most stable. Only one passage separates 
the instability observed for BeauR-eGFP 5ab from BeauR-hRluc 5ab suggesting 
that the heterologous gene itself has little impact on virus stability. Comparing the 
passaging data of BeauR-hRluc 5ab and BeauR-IBVhRluc 5ab (Table 5.2) it 
appears that codon optimization of the heterologous gene may have a small positive 
effect on stability with two additional passages achieved before non-wild type PCR 
products were observed. 
 
The replacement of the IR resulted in rIBVs that were only one or two passages less 
stable than those containing a replacement of Gene 5. Again, only one passage 
separated the eGFP and hRluc recombinants confirming that once rescued the 
heterologous gene has a limited impact on virus stability. The least stable construct 
was found to be the replacement of ORFs 3a and 3b (BeauR-hRluc 3ab), with non-
wild type PCR products detectable as early as P5. Interestingly however, this virus 
displayed the highest number of passages between the appearance of non-wild type 
PCR products and complete loss of the wild type PCR product. 
 
It was apparent from these results that once instability had arisen within the virus 
population, detection of wild type virus expressing the reporter gene was lost after 
one or two further passages, with the exception of BeauR-hRluc 3ab. This 
suggested that once instability arises there is rapid selection of a virus population in 
which the reporter gene has been deleted and the virus is, presumably, able to 
replicate more efficiently. By beginning the passaging with a P4 stock generated by 
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dilution of the rIBV between P2 and P4, an additional 3-4 passages were achieved 
prior to the appearance of instability of the virus. This suggested that some control 
could be exerted on the rIBVs to maintain a stable virus population for longer, and 
reinforced the idea of D-RNAs arising during passaging. 
 
Given the positive impact on stability observed by using a potentially D-RNA-free 
stock as the start point it was hypothesised that controlling the MOI at every passage 
would additionally benefit rIBV stability. To investigate this possibility a third 
passaging experiment was carried out with R1 of each of the hRluc rIBVs. This time, 
instead of blind passaging with a 1:100 dilution of virus, each rIBV was titrated on 
CK cells between passages and all infections were carried out at a MOI of 0.01. 
Recombinants were again passaged from P4 to P12 (Fig. 5.3). 
 
The greatest effect of passaging at a set MOI was seen with BeauR-hRluc 5ab and 
BeauR-IBVhRluc 5ab where no non-wild type PCR products were observed up to, 
or including at, P12. This equated to an increase in stability of four rounds of 
passaging compared to the blind passaging experiment shown in Fig. 5.2. Although 
the image for BeauR-IBVhRluc 5ab appears to show a reduction in size of the PCR 
product this was in fact caused by a technical error during electrophoresis resulting 
in an uneven electrical flow through the gel.  
Chapter Five 
109 
 
 
 
Fig. 5.3. MOI passaging of hRluc recombinants. Replicate 1 of each hRluc 
recombinant was re-passaged on CK cells at a MOI of 0.01. Virus was screened by 
RT-PCR from P4 to P12. DNA marker is shown as lane L with selected values 
identified on the left. 
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Passaging at a set MOI also had a small impact on BeauR-hRluc IR with non-wild 
type PCR products detected from P9 compared to P8 and wild type PCR products 
still detectable, although very faint, at P12. Recombinant BeauR-hRluc 3ab was 
again shown to be the least stable with non-wild type PCR products detected from 
P6. Similar to the previous experiment however, the wild type population was still 
clearly detected at P12 suggesting that although deletion of the reporter gene occurs 
early in this construct there is some selection pressure to also maintain the wild type 
population. 
 
The MOI passaging data confirms what was suspected from the blind passaging 
experiments that the replacement of Gene 5 yields the most stable virus 
recombinants, followed by the replacement of the IR and then replacement of ORFs 
3a and 3b. It is possible that codon optimization of the heterologous gene does 
improve rIBV stability but more data is required to fully support this hypothesis. The 
stability of the rIBVs was not found to be determined by the specific heterologous 
gene in these experiments, with similar results observed for both eGFP and hRluc 
recombinants. 
 
5.3 Investigation of the non-wild type PCR products 
 
The passaging experiments had been repeated using a set MOI on the basis that the 
suspected deletions arising in the reporter genes were occurring in combination with 
other deletions across the genome, leading to the generation of D-RNAs. This theory 
was backed up by the fact that passaging at a set MOI did control the appearance of 
non-wild type PCR products, as would be expected with true D-RNAs. Previous IBV 
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D-RNAs were shown to have major deletions in the replicase ORFs, as well as at 
positions across the structural and accessory genes (Penzes, et al. 1994). Efforts were 
made to establish the nature of the non-wild type viruses and confirm the presence of 
D-RNAs. A number of experiments were carried out to investigate the rIBVs by 
northern blot analysis however; no evidence of true D-RNAs could be obtained 
suggesting that the rIBVs are only unstable across the region of the inserted reporter 
gene. 
 
To investigate the nature of the non-wild type PCR products, and confirm the 
deletion of the reporter genes, the PCR products from two rIBVs, BeauR-eGFP IR 
and BeauR-hRluc 5ab, from P7 of the initial passaging experiment were cloned and 
sequenced. Alignments were then carried out against wild type sequences to show 
examples of which areas of the genome are deleted (Fig. 5.4). 
 
The alignments showed that four different deletions were identified for BeauR-
eGFP IR (Fig. 5.4A) while three different deletions were identified for BeauR-
hRluc 5ab (Fig. 5.4B). For both rIBVs the deletions ranged in size across the 
reporter gene. Additionally, for BeauR-eGFP IR variant four also contained a 
deletion of the Gene 5 TRS and ORF 5a start codon thus resulting in the additional 
loss of both Gene 5 accessory proteins for this individual virus. This suggested that 
deletions were not limited to the reporter gene sequence and could spread into other 
non-essential genes resulting in smaller, but viable, genomes. 
 
  
 
A 
                                                                                                                                                                                      M Stop                            eGFP TRS  eGFP Start 
BeauR-eGFP∆IR : ATAAGAAAAGGTTTGCTACGTTTGTCTATGCAAAGCAGTCAGTAGATACTGGCGAGCTAGAAAGTGTAGCAACAGGAGGAAGTAGTCTTTACACATAAATGTGTGTGGCTAGCGGCCAACTTAACAAATACGGACGATGG 
One           : ATAAGAAAAGGTTTGCTACGTTTGTCTATGCAAAGCAGTCAGTAGATACTGGCGAGCTAGAAAGTGTAGCAACAGGAGGAAGTAGTCTTTACACATAAATGTGTGTGGCTAGCGGCCAACTTAACAAATACGGACGATGG 
Two           : ATAAGAAAAGGTTTGCTACGTTTGTCTATGCAAAGCAGTCAGTAGATACTGGCGAGCTAGAAAGTGTAGCAACAGGAGGAAGTAGTCTTTACACATAAATGTGTGTGGCTAGCGGCCAACCTA----------------- 
Three         : ATAAGAAAAGGTTTGCTACGTTTGTCTATGCAAAGCAGTCAGTAGATACTGGCGAGCTAGAAAGTGTAGCAACAGGAGGAAGTAGTCTTTACACATAAATGTGTGTGGCTAGCGGCCAACTTAACAAATACGG------- 
Four          : ATAAGAAAAGGTTTGCTACGTTTGTCTATGCAAAGCAGTCAGTAGATACTGGCGAGCTAGAAAGTGTAGCAACAGGAGGAAGTAGTCTTTACACATAAATGTGTGTGGCTAGCGGCCAACTTA----------------- 
 
BeauR-eGFP∆IR : TGAGCAAGGGCGAGGAGCTGTTCACCGGGGTGGTGCCCATCCTGGTCGAGCTGGACGGCGACGTAAACGGCCACAAGTTCAGCGTGTCCGGCGAGGGCGAGGGCGATGCCACCTACGGCAAGCTGACCCTGAAGTTCATC 
One           : TGAGCA-------------------------------------------------------------------------------------------------------------------------------------- 
Two           : -------------------------------------------------------------------------------------------------------------------------------------------- 
Three         : -------------------------------------------------------------------------------------------------------------------------------------------- 
Four          : -------------------------------------------------------------------------------------------------------------------------------------------- 
 
BeauR-eGFP∆IR : TGCACCACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCGTGACCACCCTGACCTACGGCGTGCAGTGCTTCAGCCGCTACCCCGACCACATGAAGCAGCACGACTTCTTCAAGTCCGCCATGCCCGAAGGCTACGTCCA 
One           : -------------------------------------------------------------------------------------------------------------------------------------------- 
Two           : -------------------------------------------------------------------------------------------------------------------------------------------- 
Three         : -------------------------------------------------------------------------------------------------------------------------------------------- 
Four          : -------------------------------------------------------------------------------------------------------------------------------------------- 
 
BeauR-eGFP∆IR : GGAGCGCACCATCTTCTTCAAGGACGACGGCAACTACAAGACCCGCGCCGAGGTGAAGTTCGAGGGCGACACCCTGGTGAACCGCATCGAGCTGAAGGGCATCGACTTCAAGGAGGACGGCAACATCCTGGGGCACAAGC 
One           : -------------------------------------------------------------------------------------------------------------------------------------------- 
Two           : -------------------------------------------------------------------------------------------------------------------------------------------- 
Three         : -------------------------------------------------------------------------------------------------------------------------------------------- 
Four          : -------------------------------------------------------------------------------------------------------------------------------------------- 
 
BeauR-eGFP∆IR : TGGAGTACAACTACAACAGCCACAACGTCTATATCATGGCCGACAAGCAGAAGAACGGCATCAAGGTGAACTTCAAGATCCGCCACAACATCGAGGACGGCAGCGTGCAGCTCGCCGACCACTACCAGCAGAACACCCCC 
One           : ------------------------------------------------------------------------------------------TCGAGGACGGCAGCGTGCAGCTCGCCGACCACTACCAGCAGAACACCCCC 
Two           : -------------------------------------------------------------------------------------------------------------------------------------------- 
Three         : -------------------------------------------------------------------------------------------------------------------------------------------- 
Four          : -------------------------------------------------------------------------------------------------------------------------------------------- 
 
BeauR-eGFP∆IR : ATCGGCGACGGCCCCGTGCTGCTGCCCGACAACCACTACCTGAGCACCCAGTCCGCCCTGAGCAAAGACCCCAACGAGAAGCGCGATCACATGGTCCTGCTGGAGTTCGTGACCGCCGCCGGGATCACTCTCGGCATGGA 
One           : ATCGGCGACGGCCCCGTGCTGCTGCCCGACAACCACTACCTGAGCACCCAGTCCGCCCTGAGCAAAGACCCCAACGAGAAGCGCGATCACATGGTCCTGCTGGAGTTCGTGACCGCCGCCGGGATCACTCTCGGCATGGA 
Two           : ------------------------------------------------------------AGCAAAGACCCCAACGAGAAGCGCGATCACATGGTCCTGCTGGGGTTCGTGACCGCCGCCGGGATCACTCTCGGCATGGA 
Three         : -------------------------------------------------------------------------------------------------------------------------------------------- 
Four          : -------------------------------------------------------------------------------------------------------------------------------------------- 
 
                                                               eGFP Stop                                             Gene 5 TRS                  5a Start 
BeauR-eGFP∆IR : CGAGCTGTACAAGTAATAACCCGGGATATCACGCGTGGTACCTTACTTAACAAAAACTTAACAAATACGGACGATGAAATGGCTGACTAGTTTTGGAAGAGCAGTTATTTCTTGTTATAAATCCCTACTATTAACTCAAC 
One           : CGAGCTGTACAAGTAATAACCCGGGATATCACGCGTGGTACCTTACTTAACAAAAACTTAACAAATACGGACGATGAAATGGCTGACTAGTTTTGGAAGAGCAGTTATTTCTTGTTATAAATCCCTACTATTAACTCAAC 
Two           : CGAGCTGTACAAGTAATAACCCGGGATATCACGCGTGGTACCTTACTTAACAAAAACTTAACAAATACGGACGATGAAATGGCTGACTAGTTTTGGAAGAGCAGTTATTTCTTGTTATAAATCCCTACTATTAACTCAAC 
Three         : -------------------------------------------GCTAAATTTTTAACTTAACAAATACGGACGATGAAATGGCTGACTAGTTTTGGAAGAGCAGTTATTTCTTGTTATAAATCCCTACTATTAACTCAAC 
Four          : --------------------------------------------------------------------------TAGAATGGCTGACTAGTTTTGGAAGAGCAGTTATTTCTTGTTATAAATCCCTACTATTAACTCAAC
  
 
B 
BeauR-hRluc∆5ab : GAGCTATTAACGGTGTTACCTTTCAAGTAGATAATGGAAAAGTCTACTACGAAGGAACACCAGTTTTCCAAAAAGGTTGTTGTAGGATGTGGTCCAATTATAAGAAAGAATAATTGAACCACCTACTACACTTATTTTTA 
One             : GAGCTATTAACGGTGTTACCTTTCAAGTAGATAATGGAAAAGTCTACTACGAAGGAACACCAGTTTTCCAAAAAGGTTGTTGTAGGATGTGGTCCAATTATAAGAAAGAATAATTGAACCACCTACTACACTTATTTTTA 
Two             : GAGCTATTAACGGTGTTACCTTTCAAGTAGATAATGGAAAAGTCTACTACGAAGGAACACCAGTTTTCCAAAAAGGTTGTTGTAGGATGTGGTCCAATTATAAGAAAGAATAATTGAACCACCTACTACACTTATTTTTA 
Three           : GAGCTATTAACGGTGTTACCTTTCAAGTAGATAATGGAAAAGTCTACTACGAAGGAACACCAGTTTTCCAAAAAGGTTGTTGTAGGATGTGGTCCAATTATAAGAAAGAATAATTGAACCACCTACTACACTTATTTTTA 
 
                                                     Gene 5/hRluc TRS         hRluc Start 
BeauR-hRluc∆5ab : TAAGAGGTACCTTACTTAACAAAAACTTAACAAATACGGACGATGGCTTCCAAGGTGTACGACCCCGAGCAACGCAAACGCATGATCACTGGGCCTCAGTGGTGGGCTCGCTGCAAGCAAATGAACGTGCTGGACTCCTT 
One             : TAAGAGGTACCTTACTTAACAAAAACTTAACA------------------------------------------------------------------------------------------------------------ 
Two             : TAAGAGGTACCTTACTTAACAAAAACTTAACAAATACGGACGATGGCTTCCAAGGTGTACGACCCCGAGCAACGCAAACGCATGATCACTGGGCCTCAGTGGTGGGCTCGCTGCAAGCAAATGAACGTGCTGGACTCCTT 
Three           : TAAGAGGTACCTTACTTAACAAAAACTTAACAAATACGGACGATGGCTTCCAAGGTGTACGACCCCGAGCAACGCAAA-------------------------------------------------------------- 
 
BeauR-hRluc∆5ab : CATCAACTACTATGATTCCGAGAAGCACGCCGAGAACGCCGTGATTTTTCTGCATGGTAACGCTGCCTCCAGCTACCTGTGGAGGCACGTCGTGCCTCACATCGAGCCCGTGGCTAGATGCATCATCCCTGATCTGATCG 
One             : -------------------------------------------------------------------------------------------------------------------------------------------- 
Two             : CATCAACTACTATGATTCCGAGAAGCACGCCGAGAACGCCGTGATTTTTCTGCATGGTAACGCTGCCTCCAGCTACCTGTGGAGGCACGTCGTGCCTCACATCGAGCCCGTGGCTAGATGCATCATCCCTGATCTGATCG 
Three           : -------------------------------------------------------------------------------------------------------------------------------------------- 
 
BeauR-hRluc∆5ab : GAATGGGTAAGTCCGGCAAGAGCGGGAATGGCTCATATCGCCTCCTGGATCACTACAAGTACCTCACCGCTTGGTTCGAGCTGCTGAACCTTCCAAAGAAAATCATCTTTGTGGGCCACGACTGGGGGGCTTGTCTGGCC 
One             : -------------------------------------------------------------------------------------------------------------------------------------------- 
Two             : GAATGGGTAAGTCCGGCAAGAGCGGGAATGGCTCATATCGCCTCCTGGATCACTACAAGTAC------------------------------------------------------------------------------ 
Three           : -------------------------------------------------------------------------------------------------------------------------------------------- 
 
BeauR-hRluc∆5ab : TTTCACTACTCCTACGAGCACCAAGACAAGATCAAGGCCATCGTCCATGCTGAGAGTGTCGTGGACGTGATCGAGTCCTGGGACGAGTGGCCTGACATCGAGGAGGATATCGCCCTGATCAAGAGCGAAGAGGGCGAGAA 
One             : -------------------------------------------------------------------------------------------------------------------------------------------- 
Two             : -------------------------------------------------------------------------------------------------------------------------------------------- 
Three           : -------------------------------------------------------------------------------------------------------------------------------------------- 
 
BeauR-hRluc∆5ab : AATGGTGCTTGAGAATAACTTCTTCGTCGAGACCATGCTCCCAAGCAAGATCATGCGGAAACTGGAGCCTGAGGAGTTCGCTGCCTACCTGGAGCCATTCAAGGAGAAGGGCGAGGTTAGACGGCCTACCCTCTCCTGGC 
One             : -------------------------------------------------------------------------------------------------------------------------------------------- 
Two             : -------------------------------------------------------------------------------------------------------------------------------------------- 
Three           : -------------------------------------------------------------------------------------------------------------------------------------------- 
 
BeauR-hRluc∆5ab : CTCGCGAGATCCCTCTCGTTAAGGGAGGCAAGCCCGACGTCGTCCAGATTGTCCGCAACTACAACGCCTACCTTCGGGCCAGCGACGATCTGCCTAAGATGTTCATCGAGTCCGACCCTGGGTTCTTTTCCAACGCTATT 
One             : -------------------------------------------------------------------------------------------------------------------------GTTCTTTTCCAACGCTATT 
Two             : --------------------------------------------------------------------------------------------------------------------------------------GCTATT 
Three           : -------------------------------------------------------------------------------------------------------------------------------------------- 
 
                                                                                                                                                                                                                                                       hRluc Stop 
BeauR-hRluc∆5ab : GTCGAGGGAGCTAAGAAGTTCCCTAACACCGAGTTCGTGAAGGTGAAGGGCCTCCACTTCAGCCAGGAGGACGCTCCAGATGAAATGGGTAAGTACATCAAGAGCTTCGTGGAGCGCGTGCTGAAGAACGAGCAGTAATA 
One             : GTCGAGGGAGCTAAGAAGTTCCCTAACACCGAGTTCGTGAAGGTGAAGGGCCTCCACTTCAGCCAGGAGGACGCTCCAGATGAAATGGGTAAGTACATCAAGAGCTTCGTGGAGCGCGTGCTGAAGAACGAGCAGTAATA 
Two             : GTCGAGGGAGCTAAGAAGTTCCCTAACACCGAGTTCGTGAAGGTGAAGGGCCTCCACTTCAGCCAGGAGGACGCTCCAGATGAAATGGGTAAGTACATCAAGAGCTTCGTGGAGCGCGTGCTGAAGAACGAGCAGTAATA 
Three           : -----------------------------------------------------------------------------------AATGGGTAAGTACATCAAGAGCTTCGTGGAGCGCGTGCTGAAGAACGAGCAGTAATA 
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Fig. 5.4. PCR cloning sequence analysis. PCR products from P7 of initial 
passaging experiment were cloned for (A) BeauR-eGFP IR and (B) BeauR-
hRluc 5ab to demonstrate deletions arising in rIBVs. Wild type sequences are 
shown on top row with sequences from deletion variants shown below. Relevant 
genome positions are highlighted and labelled. 
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5.4 Summary 
 
This chapter outlines the findings from investigations into the stability of rIBVs 
expressing reporter genes. The main findings from this chapter are summarized 
below: 
 Initial attempts to passage rIBVs led to rapid deletion of reporter genes. 
 Passaging at a set MOI improved the overall stability of each rIBV. 
 Replacement of Gene 5 yields the most stable recombinants, followed by 
replacement of the IR and then replacement of ORFs 3a and 3b. 
 Deletion variants of rIBVs are not true D-RNAs but can be controlled in a 
similar manner. 
 Deletions are primarily located within the reporter genes but can also 
encompass non-essential flanking genes. 
 
5.5 General discussion of Chapters 3-5 
 
The aim of this project was to investigate the potential for using IBV as a vaccine 
vector and to identify factors that are important for generating stable virus 
recombinants that successfully express a heterologous protein. Chapters 3, 4 and 5 
have detailed the results of this investigation and have highlighted some of the issues 
relevant to further pursuing the use of IBV as a vaccine vector. A series of nine 
rIBVs were designed to express reporter genes eGFP or hRluc, with subsequent 
analyses to determine how best to utilize IBV as a vaccine vector. A total of six of 
these viruses resulted in the successful rescue of a rIBV, as defined by the 
observation of IBV-induced CPE and the presence of the reporter gene by RT-PCR. 
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Three of the virus constructs did not result in rescued virus due to problems at 
different stages of the reverse genetics system. 
 
Recombinant BeauR-IBVeGFP 5ab was unable to progress past the initial plasmid 
generation stage due to an inability to clone the genome fragment containing the 
codon optimized eGFP sequence in E. coli. Given the successful cloning of plasmid 
pGPT-eGFP 5ab, which utilizes the same genome fragment arrangement, it is not 
clear why pGPT-IBVeGFP 5ab could not be cloned, other than to suggest that the 
altered eGFP sequence rendered the plasmid toxic to bacterial cells. Although a 
number of different competent cells, and growth conditions, were tried none resulted 
in successful cloning of the genome fragment, therefore this potential virus could not 
be pursued further. 
 
The inability to rescue rIBV BeauR-eGFP 3ab can be explained in context of the 
findings from analysis of BeauR-hRluc 3ab in Chapter 4. Although two replicates 
of BeauR-hRluc 3ab were rescued a number of problems were identified with these 
viruses, including the presence of deletions in the inserted TRS for E, and mixed 
populations arising around the hRluc gene in R2 (Fig. 4.9). This suggested a high 
degree of instability in this virus construct due to the sequence modifications made 
to accommodate transcription of E as a new sg mRNA from an artificially introduced 
TRS. Given these observations it is probable that lethal errors arose within this 
region of the BeauR-eGFP 3ab genome during initial rounds of replication, and thus 
a viable virus population could not be established. Without complete sequencing of 
the two vaccinia virus clones used for the rescue it is not possible to rule out the 
presence of sequence errors elsewhere in the modified IBV cDNA that could have 
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led to non-viable virus. However, given the stability of the vaccinia virus system, the 
use of two distinct plaque lineages of vaccinia virus and the successful sequencing of 
the modified region makes this a less likely explanation for the failure to rescue. 
 
Recombinant virus BeauR-5a/eGFP also failed to rescue successfully. While rIBVs 
were in fact rescued, as identified from IBV-induced CPE, the eGFP gene had been 
deleted from all viruses screened by RT-PCR (Fig. 3.9). This virus had been 
designed so that eGFP was expressed as a C-terminal fusion of accessory protein 5a. 
The precise deletion of the eGFP sequence suggests that it was not tolerated in this 
construct. A possible explanation for this is the occurrence of recombination events 
that led to deletion of the eGFP sequence, as will be discussed later with regards to 
rIBV stability. It is possible that modifications to the sequence, i.e. an N-terminal 
fusion, may have yielded a successful rIBV but time constraints meant that these 
possibilities could not be followed up. 
 
The analyses of the six rescued rIBVs revealed some important points for 
considering the use of IBV as a vaccine vector. The rescue of two replicates for each 
virus was intended to allow confirmation of the viability of each virus construct but 
instead highlighted the fact that each independent rescue can result in a different 
outcome in terms of errors introduced into the virus genome. Three of the rIBVs, 
BeauR-eGFP 5ab, BeauR-hRluc 5ab and BeauR-hRluc IR, had two replicates 
rescue without any known errors introduced into the genome. For BeauR-eGFP IR 
and BeauR-IBVhRluc 5ab only one replicate of each was rescued without errors, 
while neither replicate of BeauR-hRluc 3ab rescued without errors. Differences in 
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the successful rescue of different replicates of the same virus suggest that there is an 
unpredictable element in replication for some constructs. 
 
Of the errors identified in the rescued rIBVs the one with the least impact on reporter 
gene expression or virus stability was that identified in BeauR-eGFP IR R1 (Fig. 
4.4). Interestingly, this double TA mutation, that results in a premature stop in 
ORF 5b, has been independently observed before in rIBVs generated in the IAH 
Coronavirus group (Armesto, et al. 2009). In this study by Armesto et al. the 
structural and accessory proteins of Beau-R were replaced with those of the 
pathogenic M41 strain of IBV. The resultant chimaeric virus contained several 
changes, one of which was the double TA mutation in ORF 5b witnessed here. 
The repeated occurrence of these mutations in some rIBVs suggests that they may 
arise as a result of replication pressures brought about by the modifications made to 
the virus. As Gene 5 is known to be dispensable for replication in cell culture the 
loss of ORF 5b may be a trade-off for a benefit elsewhere in the virus. As suggested 
by Armesto et al. these mutations may lead to an improved recognition of the N gene 
TRS, and subsequent N gene expression. These mutations showed no effect on virus 
replication (Fig. 4.5) or virus stability (Fig. 5.2) following comparison of R1 and R2 
of BeauR-eGFP IR, suggesting the additional loss of Gene 5 proteins does not affect 
this particular virus construct. 
 
Expression of eGFP or hRluc in cell culture was confirmed by western blot for all 
rIBVs, with the exception of BeauR-hRluc∆3ab R2 (Fig. 4.11). Protein expression 
was additionally confirmed for R1 of each rIBV by confocal microscopy (Fig. 4.12). 
This demonstrates that heterologous genes can be expressed from numerous 
Chapter Five 
119 
 
positions within the IBV genome and it is probable that genes from different avian 
viruses could therefore be expressed in a vaccine construct. 
 
Analysis of heterologous protein expression from each of the ∆5ab hRluc rIBVs 
showed that codon optimization had a slight negative impact on protein expression 
(Fig 4.15). Replicate 2 of BeauR-IBVhRluc 5ab demonstrated lower levels of 
protein expression from 24 hpi compared to sister virus BeauR-hRluc 5ab. There 
are two possible explanations for the decrease in hRluc expression. First, it is 
possible that by maximizing the codon usage for IBV, pressure has been put on the 
availability of tRNAs and, as replication proceeds over time, pools of limited tRNAs 
are depleted and translation of the optimized gene is restricted. As peak virus titres at 
24 h were identical for BeauR-hRluc 5ab and BeauR-IBVhRluc 5ab (Fig. 4.2), 
differences in protein expression levels cannot be explained by differences in virus 
replication. Additionally, at earlier time points expression levels are the same as the 
sister virus suggesting that codon optimization cannot increase translation of the 
heterologous gene above the wild type level for that gene. 
 
A second explanation relates to the efficiency of expression of the hRluc protein in 
avian cells and whether this was affected by the changes introduced into the 
nucleotide sequence. The native Renilla luciferase gene was originally substantially 
altered at the nucleotide sequence level to generate the synthetic hRluc gene, which 
was optimized for expression and sensitivity in mammalian cells (Zhuang, et al. 
2001). It is possible that sequence changes introduced during IBV codon 
optimization also introduced, or re-introduced, sequence elements that resulted in a 
reduction in the efficiency of expression of the luciferase gene in avian cells, and 
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counteracted the benefits of the original optimization process. However, it is also 
possible that these sequence changes resulted in a more stable viral RNA molecule 
thus explaining the small increase in virus stability observed for rIBV BeauR-
IBVhRluc∆5ab over BeauR-hRluc∆5ab. 
 
Interestingly R1 of BeauR-IBVhRlucΔ5ab had considerably reduced luciferase 
expression compared to R2 (Fig. 4.15). Alteration to the amino acid sequence of the 
codon optimized luciferase arose due to the insertion of two additional T nucleotides 
at position 26267 (Fig. 4.14). The active site for Renilla luciferase is proposed to 
consist of a triad of residues; D120, E144 and H285 (Woo, et al. 2008). The 
unintentional alteration to the hRluc sequence resulted in amino acid change H285F. 
This amino acid change is therefore likely to have altered the active site of hRluc 
with the result being a less efficient reaction of hRluc protein with the hRluc 
substrate and thus lower levels of luminescence detected. 
 
Although reporter gene expression was observed for the majority of rIBVs, 
expression was only possible for a limited number of rounds of replication before the 
reporter gene was deleted from the virus. This highlights an issue of virus stability 
that has been seen previously with recombinant coronaviruses, and closely related 
arteriviruses, expressing heterologous genes (de Haan, et al. 2005, de Vries, et al. 
2001, Shen, et al. 2009, Youn, et al. 2005). 
 
Stability of the rIBVs was found to correlate with the location of the reporter gene, 
which therefore indirectly correlated with the level of modifications required in order 
to accommodate the reporter gene in the IBV genome. The most stable rIBVs, in 
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terms of the number of cell culture passages prior to reporter gene deletion, were 
those replacing Gene 5 (Table 5.2). The 5ab rIBVs required a direct replacement of 
virus sequence with the reporter gene, which could then be transcribed using the 
existing TRS for Gene 5. No additional sequences needed to be included to ensure 
continued transcription of virus genes and it is likely that this contributed to the 
increased stability of these rIBVs. 
 
In contrast, the least stable construct, BeauR-hRluc 3ab, required not only alteration 
of the existing Gene 3 mRNA to incorporate the hRluc sequence in place of ORFs 3a 
and 3b, but also required the insertion of an additional TRS to ensure the 
transcription of the E gene as a new independent mRNA. Coronavirus transcription 
is a complex process that, although not completely understood, is likely to be tightly 
regulated and attempts to alter the number of mRNAs transcribed appears to be 
poorly tolerated. The IR rIBVs were also found to be less stable than the 5ab 
rIBVs, and also had more substantial changes made to the virus sequence to 
accommodate transcription of the reporter gene as a new mRNA. 
 
The finding that stability of the rIBVs could be improved by passaging at a set MOI 
raised the question of the mechanism of deletion of the reporter genes. Initially it 
was believed that reporter genes were being lost through the natural generation of D-
RNAs but no evidence to support this could be obtained. Instead it appeared that 
only the reporter gene was deleted, as well as non-essential flanking regions in some 
cases (Fig. 5.4). 
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Sequence analysis of non-wild type PCR products from BeauR-eGFP IR, generated 
during passaging, showed that deletions were not necessarily limited to the reporter 
genes and could spread into flanking regions (Fig. 5.4). In the IR constructs the 
reporter gene is flanked upstream by the essential M gene, and downstream by the 
non-essential Gene 5. It has been demonstrated that the loss of Gene 5 can be 
tolerated by the virus, raising the possibility that deletions may occur over a larger 
region, encompassing both the reporter gene and Gene 5, while still resulting in a 
viable virus population. This larger region over which deletions can occur increases 
the likelihood of a virus population arising that no longer contains the reporter gene 
and, with a smaller genome, is able to replicate more efficiently to rapidly become 
the dominant virus population. 
 
In contrast, for rIBV BeauR-hRluc 3ab the reporter gene is flanked by two essential 
genes, Spike and E. Any deletions arising that encompass these genes would be 
lethal to the virus and consequently fewer deletion variants are likely to arise that 
result in a viable virus population. This may explain why in the passaging 
experiments detection of the wild type PCR product persists over a greater number 
of passages for BeauR-hRluc 3ab than any of the other rIBVs. As any deletions are 
limited to within the reporter gene, so that a viable virus population is maintained, it 
is likely that fewer deletion variants will arise that can replicate more efficiently than 
wild type. Deletion variant populations will therefore take longer to establish than 
for other rIBVs. As a result wild type genomes would encounter less competition for 
resources and packaging into new virions, and the wild type population will persist 
for longer. 
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As mentioned there have been previous studies of corona- and arteriviruses as 
vaccine vectors and many of these showed similar deletions of heterologous genes. 
One proposed explanation for this is the occurrence of homologous recombination 
events between similar sequences of virus genomes, such as TRSs, that result in the 
loss of the heterologous gene. It is probable that this is also the situation with the 
rIBVs analysed in this study. Recombination events occur as a result of template 
switching during negative-strand synthesis of virus genomes and sg mRNAs. The 
concurrent synthesis of negative-sense copies of both genomes (anti-genomes) and 
sg mRNAs (sg RNAs) means recombination events are possible between either anti-
genome and anti-genome, or anti-genome and sg RNA. Although only changes 
introduced into the anti-genome will be hereditary, the compound effect of anti-
genome recombinations with potentially defective sg RNAs will increase the chance 
of errors being introduced into the virus population. 
 
This theory of recombination-based deletion could also explain why passaging at a 
low MOI resulted in viruses that maintained stability over a greater number of 
passages. By infecting at a low MOI it is less likely that a single cell is infected by 
more than one virus particle. This would initially limit the number of recombination 
events that can occur until replication has progressed sufficiently for an abundance 
of virus templates to be available, and so decreasing the likelihood of an early 
recombination event with a negative outcome. 
 
Overall the data shows that all vaccine vector constructs are capable of expressing a 
heterologous gene. The stability of these viruses varies considerably depending on 
genome location and/or the level of modifications required to the genome. The 
Chapter Five 
124 
 
replacement of Gene 5 proved to be the most successful in terms of both stability and 
protein expression while the replacement of ORFs 3a and 3b was found to be the 
least stable. The type of heterologous gene inserted was found to have little effect on 
protein expression or stability, although eGFP resulted in poorer growth kinetics 
than hRluc following replacement of the IR (Fig. 4.3). Unfortunately as not all eGFP 
recombinants were rescued a comparison to hRluc is limited. Codon optimization 
may result in a slight improvement in virus stability (Table 5.2) although further 
passaging at the set MOI of 0.01 (past P12) would be required to observe any 
potential differences between BeauR-hRluc 5ab and BeauR-IBVhRluc 5ab. Codon 
optimized luciferase protein levels were slightly reduced compared to wild type 
hRluc but this may not be an unfavourable outcome depending on the heterologous 
gene expression levels required for an effective vaccine. 
 
During the analysis of the rIBVs two unexpected observations were made. First, 
when attempting to establish protocols for the use of eGFP rIBVs in live cell 
imaging it was discovered that viruses lacking Gene 5 had a reduced capacity for 
cell-cell spread on Vero cells (Fig. 4.16). It is possible that this effect is also seen on 
CK cells although to a much lesser extent, as demonstrated by the plaque 
morphology data (Fig. 4.1) and growth kinetics (Fig. 4.2) of the 5ab recombinants. 
While the effects are much more pronounced in Vero cells than CK cells this may 
simply be representative of the inherently lower replication efficiency of IBV 
observed in Vero cells, as Beau-R has not been adapted for growth in this cell 
culture system. These results are the first indication of a role for the Gene 5 
accessory proteins in IBV replication. Second, there was a suggestion from northern 
blot analysis that a mRNA may be being transcribed from the IR (Fig. 4.8). This 
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finding was investigated further and led to a second project for this thesis that will 
now be described in Chapters 6 and 7. 
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Chapter 6: Investigation of the IBV intergenic region 
 
6.1 Introduction 
 
The analysis of rIBVs in Chapter 4 led to interesting observations regarding the 
uncharacterized RNA species often visible on northern blots between the M gene 
and Gene 5 mRNAs of IBV (Fig. 4.8). The uncharacterized RNA species was first 
identified by Stern and Kennedy as one of a number of minor bands occasionally 
observed by northern blot analysis of the RNA species produced by the Beaudette 
strain of IBV (Stern and Kennedy 1980). It was not determined at that time whether 
this RNA was of cellular or viral origin and this question has remained ever since. 
The lack of consistent detection of this RNA is apparent throughout the literature 
with many publications making no reference to an additional RNA species at all, 
while others simply reference back to the Stern and Kennedy paper. 
 
In Chapter 4 northern blot analysis of the 5ab rIBVs demonstrated that this 
uncharacterized RNA species shifted in size relative to the changes made to the Gene 
5 mRNA (Fig. 4.8). Additionally, this RNA species was no longer detected during 
analysis of IR rIBVs. Together, this data suggested that this RNA may in fact be a 
mRNA and furthermore may be linked to the region of the genome referred to as the 
intergenic region. 
 
As described in more detail in Chapter 1 the IR of IBV, originally determined by 
sequence analysis of the Beaudette strain, is located between the M gene and Gene 5 
and, in the majority of IBV strains, contains a putative ORF for a protein of 94 
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amino acids. The IR has also received little attention in terms of research due 
primarily to the lack of a TRS-B of CUUAACAA, or a similar sequence, upstream 
of the potential coding sequence. The presence of a TRS-B is one of the central 
principles underlying the mechanism of coronavirus sg mRNA transcription, and 
therefore despite the IR sequence being located between the M gene and Gene 5, as 
is also observed for the uncharacterized RNA species on northern blots, the two have 
never been linked. Furthermore, the theory of discontinuous transcription during 
negative strand synthesis is widely accepted, in part, due to the discovery that the 
TRS of each sg mRNA is derived from the associated TRS-B (Pasternak, et al. 2001, 
van Marle, et al. 1999, Zuniga, et al. 2004). This suggests an absolute requirement of 
a TRS-B for transcription and a lack thereof would mean no sg mRNA is transcribed 
from the IR. 
 
As mentioned the IR contains a putative ORF, encoding a protein of 94 amino acids 
in the majority of IBV strains. Some, such as Beaudette and other lab-adapted 
strains, contain deletions within the IR ORF and therefore have lost the potential to 
code for this protein. The IR ORF is also known to be present in the closely related 
gammacoronavirus, turkey coronavirus (TCoV). The more common nomenclature 
for the TCoV IR in the literature is ORF 4b, presumably based on the assumption 
that without a known TRS-B any potential protein of the IR would be translated 
from a functionally bi-cistronic M mRNA in a manner similar to Gene 3 and Gene 5. 
 
To date neither the IR and the putative ORF, nor the uncharacterized RNA have been 
studied in detail and the observation that the uncharacterized RNA may be linked to 
the IR provided the opportunity to fully investigate these two aspects of IBV 
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biology. The initial aim of this project was to determine the nature of the 
uncharacterized RNA species and what, if any, link exists between it and the IR. 
Further characterization of the RNA and the IR would be carried out in light of any 
findings. 
 
6.2 Analysis of the IBV uncharacterized RNA species 
 
The first stage of the investigation was to confirm whether a mRNA is transcribed 
from the IR, and if this mRNA corresponds to the previously uncharacterized RNA 
species seen on northern blots of IBV. To do this recombinant virus BeauR IR, as 
used in previous chapters, was subjected to northern blot analysis and the mRNA 
pattern compared to wild type Beau-R (Fig. 6.1). 
 
The northern blot showed the typical mRNA profile for Beau-R in lane 1 while in 
lane 2 the profile for BeauR IR showed an altered pattern. The RNA species located 
between the M gene and Gene 5 (the uncharacterized RNA species) was observed to 
have been reduced in size following infection with BeauR IR. This size reduction is 
equivalent to the 268nt deletion introduced into the IR. The mRNAs for all genes 
upstream of the IR were also shown to be reduced in size as would be expected due 
to the nested nature of the mRNAs. This result provided strong evidence that the 
previously uncharacterized RNA species is in fact an IBV sg mRNA and is linked to 
the IR. An additional, previously unidentified RNA was also observed below the 
Spike gene mRNA (designated by an arrow) and is investigated further in section 
6.6. 
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Fig. 6.1. Northern blot analysis of BeauR IR. Confluent monolayers of CK cells 
were infected with Beau-R or BeauR IR and 20 hpi intracellular RNA was 
harvested and subjected to northern blot analysis with a probe complementary to the 
3'-end of the Beaudette genome. Closed arrow heads point to wild type mRNAs, 
open arrow heads point to altered mRNAs. The * indicates the uncharacterized RNA 
species. Arrows point to an additional unidentified RNA species. 
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As no TRS-B resembling the conserved IBV TRS, CUUAACAA, has ever been 
identified upstream of the IR the question of how this mRNA is transcribed was 
addressed. A PCR technique known as a leader-body junction PCR was used to 
investigate the IR further. This PCR, as detailed in section 2.9, utilizes the 5' and 3' 
co-terminal nature of the coronavirus sg mRNAs to amplify specific virus mRNAs 
as determined by the position of the reverse primer (Fig. 6.2). 
 
 
Fig. 6.2. Leader-body junction PCR schematic. This schematic outlines the 
amplification of coronavirus mRNAs by PCR. A forward primer located in the 5' 
Leader sequence is paired with a reverse primer located in one of the structural or 
accessory genes. Due to the nested nature of the sg mRNAs all mRNAs upstream of 
the reverse primer will be amplified. In the example a reverse primer located in the 
IR will yield PCR products of 5123bp, 1606bp and 1001bp representing Spike, Gene 
3 and M mRNAs respectively. An additional PCR product would be amplified 
representing an IR mRNA although the size of this is unknown as the site of leader-
body TRS junction is unknown. 
 
 
Using this technique a PCR product suspected to correspond to the IR mRNA was 
amplified from Beau-R infected CK cells (Fig. 6.3). 
Spike Gene 3 M IR Gene 5 NLeader
Gene 3 M IR Gene 5 NLeader
Leader M IR Gene 5 N
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?
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Fig. 6.3. Leader-body junction PCR of Beau-R. Intracellular RNA was extracted 
from Beau-R infected CK cells and reverse transcribed. Messenger RNAs were 
amplified by PCR with primers Leader1 and IR(R). PCR products were separated by 
gel electrophoresis. Arrows point to IR and M mRNAs. Lane L: DNA marker.  
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To facilitate further analysis of the suspected IR mRNA, PCR products were cloned 
and resulting bacterial colonies were screened by PCR to identify plasmids 
containing the original IR mRNA PCR product. Appropriate PCR products from the 
colony screening were then sequenced. Sequence analysis of the suspected IR 
mRNA yielded an interesting result (Fig. 6.4). 
 
 
A 
IR-mRNA :ACACTAGCCTTGCGCTAGATTTTTAACTTAACAAAGCGGAAATAAG-N93ATG:172 
Beau-R  :CTACCGTATGGTGCAGAAATATACTGGTGACCAAAGCGGAAATAAG-N93ATG:25185 
 
B 
 
Fig. 6.4 Messenger RNA alignments. PCR products of suspected IR mRNAs were 
sequenced with primers M13(F) and M13(R). (A) The mRNA sequences were 
aligned to Beau-R genome sequence. Bottom line shows genomic sequence. Top line 
shows mRNA sequence with Leader sequence highlighted in blue and TRS 
highlighted in yellow. Relative mRNA and genome positions are given on the right 
along with the distance to the IR ATG. (B) Sequence trace of IR mRNA showing the 
CTTAACAA TRS. 
 
 
The PCR product corresponding to the potential IR mRNA was found to be 
consistent with other IBV sg mRNAs in the sense that it contained the IBV Leader 
sequence at the 5'-end, followed by a full copy of the IBV TRS, CTTAACAA, 
followed by genomic sequence corresponding to IR. The analysis of the sequence 
showed that the IR mRNA aligned to a position 105nts upstream of the IR ATG, 
within the M gene. However, unlike for all other IBV sg mRNAs, a complete TRS-B 
Chapter Six 
133 
 
was not found in the genome sequence. Interestingly, the alignment of the mRNA to 
the genome showed that only positions 6-8 of the IBV TRS, CAA, were present as a 
potential TRS-B site. This suggested that the TRS-B for the IR is a non-canonical, 
shortened TRS-B consisting of CAA, and not CUUAACAA (or CUGAACAA) as 
observed for all other Beau-R structural and accessory genes. 
 
Overall these results confirm that the RNA species present between the M gene and 
Gene 5 sg mRNAs on IBV northern blots fulfils the criteria for definition as an IBV 
sg mRNA, i.e. the 5' Leader sequence and TRS fused to genomic sequence 
corresponding to an IBV gene. 
 
As the IR is known to be present in some form in all IBV strains it was necessary to 
confirm transcription of the IR mRNA from a variety of field and vaccine strains of 
IBV. These strains included Beau-CK, the parent virus of Beau-R used to generate 
the cDNA clone and M41, a pathogenic laboratory strain of IBV. Additionally, 
vaccine strains H120 and CR88, and field strains D1466, Italy-02 and QX were 
available in the lab and had recently been deep sequenced across the entire genome. 
A leader-body junction PCR was carried out on each of these strains to confirm that 
transcription of the IR mRNA is not unique to Beau-R. Beau-R was also repeated as 
a control. Gel electrophoresis showed that for each IBV strain a product was 
amplified relating to an IR mRNA providing strong evidence that all IBVs transcribe 
a sg mRNA corresponding to the IR. The size difference between Beau-R and Beau-
CK, and all other strains is due to the known deletion present within Beaudette 
strains of IBV (Fig. 6.5). 
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Fig. 6.5. Leader-body junction PCR of IBV field and vaccine strains. CK cells 
were infected with various strains of IBV and incubated for 20 to 48 h depending on 
strain. Intracellular RNA was extracted from cells and reverse transcribed. 
Messenger RNAs were amplified by PCR with primers Leader1 and IR(R). PCR 
products were separated by gel electrophoresis. Arrows point to IR and M mRNAs. 
Lane L: DNA marker.  
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The PCR product derived from the IR mRNA of each virus was cloned and 
sequenced as before. In all cases the IR mRNA sequence showed the presence of the 
complete CTTAACAA TRS followed by genomic sequence corresponding to the 3'-
end of the M gene and the IR sequence. In all cases the alignments identified the 
same non-canonical TRS-B of CAA as for Beau-R (Fig. 6.6). These results 
confirmed that all of the IBV strains tested produce a sg mRNA corresponding to the 
IR sequence located between the M gene and Gene 5. 
 
 
IR-mRNA :ACACTAGCCTTGCGCTAGATTTTTAACTTAACAAAGCGGAAATAAGAAAAGGTTT-N84ATG:172 
Beau-CK :CTACCGTATGGTGCAGAAATATACTGGTGACCAAAGCGGAAATAAGAAAAGGTTT-N84ATG:25185 
 
IR-mRNA :ACACTAGCCTTGCGCTAGATTTCCAACTTAACAAAGCGGAAATAAGAAACGGTTT-N84ATG:172 
M41     :CTACCGTATGGTGCAGAAATATACTGGTGACCAAAGCGGAAATAAGAAACGGTTT-N84ATG:25191 
 
IR-mRNA :ACAGCAACCTTGCGCTAGATTTCCAACTTAACAAAGCGGAAGTAAGAAAAGGTTT-N84ATG:172 
CR88    :CTATCGTATGGTGCAAAAATATACTGGTGACCAAAGCGGAAGTAAGAAAAGGTTT-N84ATG:25171 
 
IR-mRNA :ACACTAGCCTTGCGCTAGATTTCTAACTTAACAAAGCGGAAATAAGAAAAGGTTT-N84ATG:172 
D1466   :CTATCGTATGGTGCAGAAATACATTGGTGACCAAAGCGGAAATAAGAAAAGGTTT-N84ATG:25128 
 
IR-mRNA :CAAGCAACCTTGCGCTAGATTTCAAACTTAACAAAGCGGAAATAAGAAAAGGTTT-N84ATG:172 
H120    :CTATCGTATGGTGCAGAAATACATTGGTGACCAAAGCGGAAATAAGAAAAGGTTT-N84ATG:25131 
 
IR-mRNA :ACACCTGCCTTGCGCTAGATTTTCAACTTAACAAAGCGGAAATAAGAAAAGGTTT-N84ATG:172 
Italy-02:TTATCGTATGGTGCAGAAATACACTGGTGACCAAAGCGGAAATAAGAAAAGGTTT-N84ATG:25179 
 
IR-mRNA :ACACTAGCCTTGCGCTAGATTTCCAACTTAACAAAGCGGAAATAAGAAAAGGTTT-N84ATG:172 
QX      :CTATCGCATGGTGCAGAAATACACTGGTGACCAAAGCGGAAATAAGAAAAGGTTT-N84ATG:25188 
 
 
Fig. 6.6. Vaccine and field strains mRNA alignments. PCR products of each IR 
mRNAs were sequenced with primers M13(F) and M13(R). The mRNA sequences 
were aligned to the genome sequence of the relevant strain. Bottom line shows 
genomic sequence. Top line shows mRNA sequence with leader sequence 
highlighted in blue and TRS highlighted in yellow. Relative mRNA and genome 
positions are given on the right along with the distance to the IR ATG. 
 
 
Finally, to confirm that transcription of the IR mRNA, using the suspected non-
canonical TRS-B, is not an artefact of growth in CK cells, analysis was carried out 
on RNA samples isolated from tracheas of chickens experimentally infected with the 
M41 strain of IBV (Fig. 6.7). 
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B 
IR-mRNA :ACACTAGCCTTGCGCTAGATTTCCAACTTAACAAAGCGGAAATAAGAAACGGTTT-N84ATG:172 
M41     :CTACCGTATGGTGCAGAAATATACTGGTGACCAAAGCGGAAATAAGAAACGGTTT-N84ATG:25191 
 
 
Fig. 6.7 Analysis of IR mRNA in vivo. Tracheal samples from IBV M41 infected 
birds were analysed for the presence of the IR mRNA. (A) Gel electrophoresis of 
leader-body junction PCR products. Lane L: DNA marker. (B) Sequence alignment 
of IR mRNA against M41 genome sequence. Bottom line shows genomic sequence. 
Top line shows mRNA sequence with leader sequence highlighted in blue and TRS 
highlighted in yellow. Relative mRNA and genome positions are given on the right 
along with the distance to the IR ATG. 
 
  
Chapter Six 
137 
 
The same PCR product corresponding to the IR was observed as for the M41 CK 
infection (Fig. 6.7A). Sequence analysis confirmed that the PCR product was a 
mRNA for the IR, as seen previously, and that the same non-canonical TRS-B was 
present (Fig. 6.7B). 
 
The data confirms that a mRNA is transcribed from the IR of all IBV strains, both in 
vitro and in vivo. Additionally, transcription is suspected to be mediated by a 
previously unseen non-canonical TRS-B consisting of only the final three 
nucleotides of the known IBV TRS. 
 
6.3 Characterization of the IR mRNA of turkey coronavirus 
 
Given the knowledge obtained for IBV, and the known presence of the IR sequence 
in TCoV (ORF 4b), it was hypothesised that an independent mRNA was also being 
transcribed from the TCoV IR, as for IBV. There is currently no cell culture system 
for growing TCoV and the virus can only be grown in embryonated turkey eggs. No 
facilities were available at the IAH to obtain virus samples that could be screened for 
the presence of the IR mRNA. Instead a request was sent to Dr. Nicolas Eterradossi 
at ANSES in France who kindly provided a sample of total RNA extracted from 
homogenised turkey embryos infected with the FR080385d strain of TCoV. 
 
The complete genome sequence was unavailable for TCoV FR080385d and so it was 
not possible to check that IBV primers Leader1 and IR(R), used for the leader-body 
junction PCR, were a sequence match to TCoV. Initial attempts at the PCR did not 
amplify any products suggesting a sequence mismatch in one, or both, of the 
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primers. To attempt to overcome this problem all of the available TCoV sequences 
in GenBank were analysed at the sites of the two primers to identify potential 
differences in sequence between TCoV and IBV. Based on the most frequent 
nucleotide differences two new primers were designed (Table 6.1). 
 
 
TABLE 6.1: Leader-Body Junction PCR Primers 
Primer Sequence
a
 
Leader1 CTATTACACTAGCCTTGCGC 
TCoV Leader1 CTATCATACTAGCCTTGTGC 
IR (R) GGTTGTTGTAGGATGTGGTC 
TCoV IR (R) GGTTGTTGTAGAATGTGGTC 
       a
 nucleotides in red highlight changes from IBV to TCoV 
 
 
A series of leader-body junction PCRs were carried out using the IBV and TCoV 
primers in each possible combination to find a pair that could amplify the viral 
mRNAs. The primer pair that was found to work was TCoV Leader1 with IBV 
IR(R) and mRNA products were amplified as previously (Fig. 6.8A). 
 
A PCR product of the same size as previously obtained from IBV RNA, and 
representing the IR, was observed for TCoV. This PCR product was cloned and 
sequenced to confirm the presence of a TCoV IR mRNA. As the complete genome 
sequence for TCoV FR080385d was not available, in order to complete the 
alignments a section of the virus was sequenced using primers BG52 and IR(R). The 
TCoV IR mRNA sequence was then aligned to this, as well a complete TCoV 
genome sequence (GenBank NC_010800) for confirmation (Fig. 6.8B). 
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B 
 
TCoV IR-mRNA:ATACTAGCCTTGTGCTAGATTTCTAACTTAACAAAGCGGAAATAAGAAAAGGTTT-N84ATG: 
FR080385d   :CTATCGTATGGTGCAGAAATACACTGGTGACCAAAGCGGAAATAAGAAAAGGTTT-N84ATG: 
NC_010800   :CTATCGTATGGTGCAGAAATACACTGGTGACCAAAGCGGAAATAAGAAAAGGTTT-N84ATG:25311 
 
 
Fig. 6.8. Characterization of turkey coronavirus IR. Intracellular RNA was 
extracted from turkey embryos infected with FR080385d strain of TCoV. (A) 
Messenger RNAs were amplified by PCR with primers TCoV Leader1 and IR(R) 
and separated by gel electrophoresis. Lane L: DNA marker. (B) The TCoV IR 
mRNA was sequenced with primers M13(F) and M13(R). The mRNA was aligned 
to FR080385d genome sequence as well as GenBank sequence NC_010800. Top 
line shows mRNA sequence with Leader sequence highlighted in blue and TRS 
highlighted in yellow. Genome position was known only for GenBank strain 
NC_010800 and is given on the right along with the distance to the IR ATG. 
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The sequence alignment confirmed that a mRNA is also transcribed from within the 
3'-end of the TCoV M gene and includes the potential TCoV ORF 4b protein 
sequence. Transcription of this mRNA also appears to be mediated by a suspected 
non-canonical TRS-B of CAA, as for the IR of IBV. Based on these findings it was 
speculated that other closely related members of the gammacoronavirus genus might 
also transcribe a mRNA from this region. Unfortunately it was not possible to test 
this using virus samples, however investigation of available complete genome 
sequences revealed that at least three further species also contain both the putative 
coding region and the conserved region of the non-canonical TRS-B; duck 
coronavirus (JF705860), a coronavirus isolated from partridge (AY646283) and 
pheasant coronavirus UK/602/95 (full sequence unpublished). 
 
6.4 Investigation of the gammacoronavirus intergenic region protein 
 
Sequence analyses have shown that the majority of gammacoronaviruses containing 
the IR contain a putative coding sequence that encodes a protein of 94 amino acids, 
but this has never been investigated due to the perceived lack of a mRNA for this 
protein. Having now identified a mRNA transcribed for the IR the question was 
raised as to whether it is possible that a 5
th
 novel accessory protein is being 
translated by these viruses. Due to the unusual nature of the potential TRS-B for the 
mRNA, and the potentially altered transcription mechanism, it was first necessary to 
confirm that a coding region contained within the IR mRNA could be translated into 
a functional protein. At this time no tools were available to detect translation of the 
potential protein itself; therefore a rIBV expressing eGFP was generated for this 
purpose. 
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This new rIBV was similar to BeauR-eGFP IR used in the vaccine vector work 
(Chapters 3-5) and was generated from a pGPT selection plasmid synthesised by 
GeneArt® (see Appendix 2 and 3 for plasmid map and sequence). The construction 
of this rIBV involved the direct replacement of the IR/ORF 4b protein coding 
sequence with the sequence for eGFP, i.e. the ATG of the IR located directly 
downstream of the M gene stop codon became the ATG for eGFP. Unlike BeauR-
eGFP IR, where a copy of the Gene 5 TRS-B was inserted to ensure transcription of 
a novel sg mRNA for eGFP, the new rIBV would utilize the suspected non-canonical 
TRS-B of the IR. To avoid confusion with rIBV BeauR-eGFP IR this new virus was 
called BeauR-eGFP 4b based on the alternative nomenclature used for the IR. 
BeauR-eGFP 4b was successfully rescued and fluorescence microscopy of CK cells 
infected with P3-derived virus showed high numbers of green fluorescent cells, 
confirming translation of eGFP (Fig. 6.9). 
 
 
 
Fig. 6.9. Fluorescence microscopy of BeauR-eGFP 4b. Confluent monolayers of 
CK cells were (A) mock infected or (B) infected with BeauR-eGFP 4b P3 virus and 
examined by fluorescence microscopy 20 hpi. Images were taken at 10x 
magnification. 
 
 
A B
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Using the leader-body junction PCR technique, the eGFP mRNA of BeauR-
eGFP 4b was amplified with primers Leader1 and eGFP S(R) and sequenced to 
confirm transcription via the suspected non-canonical TRS-B (Fig. 6.10). 
 
 
eGFP-mRNA    :CTATTACACTAGCCTTGCGCTAGATTTTTAACTTAACAAAGCGGAAATAAGAAAAGGTTT:85 
BeauR-eGFPΔ4b:AATATCTACCGTATGGTGCAGAAATATACTGGTGACCAAAGCGGAAATAAGAAAAGGTTT:25098 
 
eGFP-mRNA    :GCTACGTTTGTCTATGCAAAGCAGTCAGTAGATACTGGCGAGCTAGAAAGTGTAGCAACA:145 
BeauR-eGFPΔ4b:GCTACGTTTGTCTATGCAAAGCAGTCAGTAGATACTGGCGAGCTAGAAAGTGTAGCAACA:25158 
                              M Stop  eGFP Start 
                                   ▼  ▼                
eGFP-mRNA    :GGAGGAAGTAGTCTTTACACATAAATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGGTG:205 
BeauR-eGFPΔ4b:GGAGGAAGTAGTCTTTACACATAAATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGGTG:25218 
 
Fig. 6.10. Messenger RNA alignment of eGFP. A mRNA relating to eGFP from 
BeauR-eGFP 4b was sequenced and aligned to the virus genome. The M stop and 
eGFP start are labelled to indicate positions in the mRNA. Top line shows mRNA 
sequence with leader sequence highlighted in blue and TRS highlighted in yellow. 
Relative mRNA and genome positions are given on the right. 
 
 
Sequence analysis confirmed that the eGFP mRNA was synthesised as an 
independent mRNA transcribed from the suspected non-canonical TRS-B located at 
the 3'-end of the M gene. This provided strong evidence that the potential protein 
coded for in the IR mRNA is translated during virus infection. To obtain more 
information on this potential protein some basic analysis was carried out using the 
coding sequence of the M41 IR. Using the Compute pI/Mw programme at 
www.expasy.org the theoretical isoelectric point (pI) and molecular weight were 
calculated at 9.06 and 11kDa respectively. Unfortunately additional analysis of the 
protein sequence did not reveal the presence of any specific domains or features that 
would provide information on the nature of the protein, and BLAST searches 
revealed no matches outside of the known IBV and related gammacoronavirus 
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sequences. It is therefore not possible to infer any possible functions or roles of the 
IR protein at this time. 
 
With limited information available it was decided to try to detect the IR protein in 
virus infected CK cells. For this the generation of a peptide antibody was 
commissioned that could subsequently be used in different detection techniques. The 
antibody was generated against what was determined to be the most antigenic 
peptide within the M41 IR coding sequence. The peptide selected corresponded to 
amino acids 68-84 (5'-DNGKVYYEGKPIFQKGC-3') of the IR protein. The purified 
antibody was first tested by western blot of cell lysates from M41 infected CK cells. 
However, despite attempts to optimize the process, this did not result in visualisation 
of the expected 11kDa protein as was hoped. The antibody was further tested by 
confocal microscopy to try and visualise the protein within M41 infected CK cells 
however, this also proved to be unsuccessful and it remains to be confirmed that a 
protein is translated from the IR mRNA. 
 
6.5 Investigation of reporter gene TRS-B usage in recombinant IBVs 
 
The initial observations in Chapter 4 that led to the investigation of the IR were 
made during the analysis of rIBVs in which the IR had been replaced with one of 
two reporter genes. In both rIBVs, BeauR-eGFP IR and BeauR-hRluc IR, an 
additional copy of the Gene 5 TRS-B was inserted upstream of the reporter gene to 
ensure transcription of a sg mRNA specific to the reporter gene. However, given the 
finding that the IR potentially has an associated TRS-B the question was raised as to 
how exactly the reporter genes in these rIBVs were being transcribed. Originally it 
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was believed that the reporter genes were transcribed via the inserted Gene 5-derived 
TRS-B but it was apparent from subsequent findings that this may not be the case. 
 
Two possibilities were conceived for how the reporter genes are transcribed from 
BeauR-eGFP IR and BeauR-hRluc IR: (1) the polymerase recognises the inserted 
TRS-B and generates a mRNA with a leader-body junction at this position, (2) the 
polymerase ignores the inserted TRS-B and transcription continues until the natural 
TRS-B is reached. In this case the mRNA transcribed would be slightly larger than 
the one expected if the inserted TRS-B was utilized. 
 
To confirm which of these alternative strategies is used for synthesis of the reporter 
gene mRNAs, the mRNAs from both BeauR-eGFP IR and BeauR-hRluc IR were 
amplified by PCR, cloned and sequenced using the techniques previously described 
(Fig. 6.11). For both reporter genes the alignments show that the inserted Gene 5-
derived TRS-B is ignored by the IBV polymerase and mRNA synthesis is initiated 
from the natural TRS-B. This result confirms what was observed for the northern 
blots for these rIBVs in that the IR mRNA shifted in size according to the presence 
of the reporter gene sequence rather than a new mRNA being generated via the 
inserted TRS-B (see Chapter 4, Fig. 4.8A-D). This finding may help explain why the 
∆IR rIBVs were more stable than BeaR-hRluc∆3ab (see Chapter 5); although 
extensive sequence changes were made in both cases, replication of the ∆IR rIBVs 
ultimately did not involve synthesis of an additional mRNA that could disrupt the 
tightly regulated transcription process. This data showed that although consisting of 
only three nucleotides the proposed natural IR TRS-B is preferentially used over a 
complete TRS-B inserted nearby. 
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A 
eGFP-mRNA    :CTATTACACTAGCCTTGCGCTAGATTTTTAACTTAACAAAGCGGAAATAAGAAAAGGTTT:85 
BeauR-eGFPΔIR:AATATCTACCGTATGGTGCAGAAATATACTGGTGACCAAAGCGGAAATAAGAAAAGGTTT:25098 
 
 
eGFP-mRNA    :GCTACGTTTGTCTATGCAAAGCAGTCAGTAGATACTGGCGAGCTAGAAAGTGTAGCAACA:145 
BeauR-eGFPΔIR:GCTACGTTTGTCTATGCAAAGCAGTCAGTAGATACTGGCGAGCTAGAAAGTGTAGCAACA:25158 
                                M Stop                   Gene 5 Copy TRS 
                                   ▼                          ▼ 
eGFP-mRNA    :GGAGGAAGTAGTCTTTACACATAAATGTGTGTGGCTAGCGGCCAACTTAACAAATACGGA:205 
BeauR-eGFPΔIR:GGAGGAAGTAGTCTTTACACATAAATGTGTGTGGCTAGCGGCCAACTTAACAAATACGGA:25218 
              eGFP Start 
                ▼ 
eGFP-mRNA    :CGATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGGTGGTGCCCATCCTGGTCGAGCTGG:265 
BeauR-eGFPΔIR:CGATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGGTGGTGCCCATCCTGGTCGAGCTGG:25278 
 
 
B 
hRluc-mRNA    :CTATTACACTAGCCTTGCGCTAGATTTTTAACTTAACAAAGCGGAAATAAGAAAAGGTTT:85 
BeauR-hRlucΔIR:AATATCTACCGTATGGTGCAGAAATATACTGGTGACCAAAGCGGAAATAAGAAAAGGTTT:25098 
 
 
hRluc-mRNA    :GCTACGTTTGTCTATGCAAAGCAGTCAGTAGATACTGGCGAGCTAGAAAGTGTAGCAACA:145 
BeauR-hRlucΔIR:GCTACGTTTGTCTATGCAAAGCAGTCAGTAGATACTGGCGAGCTAGAAAGTGTAGCAACA:25158 
                                 M Stop                   Gene 5 Copy TRS 
                                    ▼                          ▼ 
hRluc-mRNA    :GGAGGAAGTAGTCTTTACACATAAATGTGTGTGGCTAGCGGCCAACTTAACAAATACGGA:205 
BeauR-hRlucΔIR:GGAGGAAGTAGTCTTTACACATAAATGTGTGTGGCTAGCGGCCAACTTAACAAATACGGA:25218 
               eGFP Start 
                 ▼ 
hRluc-mRNA    :CGATGGCTTCCAAGGTGTACGACCCCGAGCAACGCAAACGCATGATCACTGGGCCTCAGT:265 
BeauR-hRlucΔIR:CGATGGCTTCCAAGGTGTACGACCCCGAGCAACGCAAACGCATGATCACTGGGCCTCAGT:25278 
 
Fig. 6.11. Reporter gene mRNA alignments. Intracellular RNA was extracted from 
CK cells infected with BeauR-eGFP IR or BeauR-hRluc IR. Reporter gene 
mRNAs were amplified using primers Leader1 and (A) eGFP S(R) or (B) hRluc 
S(R). PCR products were cloned and sequenced with primers M13(F) and M13(R). 
Top line shows mRNA sequence with Leader sequence highlighted in blue and TRS 
highlighted in yellow. The inserted copy of a TRS-B is highlighted in red. Relative 
mRNA and genome positions are given on the right. 
 
 
6.6 Identification of an additional mRNA also transcribed via a non-canonical 
TRS-B 
 
Further analysis of the northern blot shown in Fig. 6.1 revealed the presence of an 
additional RNA species for Beau-R just below the Spike mRNA (indicated by an 
arrow). This RNA species was seen to decrease in size when produced from rIBV 
BeauR IR suggesting that this was also a potential IBV sg mRNA and, based on the 
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size, transcribed from within the Spike gene. Examination of a number of northern 
blot analyses of IBV showed that they also had a faint RNA species at this position 
in some but not all blots, mirroring the inconsistent detection originally seen with the 
IR mRNA. Using the approximate size of the RNA as a guide the genome sequence 
was screened upstream of the Spike S1/S2 cleavage site for a potential TRS-B but 
none could be identified. 
 
To investigate whether this was an additional mRNA for IBV transcribed via a non-
canonical TRS-B the same analysis was applied as for the IR mRNA. To amplify 
this potential mRNA by PCR, a reverse primer (BG137) located downstream of the 
S1/S2 cleavage site was used along with the forward primer Leader1 (Fig. 6.12A). 
Two PCR products were visualised by gel electrophoresis corresponding to the 
Spike-derived RNAs identified on the northern blot: the Spike mRNA resulted in a 
2334bp product as expected and a smaller product (Spike*) that resolved between 
1000- and 1650bp. Sequence analysis of cloned PCR products confirmed the larger 
PCR product to be generated from the Spike mRNA, and indicated that the Spike* 
RNA was also a potential IBV mRNA (Fig. 6.12B, C). 
 
The sequence alignment of the Spike* mRNA showed that this mRNA is potentially 
transcribed via a non-canonical TRS-B in a similar manner to the IR mRNA. In this 
case the potential TRS-B encompasses positions 4-8 of the canonical CTTAACAA 
TRS, compared to positions 6-8 for the IR mRNA. This non-canonical TRS-B is 
located at nucleotide position 21249-21253 of the Beau-R genome, 879nts 
downstream of the Spike ATG. To investigate whether this mRNA contains a protein 
coding sequence, the genome sequence downstream of the non-canonical TRS-B 
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was scanned for a potential ATG. The first ATG in the sequence is located at 
position 21328-21330, 74nts downstream of the non-canonical TRS-B. This distance 
is consistent with the gap between the TRS-B and ATG of all other IBV mRNAs and 
it is therefore possible that this ATG represents the start of an additional coding 
region. Using this ATG as a start codon it was observed that the proceeding 
sequence was in frame with the full Spike coding sequence and could therefore 
theoretically encode for a truncated version of the Spike protein, 320 amino acids 
shorter than the full-length protein. This truncated protein would encompass 
approximately the 3'–most third of the S1 subunit plus the S2 subunit. 
 
To determine if this truncated Spike mRNA is a feature of all IBV strains attempts 
were made to amplify the Spike and truncated Spike mRNAs from the field and 
vaccine strains used to study the IR mRNA. No consistent PCR products could be 
obtained for any of the other strains that resembled the truncated Spike with the 
exception of parent virus Beau-CK, which showed the same result as Beau-R. The 
lack of identification of this mRNA in any other strain suggests that this may be 
unique to Beau-R, and the parent virus Beau-CK, and is possibly an artefact of the 
repeated passaging undergone by this virus during adaptation to growth on CK cells. 
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A 
 
 
B 
Spike-mRNA:ACACTAGCCTTGCGCTAGATTTTTAACTGAACAAAAGACAGACTTA-N40ATG:119 
Beau-R    :AGCAACGCCAGTTGTTAATTTGAAAACTGAACAAAAGACAGACTTA-N40ATG:20370 
 
 
C 
Spike*-mRNA:ACACTAGCCTTGCGCTAGATTTTTAACTTAACAAAAACAGCTCAGA:76  
Beau-R     :AGTGGTGTTCAGAATATTCAAACTTACCAAACAAAAACAGCTCAGA:21265 
 
Fig. 6.12 Characterization of additional spike mRNA. Intracellular RNA was 
extracted from Beau-R infected CK cells and reverse transcribed. Messenger RNAs 
were amplified by PCR with primers Leader1 and BG137. (A) PCR products were 
separated by gel electrophoresis. Arrows indicate Spike and Spike* mRNAs. Lane L: 
DNA marker. (B, C) Clones of PCR products for Spike (B) and Spike* (C) were 
sequenced with primers M13(F) and M13(R) and aligned to Beau-R genome. Top 
line shows mRNA sequence with Leader sequence highlighted in blue and TRS 
highlighted in yellow. Relative mRNA and genome positions are given to the right 
along with (B) distance to the spike ATG. 
  
1000 –
2000 –
3000 –
B
ea
u
-R
Spike*
Spike
L
1650 –
Chapter Six 
149 
 
6.7 Discussion 
 
The work in this chapter describes the investigation of a previously uncharacterized 
RNA species observed during IBV infection, and the possibility that this RNA is 
linked to the region of the IBV genome known as the IR. The analysis of rIBV RNA 
species by northern blot analyses for the vaccine vector project had provided initial 
evidence that a previously described, but uncharacterized RNA species (Stern and 
Kennedy 1980) was in fact an IBV sg mRNA. This was based on the pattern of RNA 
species observed by northern blot analyses and the fact that the uncharacterized 
RNA had shifted in size relative to changes made in the recombinant viruses (Fig. 
4.8). 
 
The fact that the RNA has previously been inconsistently observed is likely due to 
the quality and clarity of northern blots combined with the potentially low levels of 
synthesis of this RNA. Many of the northern blots available for analysis used 
formaldehyde denaturing gels and/or radioactive isotope detection methods which 
can result in blots with less well defined bands and higher levels of background. The 
methods used during this project resulted in much clearer blots and therefore 
consistent detection of the RNA. Given the previous lack of consistent detection, 
compared to each of the other viral mRNAs, it is easy to understand why there were 
doubts over the nature and source of this RNA. 
 
Utilizing rIBV BeauR IR it was possible to demonstrate that the RNA species is a 
viral mRNA and that it is associated with the IR of IBV (Fig. 6.1). The RNA species 
was reduced in size when produced from BeauR IR indicating that it was a potential 
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mRNA. Furthermore, this reduction correlated to the size of the deletion introduced 
into the IR sequence confirming that the mRNA was derived from the IR. To 
understand how this mRNA is transcribed, given the apparent lack of a TRS-B, a 
technique known as a leader-body junction PCR was applied to virus samples to 
amplify and analyse the IR mRNA. 
 
Sequence analysis of the potential mRNA produced by Beau-R, and corresponding 
to the IR, identified the presence of the IBV 5' Leader sequence as would be 
expected for all IBV mRNAs thus confirming that this RNA is an IBV sg mRNA 
(Fig. 6.4). However, it was surprising to find that the mRNA contained a complete 
copy of the IBV TRS, CTTAACAA, as alignments showed that only nucleotide 
positions 6-8 of the TRS were present in the genomic sequence upstream of the IR. 
This suggested that a short, non-canonical TRS-B of CAA is utilized for synthesis of 
the IR sg mRNA and explains why there has previously been no identification of a 
TRS-B for the IR, as no genome search would be carried out for such a short 
sequence. 
 
As mentioned, the presence of the full-length TRS in the IR mRNA was surprising 
given the non-canonical nature of the TRS-B, as there is substantial evidence 
demonstrating that the TRS of a mRNA is derived solely from the associated TRS-B 
(Pasternak, et al. 2001, van Marle, et al. 1999, Zuniga, et al. 2004). This observation 
was investigated further and forms part of the work described in Chapter 7. 
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The position of the proposed TRS-B in the genome, and the distance from the IR 
ATG, fits with what is known for the other viral mRNAs and corroborates the 
suggestion that this is the true TRS-B for the IR (Table 6.2). 
 
TABLE 6.2: Distance of TRS-B from Associated Gene 
Gene Distance of TRS-B from ATG
a
 
Spike 60 
Gene 3 31 
M 85 
IR 105 
Gene 5 TRS 1
b
 
Gene 5 TRS 2
b
 
28 
17 
N 101 
                                a
Nucleotides from position 1 of TRS-B (CTTAACAA) 
                                b
IBV Beaudette Gene 5 has a duplicated TRS-B 
 
 
Having confirmed the existence of a sg mRNA for the IR of Beau-R it was necessary 
to rule out the possibility that this mRNA was an artefact of Beau-R transcription or 
a result of in vitro replication in CK cells (Fig. 6.6; Fig. 6.7). The data obtained from 
sequence analysis of the mRNAs from a variety of field and vaccine strains of IBV, 
as well as analysis of RNA samples from chickens experimentally infected with the 
M41 strain of IBV, confirmed that this mRNA is transcribed during IBV replication 
under all conditions. Furthermore, analysis of a second gammacoronavirus, TCoV, 
confirmed that this mRNA and the non-canonical TRS-B are not unique to IBV (Fig. 
6.8). Analysis of genomic sequences revealed that all closely related members of the 
gammacoronavirus genus (Avian coronaviruses) contain the IR sequence between 
the M gene and Gene 5 and also contain the associated non-canonical TRS-B, 
suggesting a conserved mechanism for transcription of the IR gene. 
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Supporting the argument for the existence of the CAA TRS-B was the finding that 
rIBVs BeauR-eGFP IR and BeauR-hRluc IR both utilized the non-canonical TRS-
B for transcription of the reporter genes (Fig. 6.11). In spite of the presence of a 
complete TRS-B, inserted upstream of the IR ATG, transcription of the reporter 
genes proceeded via the natural, non-canonical TRS-B. This demonstrates that 
despite its shortened form the natural TRS-B is preferentially used for transcription 
of mRNAs from this region. 
 
The discovery of a second mRNA transcribed from the Beau-R genome via a 
shortened version of the IBV TRS suggests that non-canonical TRS-Bs may be an 
alternative method for the transcription of coronavirus mRNAs (Fig. 6.12). For the 
truncated Spike mRNA the TRS-B was slightly longer than for the IR, AACAA 
compared to CAA, but still sufficiently short that this too was not identified in 
genome searches, and amplification and sequence analysis of the mRNA was 
required to establish the nature of the TRS-B. Unlike for the IR, this mRNA could 
not be isolated from any other IBV strains and for this reason no attempts were made 
to isolate the mRNA from in vivo or TCoV samples. While it appears unlikely that a 
functional protein is translated from the truncated Spike mRNA it demonstrates the 
possibility that some coronaviruses may utilize similar shortened versions of a TRS-
B to transcribe additional mRNAs that have yet to be identified. 
 
Following confirmation of the presence of an IR mRNA it was speculated that the 
11kDa protein coded for within this mRNA would be translated. While there is no 
evidence to suggest that there would be an impact on the ability of proteins to be 
translated from a mRNA derived via a non-canonical TRS-B, the lack of information 
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regarding the IR meant that this needed to be investigated. Recombinant IBV 
BeauR-eGFP 4b was generated to show that functional protein, in the form of 
eGFP, could be translated from a mRNA transcribed via the non-canonical TRS-B 
(Fig. 6.9). 
 
This finding supported the idea that the 11kDa IR protein is translated during virus 
replication. In an attempt to identify this protein a peptide antibody was generated 
against the IR protein sequence. As Beau-R contains a 50nt deletion within the IR, 
disrupting the protein coding sequence, laboratory strain M41 was used for this 
work. All experiments attempting to visualise the IR protein were unsuccessful, but 
this was believed to be a failure of the antibody rather than indicating a lack of the 
protein. 
 
Given the data outlined in this chapter it is clear that a mRNA is transcribed from the 
IR of IBV and that this is achieved via a previously unseen non-canonical TRS-B. In 
addition, although the evidence of its existence is yet to be obtained it is proposed 
that this mRNA codes for an 11kDa protein that constitutes a 5
th
 novel accessory 
protein of IBV and closely related gammacoronaviruses. 
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Chapter 7: Investigation of the non-canonical IR TRS-B 
and the role of the TRS in regulating subgenomic mRNA 
synthesis 
 
7.1 Introduction 
 
In Chapter 6 a series of experiments were described that led to the identification of a 
novel sg mRNA of IBV. Work presented in Chapter 6 showed that this mRNA is 
transcribed from within the 3'-end of the M gene of all strains of IBV, and closely 
related gammacoronaviruses, via a suspected non-canonical TRS-B consisting of 
only the final three nucleotides of the consensus IBV TRS of CUUAACAA. 
Sequence analysis of the IR mRNA showed that it contained a complete copy of the 
consensus IBV TRS. However, the origin of this TRS was unknown as the lack of a 
consensus TRS-B meant that the current model of coronavirus sg mRNA 
transcription, in which the TRS of a mRNA is derived from the TRS-B of the 
associated gene, was not appropriate. 
 
This chapter details the experiments carried out, utilizing IBV reverse genetics 
technology, to investigate the IR mRNA further and determine the origin of the TRS 
within the IR mRNA. This investigation also aimed to understand the role that a non-
canonical TRS-B may play in transcription of the IR mRNA and how that fits with 
the current model of coronavirus transcription. 
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7.2 Generation of recombinant IBVs to study the IR mRNA 
 
Sequence analysis of each of the IR mRNAs for IBV and TCoV in Chapter 6 was 
highly suggestive of a TRS-B for the IBV IR consisting of only the final three 
nucleotides of the consensus IBV/TCoV TRS of CUUAACAA. However, the IR 
mRNA did contain a complete copy of the CUUAACAA TRS suggesting that for 
the IR mRNA TRS positions 1-5 are derived from an alternative source to the TRS-
B. The current model of coronavirus transcription, in which the discontinuous step 
occurs during negative-strand synthesis, implies that the TRS of each mRNA is 
derived from the TRS-B. However, Pasternak et al. had previously shown in a study 
of the related arterivirus EAV that mutations in the TRS could result in TRS-L-
derived nucleotides being present in the mRNA TRS (Pasternak, et al. 2001) and 
thus raising the possibility of mRNA TRSs derived partly from the TRS-L. 
 
In recent years a greater understanding of the process of coronavirus sg mRNA 
transcription has been sought with evidence strongly suggesting that, along with 
recognition of the TRS-B, elements such as RNA structures and/or protein 
interactions are also involved (Dufour, et al. 2011, Ozdarendeli, et al. 2001, Yang, et 
al. 2011). With this in mind it was hypothesised that in the case of the IR mRNA 
these additional factors may play a greater role in initiating the template switch of 
the RTC than recognition of/signalling from the TRS-B, and transcription of a sg 
mRNA for the IR is possible despite the lack of a consensus TRS-B. This hypothesis 
dictates that the non-canonical TRS-B acts in a similar manner to all other TRS-Bs 
by mediating hybridisation of the nascent negative-sense RNA to the 5' Leader 
sequence at positions 6-8 only of the TRS-L. The majority of the IR mRNA TRS 
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would subsequently be derived from transcription of the TRS-L, contrary to the 
current model of coronavirus transcription, but in keeping with the findings of 
Pasternak et al.(Pasternak, et al. 2001). 
 
The availability of the IBV reverse genetics system opened the possibility of 
investigating this theory and for identifying the origin of the IR mRNA TRS. For 
example, the introduction of point mutations into the TRS-L of Beau-R, and 
subsequent analysis of the IR mRNA, would allow the source of the IR mRNA TRS 
to be established. To investigate this it was necessary to construct two rIBVs: (1) to 
identify the source of positions 1-5 of the mRNA TRS and (2) to confirm positions 
6-8 of the mRNA TRS are derived from the non-canonical TRS-B. 
 
In order to generate the two rIBVs with modified TRS-Ls a genome fragment had to 
be produced that contained the TRS-L with approximately 400bp of virus sequence 
either side to allow for recombination events. Due to the proximity of the TRS-L to 
the 5'-end of the IBV genome this meant that the genome fragment would also need 
to encompass vaccinia virus sequence. A suitable region of vNotI/IBVFL was 
amplified by PCR using a forward primer within the vaccinia virus sequence: (5'-
TTAATTAACACACCGATTGATACATATC-3') and a reverse primer within the 
IBV cDNA virus sequence: (5'-AAGCTTTCACTAAACACCACCAGAAC-3'). To 
facilitate cloning of the genome fragment into plasmid pGPTNEB193 restrictions 
sites PacI and HindIII were added to the 5'- and 3'-end respectively during PCR. The 
genome fragment was ligated into PacI/HindIII digested pGPTNEB193 to give 
plasmid pGPT-Vaccinia/IBV (Fig. 7.1). 
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Fig. 7.1. Plasmid map of pGPT-Vaccinia/IBV. The location of the genome 
fragment of vaccinia virus and IBV sequence is shown in the pGPTNEB193 
plasmid. The IBV TRS-L is shown approximately central to the virus cDNA 
fragment. 
 
 
Due to the importance of the TRS-L in transcription of all IBV genes it was 
necessary to ensure that any mutations introduced into the TRS-L would not be 
detrimental to the virus. For this reason in the first rIBV a single TG point 
mutation was introduced at position 3 of the TRS-L to mutate the TRS-L from 
CTTAACAA to CTGAACAA, and yield rIBV BeauR-CTGAACAA. This mutation 
was chosen because the TRS-B for both Spike and Gene 3 of Beau-R is 
CTGAACAA and so it was already known that a T/G mismatch between the TRS-B 
and TRS-L at this position could be tolerated during transcription. 
 
The second of the TRS-L rIBVs was required to confirm that the proposed TRS-B is 
the source of positions 6-8 of the IR mRNA. A mutation at TRS-L position 8 was 
hypothesised to be less disruptive to transcription than a mutation at position 6 or 7 
pGPT-Vaccinia/IBV 
4844bp
EcoRI (4825)
SacI (4835)
KpnI (4841)
PacI (1129)
HindIII (2190)
AgeI (471)
EcoRV (369)
KpnI (632)
E. coli GPT
VV p7.5
Vaccinia 
(frag)
IBV (frag) 
IBV Start (1687)
TRS-L (1743)
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and so recombinant virus BeauR-L-CTTAACAT was generated with an AT 
mutation at position 8 of the TRS-L. As there was no evidence to suggest which 
alternative base at position 8 would be least disruptive to virus replication this 
mutation was chosen to maintain the AU-rich nature of the TRS whilst also 
maintaining the free energy of the wild type A-U base pairing with that of a U-U 
base pairing. 
 
To create rIBVs BeauR-L-CTGAACAA and BeauR-L-CTTAACAT the TG and 
AT point mutations were individually introduced into the IBV sequence of pGPT-
Vaccinia/IBV by site directed PCR mutagenesis using primers given in Table A1.3, 
and reaction parameters as described in section 2.9. PCR products were DpnI 
digested for 3 h at 37°C and concentrated by processing through a nucleotide 
removal column. The resulting plasmid DNA was used to transform TOP10 cells and 
colonies were screened by PCR and sequence analysis to identify plasmids 
containing the required mutations. Plasmid DNA stocks of pGPT-BeauR-L-
CTGAACAA and pGPT-BeauR-L-CTTAACAT were obtained by maxi-prep of 
appropriate cultures and subsequently used for reverse genetics as described in 
section 2.10. Two replicates each of BeauR-L-CTGAACAA and BeauR-L-
CTTAACAT were successfully rescued as determined by sequence analysis of the 
TRS-L region of the genome (Fig. 7.2). 
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Fig. 7.2. Genome sequence analysis of TRS-L mutants. CK cells were infected 
with passage 4-derived (A) BeauR-L-CTGAACAA or (B) BeauR-L-CTTAACAT. 
Extracellular virus was harvested at 20 hpi. TRS-L region was amplified by RT-PCR 
with primers Leader1 and BG2 and sequenced with primer BG2. Sequence traces 
show the modified TRS-L outlined with grey boxes and mutations indicated by black 
arrows. 
 
 
7.3 Analysis of IR mRNAs of BeauR-L-CTGAACAA and BeauR-L-
CTTAACAT 
 
Following the successful rescue of rIBVs BeauR-L-CTGAACAA and BeauR-L-
CTTAACAT the IR mRNAs of these viruses could be analysed for presence or 
absence of the mutations. Working with the hypothesis that positions 1-5 of the IR 
mRNA TRS are transcribed from the TRS-L the IR mRNA of rIBV BeauR-L-
CTGAACAA was analysed to determine whether this mutation was incorporated 
into the mRNA sequence. The IR mRNA was obtained by leader-junction PCR, as 
described in section 2.9 and Fig. 6.2, and subjected to sequence analysis. The IR 
mRNA sequence was aligned to the virus genome as well as an IR mRNA from a 
control infection with Beau-R (Fig. 7.3). 
A
B
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A 
                                TG 
                                 ▼ 
L-CTGAACAA IR-mRNA:CTAGATTTTTAACTGAACAAAGCGGAAATAAG-N93ATG:172 
Beau-R IR-mRNA    :CTAGATTTTTAACTTAACAAAGCGGAAATAAG-N93ATG:172 
Beau-R            :AGAAATATACTGGTGACCAAAGCGGAAATAAG-N93ATG:25185 
 
B 
 
Fig. 7.3. Characterization of BeauR-L-CTGAACAA IR mRNA. CK cells were 
infected with either Beau-R or rIBV BeauR-L-CTGAACAA and 20 hpi intracellular 
RNA was harvested. IR mRNA was amplified with primers Leader1 and IR(R). (A) 
IR mRNA alignments. Leader sequence highlighted in blue and TRS highlighted in 
yellow. (▼) indicates position of the point mutation. Relative mRNA and genome 
positions are given on the right along with distance to the IR ATG. (B) Sequence 
trace of BeauR-L-CTGAACAA IR mRNA. Grey box outlines the TRS with 
position of TRS-L point mutation indicated by a black arrow. 
 
 
The IR mRNA of BeauR-L-CTGAACAA was shown to contain the TG point 
mutation that had been introduced into the TRS-L thus confirming the hypothesis 
that the IR mRNA TRS is partly transcribed from the TRS-L. 
 
To confirm the source of positions 6-8 of the mRNA TRS as the non-canonical TRS-
B the second rIBV, BeauR-L-CTTAACAT was analysed. The IR mRNA was 
subjected to sequence analysis to look for incorporation of the AT mutation in the 
mRNA TRS (Fig. 7.4). 
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A 
                                      A 
                                      ▼ 
L-CTTAACAT IR-mRNA:CTAGATTTTTAACTTAACAAAGCGGAAATAAG-N93ATG:172 
Beau-R IR-mRNA    :CTAGATTTTTAACTTAACAAAGCGGAAATAAG-N93ATG:172 
Beau-R            :AGAAATATACTGGTGACCAAAGCGGAAATAAG-N93ATG:25185 
 
B 
 
Fig. 7.4. Characterization of BeauR-L-CTTAACAT IR mRNA. CK cells were 
infected with either Beau-R or rIBV BeauR-L-CTTAACAT and 20 hpi intracellular 
RNA was harvested. IR mRNA was amplified with primers Leader1 and IR(R). (A) 
IR mRNA alignments. Leader sequence highlighted in blue and TRS highlighted in 
yellow. (▼) indicates position of the point mutation. Relative mRNA and genome 
positions are given on the right along with the distance to the IR ATG. (B) Sequence 
trace of BeauR-L-CTTAACAT IR mRNA. Grey box outlines the TRS with position 
of TRS-L point mutation indicated by a black arrow. 
 
Sequence analysis showed that the AT mutation was not present in the IR mRNA 
of BeauR-L-CTTAACAT thus confirming that the 3'-end of the IR mRNA TRS is 
derived from the non-canonical TRS-B. The data obtained from analysis of these two 
rIBVs demonstrates that although part of the IR mRNA TRS is derived from a non-
canonical TRS-B, in line with the current model of coronavirus transcription, the IR 
is unique amongst currently known, naturally occurring, coronavirus mRNAs in that 
the majority of the mRNA TRS is derived from the TRS-L. 
 
7.4 Generation of a rIBV to investigate the role of the IR TRS-B 
 
The function of the TRS-B in coronavirus transcription is believed to be as a signal 
for the pausing/stopping of the replication complex during negative-sense RNA 
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transcription, and facilitating hybridisation of the nascent RNA to the TRS-L for 
addition of a negative-sense copy of the genomic 5' Leader sequence to the 3'-end of 
the nascent RNA. The finding that the TRS-B for the IR mRNA consists only of the 
sequence CAA brings into question the role of this TRS-B in acting as a pause/stop 
signal for the replication complex as this triplicate nucleotide sequence occurs >250 
times throughout the genome without resulting in production of a mRNA. This 
suggests that the primary role of the TRS-B is to facilitate hybridisation of the 
nascent negative-sense RNA to the TRS-L to ensure the addition of a negative-sense 
copy of the 5' Leader sequence to the nascent RNA. As sg mRNAs can only be 
synthesised by copying of the completed negative-sense RNAs, the number of 
negative-sense RNAs synthesised based on the TRS-B/TRS-L interaction will 
subsequently determine the level of sg mRNAs observed. 
 
Previous work has shown that the introduction of mismatches between the TRS-B 
and TRS-L can alter the mRNA level of the associated gene (Yount, et al. 2006, 
Zuniga, et al. 2004). Historically, northern blot analysis of IBV sg mRNAs has 
demonstrated that the IR mRNA is not always detected, or if it is, is detected in 
much lower amounts than the mRNAs representing the flanking genes at the same 
time point of infection. Having established that the TRS-B for the IR consists of only 
3 nucleotides it was hypothesised that this shortened sequence may affect the 
efficiency of the hybridisation event between the TRS-B and TRS-L therefore 
resulting in lower levels of this mRNA. Consequently, it was further hypothesised 
that if a complete IBV TRS-B for the IR mRNA were introduced into the Beau-R 
genome the levels of the IR mRNA would increase due to a 100% match between 
the TRS-L and TRS-B. 
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To investigate this hypothesis a third rIBV was generated in which the TRS-B of the 
IR was extended. Initially the genome sequence was analysed to identify what 
changes could be made to accommodate a consensus IBV TRS-B. The non-
canonical TRS-B of the Beau-R IR is located at nucleotides 25075-25077 within the 
M gene coding region. To generate a complete TRS-B at nucleotides 25070-25077 it 
was not possible to use the consensus CTTAACAA TRS as this would have 
introduced a premature stop codon into the M gene at amino acid 190. Instead a 
TRS-B of CTGAACAA, as found for the Beau-R Spike gene and Gene 3, was 
adopted. This required two modifications to the genome sequence, a GC mutation 
at 25070 and a CA mutation at 25074, resulting in amino acid changes G189A and 
D190E within the M gene (Fig. 7.5). 
 
 
Fig. 7.5. Sequence modifications for replacement of IR TRS-B. Section of Beau-
R genome sequence showing M highlighted in grey and IR in white, with the M stop 
and IR ATG shown in bold. (A) The sequence of the proposed TRS-B site is 
enlarged and underlined. (B) Point mutations required for a complete TRS-B of 
CTGAACAA are highlighted in red. (C) Resulting amino acid changes within M. 
 
 
Initial attempts at site directed mutagenesis to generate a modified version of 
pGPTNEB193 containing a genome fragment with both point mutations proved 
unsuccessful, with large deletions occurring within the IBV sequence following 
introduction of the second mutation. The modified genome fragment sequence was 
(A)GGT GAC CAA 
(B)GCT GAA CAA 
(C)G:A D:E
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therefore sent to GeneArt® for synthesis and cloning into pGPTNEB193 to yield 
plasmid pGPT-BeauR-IR-CTGAACAA (Fig. 7.6). 
 
 
 
Fig. 7.6. Plasmid map of pGPT-BeauR-IR-CTGAACAAA. The location of the 
genome fragment containing the IR TRS-B is shown in the pGPTNEB193 plasmid. 
The IR TRS-B is shown approximately central to the virus cDNA fragment. 
 
 
Two replicates of rIBV BeauR-IR-CTGAACAA were subsequently rescued using 
the reverse genetics system for IBV with the presence of the two mutations 
confirmed in both replicates by sequence analysis (Fig. 7.7). However, the sequence 
data also identified additional mutations arising independently upstream of the 
altered sequence. These mutations were not present in the IBV cDNA sequence in 
either vaccinia virus suggesting they had arisen during passage of the rescued virus 
on CK cells. 
 
pGPT-BeauR-IR-CTGAACAA 
4689bp
EcoRI (4670)
KpnI (4686)
AscI (1111) 
AgeI (471)
EcoRV (369)
KpnI (632)
E. coli GPT
VV p7.5
M gene
(frag)
IR
ORF 5a (frag) 
HindIII (2035)
PstI (2027)
SalI (2008)
XbaI (2002)
PacI (1999)
IR TRS (1548)
Gene 5 TRS (1938)
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Fig. 7.7. Genome sequence analysis of BeauR-IR-CTGAACAA. CK cells were 
infected with passage 4 derived BeauR-IR-CTGAACAA. Extracellular virus was 
harvest 20 hpi. The IR TRS-B region was amplified by RT-PCR, and sequenced with 
primers BG51 and IR(R). Sequence traces show the modified TRS-B of (A) R1 and 
(B) R2 outlined with grey boxes and engineered mutations indicated by black 
arrows. Black boxes outline regions of additional mutations. 
 
 
Given the amino acid changes introduced into the M gene sequence it was suspected 
that the mutations that arose upstream of the IR TRS-B were compensatory 
mutations. However, as the engineered mutations had been maintained it was 
decided to proceed with analysis of this virus despite the additional changes 
developing in the virus sequence. It was first necessary to analyse the IR mRNA of 
BeauR-IR-CTGAACAA to determine the origin of the IR mRNA TRS as two 
possibilities were conceived of: (1) the IR mRNA TRS is derived entirely from the 
engineered complete TRS-B as predicted by the model of coronavirus transcription 
or (2) the IR mRNA TRS is still partly derived from the TRS-L via a modified 
version of the transcription model. 
 
A
B
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Sequence analysis of the IR mRNA for BeauR-IR-CTGAACAA showed the 
presence of a TRS of CTGAACAA, matching the sequence of the extended TRS-B 
and differing from the TRS of CTTAACAA observed for Beau-R (Fig. 7.8). This 
suggested that the IR mRNA TRS was derived from the entire TRS-B and no longer 
involved transcription of the TRS-L. However, while the G at position 3, and 
therefore the downstream CA mutation at position 5 must now be derived from the 
TRS-B, and not the TRS-L, it cannot be ruled out that positions 1 and 2 are still 
derived from the TRS-L, as the now perfect match of these two nucleotides between 
the TRS-B and TRS-L means it is not possible to determine their source from 
sequence analysis. This finding suggested that the wild type IR mRNA TRS is partly 
derived from the TRS-L only in the absence of a complete TRS-B, and not because 
of any major differences in the mechanism of transcription for this mRNA. 
 
A 
                                   GC CA  
                                ▼   ▼ 
IR-CTGAACAA IR-mRNA:CTAGATTTTTAACTGAACAAAGCGGAAATAAG-N93ATG:172 
BeauR-IR-CTGAACAA  :AGAAATATACTGCTGAACAAAGCGGAAATAAG-N93ATG:25185 
Beau-R             :AGAAATATACTGGTGACCAAAGCGGAAATAAG-N93ATG:25185 
 
B 
 
Fig. 7.8. Characterization of BeauR-IR-CTGAACAA IR mRNA. CK cells were 
infected with either Beau-R or rIBV BeauR-IR-CTGAACAA and 20 hpi 
intracellular RNA was harvested. (A) IR mRNA alignment. Leader sequence 
highlighted in blue and TRS highlighted in yellow. (▼) indicates positions of the 
point mutations. Relative mRNA and genome positions are given on the right.  (B) 
Sequence trace of BeauR-IR-CTGAACAA IR mRNA. Grey box outlines the TRS-
B and point mutations are indicated by black arrows. 
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Prior to using each of the TRS mutants to investigate of the role of the TRS in 
transcription it was necessary to confirm that the mutations introduced in the three 
rIBVs had not otherwise altered the replication kinetics of the virus. Growth curves 
were carried out for R1 of each rIBV to determine any effects of the introduced 
mutations on virus growth (Fig. 7.9). The growth curves demonstrated that 
replication kinetics were not altered for either of the TRS-L mutants, BeauR-L-
CTGAACAA or BeauR-L-CTTAACAT. However, BeauR-IR-CTGAACAA 
showed peak titres at 24 h approximately 1-log10 lower than Beau-R, or the TRS-L 
mutants. This was suspected to be due to the amino acid changes introduced into the 
M gene resulting in a mildly impaired M protein. 
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Fig. 7.9. Replication kinetics of TRS mutants. Confluent monolayers of CK cells 
were infected with 1x10
5
 pfu virus and extracellular virus harvested at various time 
points for plaque assay. Error bars represent SD of results from three independent 
experiments each assayed in triplicate. 
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7.5 Investigating the role of the TRS in regulating mRNA levels 
 
As a consequence of the non-canonical nature of the IR TRS-B the IR mRNA 
provided a tool for studying the effects of altering the IBV TRS-B/TRS-L interaction 
on mRNA levels. Following the generation of the three rIBVs in this project, BeauR-
L-CTGAACAA, BeauR-L-CTTAACAT and BeauR-IR-CTGAACAA, it was 
hypothesised that the point mutations may alter the IR mRNA levels, when 
compared to the expression levels of the IR mRNA of parental virus Beau-R, due to 
changes in the number of nucleotide matches between the TRS-L and the IR TRS-B. 
 
The expression levels of the IR mRNA for each of the TRS mutant viruses were 
compared to Beau-R using northern blot analysis to visualise any changes resulting 
from the TRS mutations (Fig. 7.10). As can be seen in Figure 7.10 it was clear from 
this analysis that the nucleotides comprising the TRS have an important role to play 
in regulating mRNA levels. No change in expression level was observed in any 
mRNA between Beau-R and Beau-R-L-CTGAACAA (Fig. 7.10A). This was 
expected as no changes in replication kinetics were observed for this virus and the 
mutation introduced into the TRS-L is not involved in the non-canonical IR TRS-
B/TRS-L interaction. Analysis of BeauR-L-CTTAACAT however revealed that 
while no other mRNA levels were altered the IR mRNA was now almost 
undetectable (Fig. 7.10B). In contrast, the introduction of the complete IR TRS-B in 
BeauR-IR-CTGAACAA resulted in an increase in IR mRNA levels comparable to 
the levels of the flanking genes, M and Gene 5 (Fig. 7.10C). The northern blot 
analysis data was strongly suggestive that the TRS-B/TRS-L interaction is important 
for regulating the amount of mRNA transcribed from a particular gene.  
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Fig. 7.10, Northern blot analysis of TRS mutants. CK cells were infected with 
Beau-R and rIBVs, intracellular RNA harvested 20 hpi and subjected to northern 
blot analysis. Each recombinant was compared to Beau-R. Data is shown for one 
replicate only of rIBV (A) BeauR-L-CTGAACAA, (B) BeauR-L-CTTAACAT and 
(C) BeauR-IR-CTGAACAA. 
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Although the changes in IR mRNA levels were visible by northern blot the 
techniques used did not allow for direct quantification of each mRNA. In order to 
obtain quantitative data that could be used to confirm the changes in mRNA levels 
the IR mRNA levels were additionally analysed by 2-step qRT-PCR. The IR mRNA 
levels were quantified for each of the rIBVs and expressed as a fold-change in 
amount compared to Beau-R (Fig. 7.11) (see Appendix 5 for sample standard curves 
and data calculations). 
 
 
B
ea
u-
R
B
ea
uR
-L
-C
T
G
A
A
C
A
A
B
ea
uR
-L
-C
T
T
A
A
C
A
T
B
ea
uR
-I
R
-C
T
G
A
A
C
A
A
0
2
4
6
8
F
o
ld
 C
h
a
n
g
e
 
Fig. 7.11. Quantitative PCR analysis of IR mRNA levels. CK cells were infected 
with 1x10
5
 pfu of Beau-R, BeauR-L-CTGAACAA, BeauR-L-CTTAACAT or 
BeauR-IR-CTGAACAA. Intracellular RNA was harvested 18 hpi and IR mRNA 
levels quantified by qRT-PCR using 28S expression as an internal standard. Values 
were additionally normalised to Gene 3 mRNA levels to account for variations in 
infection rates. Error bars represent the SD of the mean of two independent 
experiments assayed in triplicate. 
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The qRT-PCR data confirmed the northern blot analysis data, showing a 6-fold 
increase in IR mRNA for BeauR-IR-CTGAACAA. A 0.1-fold change was observed 
for BeauR-L-CTTAACAT demonstrating that although barely detectable by 
northern blot analysis the IR mRNA is still transcribed during virus replication. 
Given that for this rIBV there is only a two-nucleotide match between the IR TRS-B 
and the TRS-L (at positions 6 and 7) this reduction is consistent with the knowledge 
that mismatches between the TRS-L and TRS-B can reduce mRNA levels. Again, no 
change is observed for the IR of BeauR-L-CTGAACAA as the mutation introduced 
into this virus does not alter the IR TRS-B/TRS-L interaction. 
 
The experiments with the TRS mutants confirmed that the TRS can be responsible 
for regulating sg mRNA levels, with the number of nucleotide matches between the 
TRS-B and TRS-L the key factor in this regulation. 
 
7.6 Flexibility of TRS usage 
 
During analysis of the BeauR-L-CTGAACAA IR mRNA the mRNA corresponding 
to the M gene was also sequenced as a control. This was to confirm that the M 
mRNA TRS was derived from the complete M TRS-B as per the current 
understanding of sg mRNA transcription, and that the TG mutation was not 
incorporated into the mRNA TRS in a similar mechanism to the IR mRNA. 
However, this was not found to be the case with the first M mRNA clone sequenced 
from BeauR-L-CTGAACAA unexpectedly showing the presence of the TG 
mutation at position 3 of the mRNA TRS (Fig 7.12A). A second clone of the M 
mRNA was subsequently sequenced and while the consensus sequence gave the 
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mRNA TRS as CTTAACAA analysis of the sequence traces showed this was an 
error and that the dominant nucleotide at position 3 was a G with a minor T 
population (Fig. 7.12B). 
 
 
 
Fig. 7.12. Sequence traces of M gene mRNAs. CK cells were infected with BeauR-
IR-CTGAACAA and 20 hpi intracellular RNA was harvested. M gene mRNAs were 
amplified with primers Leader1 and IR(R) and PCR cloned for sequence analysis 
with primers M13(F) and M13(R). (A, B) Sequence traces for two clones of M 
mRNA. Grey boxes outline the TRS-B with position of the TRS-L mutation 
indicated by black arrow. 
 
 
Given this finding other sg mRNAs from a BeauR-L-CTGAACAA infection were 
cloned and sequenced to establish whether the TG mutation is consistently 
incorporated into mRNA TRSs and therefore suggestive of a greater degree of 
flexibility in TRS usage than previously supposed (Fig. 7.13).  
A
B
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Fig. 7.13. Sequence traces of IBV mRNAs. CK cells were infected with (A, B) 
BeauR-L-CTGAACAA or (C, D, E) Beau-R and 20 hpi intracellular RNA was 
harvested. Messenger RNAs were amplified with primers Leader1 and (A) BG147, 
(B) BG149, (C) BG133, (D, E) BG142, and PCR cloned for sequence analysis with 
primers M13(F) and M13(R). Sequence traces are shown for (A) Gene 5 (B) N (C) 
Spike (D, E) Two clones of Gene 3. Grey boxes outline the TRS-B with TRS-L 
point mutation indicated by black arrow. 
A
B
C
D
E
Chapter Seven 
174 
 
Two clones each of Gene 5 (Fig. 7.13A) and N gene (Fig. 7.13B) mRNAs were 
subject to sequence analysis and in all cases showed the incorporation of the TG 
mutation. Given that for BeauR-L-CTGAACAA both the TRS-L and the TRS-Bs for 
Spike and Gene 3 are CTGAACAA it was not possible to determine the source of 
the G at position 3 by sequence analysis. However, it was possible to analyse the 
Spike and Gene 3 mRNAs from a Beau-R infection to investigate whether the 
mRNA TRS position 3 is a G, as derived from the TRS-B, or a T, as derived from 
the TRS-L. Due to limited availability of clones only one clone of the Spike mRNA 
was sequenced and found to contain a T at position 3 (Fig. 7.13C). Two clones of the 
Gene 3 mRNA were available and sequenced, with one containing a T and one 
containing a G at position 3 of the TRS (Fig. 7.13D, E). 
 
This result demonstrated that even in a wild type virus infection the TRS of a mRNA 
can be partly derived from the TRS-L. Although limited numbers of clones were 
analysed the data suggests that for IBV mRNAs the complete TRS-B is not 
necessary to permit hybridisation to the TRS-L, and there may be some flexibility in 
the TRS-B requirements for generation of mRNAs. 
 
These findings could be investigated further via a more in depth analysis of the IR 
mRNAs transcribed during infection with rIBV BeauR-IR-CTGAACAA. The 
original IR mRNA clone sequenced from this virus showed the incorporation of the 
entire TRS-B in the mRNA TRS (see Fig. 7.8). By carrying out sequence analysis of 
a further four clones of IR mRNA from each replicate of BeauR-IR-CTGAACAA it 
was possible to determine whether the mRNA TRS is consistently derived from the 
TRS-B alone, as demonstrated by the first clone, or if the IR mRNA TRS is often 
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derived from both the TRS-B and TRS-L as seen with the wild type IR mRNA. The 
sequence alignments of the IR mRNA showed that 4/4 clones for R1 and 2/4 clones 
for R2 contained a T nucleotide at position 3 of the TRS confirming that in many 
cases the mRNA TRS is still partly derived from the TRS-L (Fig. 7.14)  
 
 
                               T/G 
                                ▼ 
R1 IR-mRNA (1)   :CTAGATTTTTAACTTAACAAAGCGGAAATAAG-N93ATG:172 
R1 IR-mRNA (2)   :CTAGATTTTTAACTTAACAAAGCGGAAATAAG-N93ATG:172 
R1 IR-mRNA (3)   :CTAGATTTTTAACTTAACAAAGCGGAAATAAG-N93ATG:172 
R1 IR-mRNA (4)   :CTAGATTTTTAACTTAACAAAGCGGAAATAAG-N93ATG:172 
R2 IR-mRNA (1)   :CTAGATTTTTAACTGAACAAAGCGGAAATAAG-N93ATG:172 
R2 IR-mRNA (2)   :CTAGATTTTTAACTTAACAAAGCGGAAATAAG-N93ATG:172 
R2 IR-mRNA (3)   :CTAGATTTTTAACTTAACAAAGCGGAAATAAG-N93ATG:172 
R2 IR-mRNA (4)   :CTAGATTTTTAACTGAACAAAGCGGAAATAAG-N93ATG:172 
BeauR-IR-CTGAACAA:AGAAATATACTGCTGAACAAAGCGGAAATAAG-N93ATG:25185 
Beau-R           :AGAAATATACTGGTGACCAAAGCGGAAATAAG-N93ATG:25185 
 
Fig. 7.14. Sequence alignments of BeauR-IR-CTGAACAA IR mRNA. Confluent 
monolayers of CK cells were infected with replicate 1 (R1) or replicate 2 (R2) of 
BeauR-IR-CTGAACAA and intracellular RNA extracted 20 hpi. IR mRNAs were 
amplified by PCR with primers Leader1 and IR(R) and PCR cloned for sequence 
analysis. Sequence alignments are shown for four clones of each replicate against 
BeauR-IR-CTGAACAA and Beau-R genomic sequence. Leader sequence 
highlighted in blue and TRS highlighted in yellow. (▼) indicates position of the 
variable nucleotide. Relative positions of the mRNA and genome are given on the 
right along with the distance to the IR ATG. 
 
 
Overall the results in this chapter have demonstrated that the IBV IR mRNA is 
unique among the known IBV sg mRNAs in that the associated TRS-B is a non-
canonical shortened TRS-B of CAA, not CTTAACAA, and that the IR mRNA TRS 
is mostly derived from the TRS-L and not the TRS-B as would be expected. 
Furthermore, by introducing point mutations into the IR TRS-B to extend it from 
CAA to CTGAACAA, thus better resembling the consensus TRS, it was shown that 
the IR mRNA expression level could be increased 6-fold over wild type and 
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demonstrated the importance of the TRS-L/TRS-B interaction in regulating mRNA 
expression levels. Sequence analysis of all IBV sg mRNAs showed that the TRS of 
individual mRNAs can be derived, in part, from the TRS-L, suggesting a greater 
degree of flexibility during transcription of IBV sg mRNAs with regards to the 
origin of individual mRNA TRSs. 
 
7.7 Discussion 
 
In this chapter the IR mRNA was investigated to determine the transcription 
mechanisms underlying the use of the non-canonical TRS-B. Until now the evidence 
has been strongly suggestive that the TRS of each sg mRNA is derived from the 
TRS-B of the associated gene, and this has led to the general acceptance of the 
model of transcription in which the discontinuous step occurs during negative-strand 
synthesis (Sawicki and Sawicki 1995, Schaad and Baric 1994, van Marle, et al. 
1999, Zuniga, et al. 2004). Transcription of nascent negative-sense RNAs is 
understood to proceed 3'-5' until a TRS-B has been transcribed. The nascent 
negative-sense RNA then dissociates from the body sequence, is translocated to the 
5'-end of the genome and the negative-sense TRS-B complementarily binds to the 
TRS-L. This initiates a template switch and transcription continues to the very 5'-end 
of the genome resulting in the addition of a negative copy of the leader sequence to 
the nascent RNA. The discovery that the IBV IR mRNA contains a complete copy of 
the IBV CTTAACAA TRS while the associated TRS-B consists of only the final 3 
nucleotides of this sequence suggested an altered mechanism of transcription for the 
IR mRNA. 
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It was clear that at least part of the IR mRNA TRS originated from virus sequence 
other than the TRS-B, as would be expected. The IBV reverse genetics system was 
therefore used to produce a series of rIBVs that could be used to establish the source 
of the IR mRNA TRS. A hypothesis was established which centred on the idea that 
the switch in transcription from the genome body to the 5' Leader sequence could 
occur without the need for a complete TRS-B. This was founded on the 
understanding that, as well as recognition of the TRS-B, additional elements are 
involved in controlling the template switch of the RTC during transcription (Dufour, 
et al. 2011, Moreno, et al. 2008, Ozdarendeli, et al. 2001, Pasternak, et al. 2001, 
Yang, et al. 2011). Following hybridisation of the shortened TRS-B to positions 6-8 
of the TRS-L transcription would then proceed 3'-5' through positions 5 to 1 of the 
TRS-L and continue to the 5'-end of the genome. This hypothesis explained the 
presence of a complete TRS within the IR mRNA and suggested that it is partly 
derived from the TRS-L. 
 
The first rIBV generated to test this hypothesis, BeauR-L-CTGAACAA, included a 
TG point mutation at position 3 of the TRS-L. Analysis of the IR mRNA from this 
virus showed that this mutation was incorporated into the mRNA TRS and 
confirmed that the TRS-L was involved in generation of the IR mRNA TRS (Fig. 
7.3). While the presence of this mutation confirms that positions 1-3 of the mRNA 
TRS are derived from the TRS-L it does not necessarily confirm the source of the 
nucleotides at positions 4 and 5 (AA) as these lie downstream of the point mutation. 
The A at position 4 of the TRS does align with an A at what would be the 
corresponding position of a complete IR TRS-B. However, the A at position 5 of the 
TRS does not correlate with the sequence upstream of the shortened TRS-B and is 
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therefore most likely derived from the TRS-L, as for positions 1-3. Given the 
direction of RNA synthesis it is difficult to conceive of a mechanism in which 
positions 3 and 5 of the mRNA TRS, but not position 4, are derived from the TRS-L. 
It is therefore proposed that nucleotides 1-5 of the IR mRNA TRS are all derived 
from transcription of the TRS-L. 
 
A previous model of coronavirus transcription, termed leader-primed transcription, 
proposed that the discontinuous step occurs during positive-strand RNA synthesis 
with transcription of the leader sequence occurring prior to hybridisation to a TRS-B 
(Baric, et al. 1983). This theory would suggest that each mRNA TRS is derived from 
the TRS-L and not the TRS-B. Given the proposed extent of involvement of the 
TRS-L in the IR mRNA TRS it was necessary to confirm that this alternative model 
was not the basis for generation of the IR mRNA and that the current model of 
transcription is valid, albeit in a modified form. 
 
A second rIBV was generated, BeauR-L-CTTAACAT, in which an AT point 
mutation was introduced at position 8 in the TRS-L of Beau-R. The IR mRNA TRS 
from this rIBV did not contain the AT mutation, confirming that position 8 of the 
TRS is derived from the TRS-B, with positions 6 and 7 also likely to be derived 
from the non-canonical TRS-B, as suggested by sequence alignments (Fig. 7.4). 
Although it is possible that under the leader-primed model the nascent RNA could be 
transferred to a TRS-B prior to complete transcription of the TRS-L it is unlikely 
that two different transcription mechanisms are utilized by the virus. Therefore, it is 
proposed that the IBV IR mRNA is transcribed using an altered form of the model of 
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discontinuous transcription during negative-strand synthesis, in which part of the 
mRNA TRS is derived from the TRS-L. 
 
During the identification of the IBV IR mRNA in the work described in Chapter 6 it 
was clear that one of the main reasons for the previous lack of identification of this 
mRNA is the low detection level observed by northern blot analysis. One possible 
explanation for this low level of detection is that the IR mRNA is only transcribed at 
late stages of replication and is therefore transcribed in lower amounts than all other 
mRNAs. However, the discovery of the non-canonical TRS-B led to the hypothesis 
that the lower transcription levels were in fact a direct result of an impaired 
interaction between the non-canonical TRS-B and the TRS-L and may be a strategy 
used by the virus to control sg mRNA synthesis and translation of the associated 
11kDa protein. It was further hypothesised that the low expression level could be 
overcome by extending the IR TRS-B to the complete consensus sequence, 
CTTAACAA. 
 
To test this hypothesis a rIBV, BeauR-IR-CTGAACAA, was generated in which two 
point mutations were introduced into the IBV genome to extend the non-canonical 
TRS-B from CAA to CTGAACAA. As mentioned in the results the CTGAACAA 
sequence was chosen over CTTAACAA to avoid the introduction of a premature 
stop codon within the M gene sequence, and maximise the chances of a successful 
rescue. Levels of IR mRNA from BeauR-IR-CTGAACAA were investigated by 
northern blot analysis and qRT-PCR. 
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The results showed that the IR mRNA level from BeauR-IR-CTGAACAA was 
increased 6-fold over the IR mRNA level observed for Beau-R (Fig. 7.10C; Fig. 
7.11). This confirmed that the amount of mRNA transcribed from a gene correlates 
with the number of nucleotide matches between the TRS-L and TRS-B. This 
hypothesis was further confirmed by the IR mRNA level observed from BeauR-L-
CTTAACAT (Fig. 7.10B; Fig. 7.11). For BeauR-L-CTTAACAT the presence of 
only two nucleotide matches between the TRS-L and TRS-B (positions 6 and 7) led 
to a further reduction in the IR mRNA level compared to wild type. This was an 
interesting result as it indicated that an IBV mRNA could be produced from only 
two common nucleotides within the TRS-L and TRS-B, suggesting that other factors 
may play a role in generation of a coronavirus sg mRNA, not simply 
complementation between the two TRSs. 
 
Investigation of the replication kinetics of the TRS mutants demonstrated that the 
individual mutations introduced into the TRS-L had no effect on virus replication 
(Fig. 7.9). This suggests that IBV can tolerate minor changes to the TRS-L. In 
contrast, the peak titre for BeauR-IR-CTGAACAA was approximately 1-log10 lower 
than Beau-R. One possible explanation for this reduction in peak titres was that the 
increased efficiency of the IR TRS-L/TRS-B interaction for BeauR-IR-CTGAACAA 
led to a decrease in the levels of mRNA synthesis for the genes upstream of the IR, 
i.e. M, Gene 3 and Spike, which would have a negative impact on virus replication. 
If the RTC is halted more frequently at the IR TRS-B due to the increased 
complementarity between the TRSs, it is possible that initiation of mRNA synthesis 
from upstream TRS-Bs is reduced. However, northern blot analysis did not indicate 
any changes to mRNA levels for the upstream genes (Fig. 7.10C). 
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The reduction in peak virus titres was therefore most likely due to the generation of a 
slightly impaired M protein brought about by the amino acid changes introduced into 
the M gene sequence to accommodate the extension of the IR TRS-B. The amino 
acid changes G189A and D190E are located in the cytoplasmic tail of the M protein, 
a region that has been demonstrated to be important for interaction with the virus E 
protein and subsequently virus particle assembly (Corse and Machamer 2003). It is 
possible that the changes introduced into M have affected this interaction with the 
result being an impairment of virus particle assembly and therefore a reduction in 
virus titre. 
 
It is interesting to note that in both replicates of BeauR-IR-CTGAACAA mutations 
independently arose directly upstream of the modified TRS-B. At passage 4 these 
mutations were not stable in the virus population with several interpretations of the 
sequence data possible, presumably owing to a mixed virus population. However, 
subsequent work by colleague Sarah Keep has shown that by passage 8 these 
mutations had settled into dominant populations resulting in additional amino acid 
changes A189T for R1, and T188L and A189T for R2. It is proposed that these 
mutations are potential compensatory mutations arising to counteract the changes 
made to the M gene. 
 
During analysis of the IR mRNAs of each of the TRS-L rIBVs mRNAs 
corresponding to the M gene were also sequenced as controls. It was expected that 
the M mRNAs would fit the current understanding of coronavirus transcription, i.e. 
the mRNA TRS is derived wholly from the TRS-B, and neither TRS-L mutation 
would be incorporated into the M mRNA TRS. However, it was found that for the 
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M, and subsequently for the Gene 5 and N, mRNAs from a BeauR-L-CTGAACAA 
infection all showed incorporation of the TG mutation (Fig. 7. 12; Fig. 7.13A, B). 
Similarly, the Spike and Gene 3 mRNAs from a Beau-R infection showed the 
incorporation of the T nucleotide from position 3 of the TRS-L and not the G 
nucleotide from the TRS-B as was expected (Fig. 7.13C, D, E). Although these 
observations are based on sequence analysis of only a very small number of mRNA 
clones this finding, due to the presence of variant mRNA species for a few clones, 
raises the possibility that the derivation of the mRNA TRS is more flexible than 
previously thought. 
 
Attempts were made to investigate this finding in more depth by examining the 
whole virus population during cellular infection with either Beau-R or BeauR-L-
CTGAACAA. The aim was to use alternative techniques to PCR cloning and 
sequence analysis that would allow the sequence of every mRNA transcribed during 
infection to be analysed. Initially the possibility of developing a qRT-PCR assay 
based on existing allelic discrimination assays was investigated. However, due to the 
limited sequence over which to design primers no primer-probe sets could be 
identified for several of the IBV mRNAs and it was not possible to pursue this 
method further. 
 
An alternative approach was also investigated using locked nucleic acid (LNA
TM
) 
primer technology (Exiqon) and PCR to specifically amplify mRNAs containing 
either a T or G at position 3 of the mRNA TRS, and thus demonstrate the presence 
of one, or both, mRNA species in a virus population. This technology uses a class of 
nucleic acid analogues in which the ribose ring is “locked” by a methylene bridge 
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connecting the 2'-O atom with the 4'-C atom. The LNA nucleosides conform to 
normal Watson-Crick base pairing rules; however the thermal stability of an 
LNA/DNA duplex is increased over standard DNA/DNA duplexes. Primers 
containing LNA nucleosides therefore have an increased Tm and can increase the 
specificity of a PCR. 
 
By designing primers containing either a T or a G LNA nucleoside at the variable 
position of the TRS it was hoped that the mRNA populations present during virus 
replication could be established. For example, a PCR to amplify the IR mRNA from 
a Beau-R infection should yield a product when the primer contains a T LNA 
nucleoside at position 3 of the TRS, but no product should be amplified if the primer 
contains a G LNA nucleoside at this position. However, despite several attempts to 
develop a PCR assay the control PCRs did not show the expected results with 
products being amplified by primers that should not have been able to base pair to 
the template DNA. It was suspected that the difference in TM between a perfect 
match and a 1-nucleotide mismatch at the T/G position was not great enough to 
generate the required specificity in the PCR and therefore these experiments were 
not pursued further. 
 
Two theories are proposed for the incorporation of nucleotides from the TRS-L into 
all mRNA TRSs. First, it is possible that for IBV there is a natural wobble during 
transcription that may, or may not lead to complete transcription of the TRS-B prior 
to the switch to the 5'-end of the genome. This would suggest that the true core TRS 
for IBV might be the shorter sequence AACAA with the CUU not essential for 
hybridisation to the TRS-L. Evidence for this theory came from analysis of the 
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BeauR-IR-CTGAACAA IR mRNA. Sequence analysis of four IR mRNA clones for 
each of the two replicates of virus showed that in 4/4 clones for R1 and 2/4 clones 
for R2 the IR mRNA contained the position 3 nucleotide T, as derived from the 
TRS-L (Fig. 7.14). However, the IR mRNA level of R1 was greatly increased over 
Beau-R despite the apparent switch to the TRS-L at position 3 in a large proportion 
of those mRNAs sequenced. This suggests that the increase in mRNA level is 
largely, if not entirely, due to the extension of the TRS-L/TRS-B interaction to 
include positions 4 and 5 of the TRS-B. 
 
The second possibility is that the presence of a mismatch between the two 
nucleotides at position 3, either naturally occurring or introduced, forces the early 
translocation and hybridisation of the nascent RNA to the TRS-L. Testing of this 
theory would require the generation of a large series of rIBVs, in which each 
nucleotide of the TRS-L and TRS-B of a gene are individually mutated, to examine 
the effects on the origin of the mRNA TRS. 
 
Overall the experiments detailed in this chapter have highlighted some important 
issues for coronavirus transcription. It has been confirmed that the IBV IR mRNA is 
transcribed via a non-canonical, shortened TRS-B with the sequence CAA. In a 
departure from the current model of coronavirus transcription this non-canonical 
TRS-B leads to a mRNA in which the TRS is derived from transcription of the TRS-
L as well as the TRS-B. Analysis of other mRNAs demonstrated that the presence of 
nucleotides in the mRNA TRS that are derived from the TRS-L might be a more 
common occurrence than previously suspected. It has additionally been shown for 
the first time with IBV that the TRS-L/TRS-B interaction directly mediates mRNA 
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levels during infection via the number of nucleotide matches existing between the 
two sequences. This work also raises the possibility that additional virus sg mRNAs 
may be produced by coronaviruses for the expression of as yet unidentified proteins. 
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Chapter 8: Discussion and Further Work  
 
8.1 Discussion 
 
The avian coronavirus IBV is a positive-sense, single stranded RNA virus belonging 
to the family Coronaviridae. Coronaviruses possess the largest RNA genomes 
ranging in size from 26-31kb and this, combined with the development of reverse 
genetics systems that allow manipulation of the genome, has resulted in the 
suggestion that coronaviruses may be suitable to use as viral vectors for the 
expression of heterologous genes. The initial aim of this PhD was to investigate the 
potential for utilizing IBV as a vaccine vector that could be used to vaccinate 
chickens against both IBV and a second avian viral disease based on the 
heterologous gene being expressed. 
 
Utilizing the reverse genetics systems developed in the Coronavirus group at the 
IAH a series of rIBVs, expressing either eGFP or hRluc, were generated to establish 
what factors are important for the stable expression of foreign genes from IBV, and 
thereby demonstrating the potential to use IBV as a vaccine vector. Recombinant 
viruses were designed with the aim of investigating the effect on virus stability of 
four different factors: (1) genome position of the foreign gene, (2) the nature of the 
foreign gene, (3) codon optimization of the foreign gene and (4) fusion of the foreign 
gene to an existing IBV gene. The successful rescue of six different rIBVs out of a 
planned nine constructs allowed for investigation of factors 1-3 using a variety of 
analysis techniques as detailed in Chapters 3-5. 
 
Chapter Eight 
187 
 
Two replicates each of rIBVs BeauR-eGFP 5ab, BeauR-hRluc 5ab, BeauR-
eGFP IR, BeauR-hRluc IR, BeauR-IBVhRluc 5ab and BeauR-hRluc 3ab were 
rescued as defined by the observation of IBV-induced CPE, as well as detection of a 
PCR product corresponding to the appropriate reporter gene. However, as was 
discovered during analysis, in some cases nucleotide changes had occurred during 
the rescue process that differed between the two replicates of a particular rIBV. This 
was an important observation as it demonstrated an element of unpredictability in the 
rescue of rIBVs that could lead to inconsistent production of viruses for vaccine 
purposes. It is not always clear in the literature, when looking at similar studies of 
recombinant coronaviruses, whether the data presented represents one or more virus 
replicates, and whether any nucleotide changes outside of the heterologous genes 
have been presented. It is difficult therefore to establish whether the inconsistencies 
observed here are due to the specific rescue process, the basic design of the rIBV 
constructs, or whether this is a feature of all coronavirus recombinants expressing 
foreign genes. 
 
The analyses of the rIBVs revealed that, in the absence of sequence changes within 
the heterologous genes, all rIBV constructs were capable of expressing the relevant 
protein. However, problems were encountered with the stability of the rIBVs 
following repeated passage on CK cells. Previous studies investigating the 
expression of heterologous genes from coronaviruses have also reported varying 
degrees of instability for recombinant viruses following passaging, suggesting that 
this is a common problem, potentially with the same general underlying cause. A 
summary of the stability of successfully rescued recombinant viruses is given in 
Table 8.1. 
  
 
TABLE 8.1: Stability of Recombinant Coronaviruses 
Virus 
Backbone 
Recombinant Reporter 
Gene 
Stability (Passage at which 
expression no longer detected) 
Reference 
IBV (Vero cell-
adapted strain 
P65) 
IBV-EGFP25180 (insertion into IR) 
IBV-EGFP27105 (insertion between N and 3'UTR) 
IBV-S-EGFP (fusion to carboxy terminus of S) 
IBV-Luc 3ab (replacement of ORFs 3a and 3ab) 
IBV-Luc25180 (insertion into IR) 
IBV-Luc27105 (insertion between N and 3'UTR 
eGFP 
eGFP 
eGFP 
fLuc 
fLuc 
fLuc 
P5 (Vero cells) 
P5 (Vero cells) 
P5 (Vero cells) 
P15 (Vero cells) 
P2 (Vero cells) 
P2 (Vero cells) 
Shen et al. 
2006 
IBV (Vero cell-
adapted strain) 
GIBV (replacement of ORF 5a) GFP P5 (Vero cells) Youn et al. 
2005 
TGEV 
(PUR46-MAD 
strain) 
rTGEV- 3-TRS3a-GFP (replacement of ORFs 3a and 
3b) 
GFP  P20 (Swine testis cells) 
Sola et al. 
2003 
FCoV (Black 
strain) 
recFCoV-GFP (replacement of ORFs 3a, 3b and 3c) 
recFCoV-RL (replacement of ORFs 3a, 3b and 3c) 
GFP 
Renilla 
 P6 (FCWF-4 cells) 
 P6 (FCWF-4 cells) 
Tekes et al. 
2008 
HCoV-NL63  icNL63gfp (replacement of ORF 3) GFP  2 months in human ciliated 
airway epithelium cultures
a
  
Donaldson et 
al. 2008 
MHV-A59 MHV-SGFP (Fusion to carboxy terminus of Spike) GFP P6 – but mixed population as 
early as P2 (LR7 cells) 
Bosch et al. 
2004 
MHV-A59 MHV-ERLM (insertion between E and M) 
MHV-EFLM (insertion between E and M) 
Renilla 
fLuc 
 P8 (LR7 cells) 
 P5 – but decreased expression 
from P5 (LR7 cells) 
de Haan et al. 
2005 
FIPV
b
  FIPV- 3abcRL (replacement of ORFs 3a, 3b and 3c) 
FIPV- 3abcFL (replacement of ORFs 3a, 3b and 3c) 
Renilla 
fLuc 
 P8 (FCWF-4 cells) 
 P8 (FCWF-4 cells) 
a
No passage number indicated 
b
Feline infectious peritonitis virus 
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As indicated in Table 8.1 only two recombinants remained stable for over ten 
passages in cell culture, with the majority losing heterologous gene expression 
between P2 and P8; a similar result to that observed in this study where instability 
arose between P4 and P10 depending on the rIBV and conditions of passaging 
(Table 5.2). Several additional studies have also demonstrated the ability of 
coronaviruses to express heterologous genes, thus adding to the evidence in support 
of coronaviruses as viral vectors (de Haan, et al. 2005, Fischer, et al. 1997, Raaben 
2009, Ribes, et al. 2011, van den Worm, et al. 2012). However, no passaging 
experiments were conducted in these reports and therefore the stability of the 
recombinant viruses is unclear. 
 
In this study the differences observed in stability between those rIBVs expressing 
eGFP and those expressing hRluc was minimal, with only one or two passages 
between the related constructs, suggesting that the type of heterologous gene had 
little effect on virus stability. This was in contrast to the observations of Shen et al. 
(Shen, et al. 2009) where recombinants IBV-Luc25180 and IBV-Luc27105, 
expressing fLuc, were less stable than similar recombinants expressing eGFP, and 
expression of fLuc was not detected past P1 of the virus. This apparent discrepancy 
may be explained by the differences between fLuc and hRluc, such as protein size, 
and correlates with previous findings that fLuc could not be stably expressed from 
IBV D-RNAs (Stirrups, et al. 2000). Similarly, the work of de Haan et al. (de Haan, 
et al. 2005) demonstrated that fLuc was less stable than Renilla luciferase when 
expressed from between the E and M genes of MHV, although an investigation into 
the problems with fLuc determined that the reduced stability was not a consequence 
of the larger size of fLuc. 
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It has been suggested previously that the replacement of accessory genes results in 
recombinants with increased stability over those in which the heterologous gene has 
been inserted as an additional expression cassette. This was clearly demonstrated by 
Shen et al. (Shen, et al. 2009) where the authors found that the replacement of ORFs 
3a and 3b by fLuc was considerably more stable than any other construct in the 
study, with expression of fLuc still detected at P15 compared to all others where 
expression was lost by P5 at the latest. 
 
This finding can be compared to the results obtained in this study for BeauR-
hRluc 3ab as, although the exact sequence of IBV-Luc 3ab (Shen, et al. 2009) has 
been difficult to determine from the publication, the two recombinant viruses consist 
of the replacement of the same genome region, albeit in different virus strains. 
Analysis of BeauR-hRluc 3ab showed that although instability in the form of 
deletion variants of the virus arose in early passages, the wild type virus was also 
maintained up to P12 when passaged at an MOI of 0.01 (Fig. 5.3). Had this 
recombinant been assessed purely on the basis of detection of luciferase activity it 
would have been classed as a highly stable rIBV. With no analysis given in the Shen 
paper as to the virus populations present, it is interesting to speculate that at P15 
IBV-Luc 3ab was in fact present as a mixed population containing deletion variants, 
and therefore not as stable as suggested. 
 
If no mixed populations are assumed for IBV-Luc 3ab at P15 (Shen, et al. 2009) 
then comparison to rIBV BeauR-hRluc 3ab may highlight the importance of the 
sequence alterations made to viruses to accommodate the expression of heterologous 
genes. Sequence analysis of BeauR-hRluc 3ab showed that several unintended 
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changes had arisen in the two replicates of this rIBV in the region of the inserted 
TRS-B for expression the E gene, and along with the failure to rescue BeauR-
eGFP 3ab, suggested that the sequence alterations made were not favourable to 
successful rescue. As mentioned, the precise sequence of IBV-Luc 3ab was difficult 
to determine and so it is not clear how the expression of E was achieved for this 
virus. It is possible therefore that the overall construction of IBV-Luc 3ab was more 
conducive to successful rescue and stable passaging than BeauR-hRluc 3ab. This 
would suggest that the specific sequence construction of a recombinant may be more 
important than either the heterologous gene being expressed, or the position it is 
located, and may help explain the differences observed in stability between 
seemingly analogous viruses. 
 
The data from this, and similar, studies suggest that overall, the stability of 
coronaviruses expressing heterologous genes is low, and raises the question of how 
feasible it is to utilize coronaviruses as vectors. A second family of positive-strand 
RNA viruses, the Togaviridae, also utilize sg RNAs for the expression of virus 
structural proteins, in this case a single sg mRNA known as 26S, which is 
transcribed from an internal promoter present in the minus-strand RNA. As a result 
viruses from this family, particularly those in the alphavirus genus, have also been 
extensively studied as potential viral vectors. Alphaviruses have been utilized as 
expression vectors in several formats including, as replication-competent vectors, in 
which heterologous genes are expressed from additional sg mRNAs (Hahn, et al. 
1992, Pugachev, et al. 1995) or as virus-like particles, in which the heterologous 
gene is expressed from the 26S sg mRNA through replacement of the structural 
genes (reviewed in (Rayner, et al. 2002)). 
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As with coronaviruses however, initial attempts to generate stable replication-
competent vectors, in which a heterologous gene was expressed as an additional sg 
mRNA, showed little promise. Heterologous genes were found to be deleted 
following only a few passages in cell culture; a result presumed to be due to various 
aspects including homologous recombination between duplicated promoter 
sequences, the location of the additional promoter sequence and the nature of the 
heterologous gene (Hahn, et al. 1992, Pugachev, et al. 1995). A solution to this 
problem was found with the insertion of a picornavirus, encephalomyocarditis virus 
(EMCV), IRES element between ORFs instead of a second sg promoter, thus 
allowing expression of the heterologous gene from the existing sg mRNA 
(Pugachev, et al. 2000). A similar strategy was attempted for IBV using D-RNAs for 
the expression of CAT via an EMCV IRES (Dove, et al. 2004). However, during 
IBV helper virus rescue no IRES-mediated translation of the CAT protein could be 
detected, suggesting that this mechanism may not be suitable to improve the stability 
of recombinant coronaviruses, although D-RNAs may not be representative of the 
situation observed with full-length genomic RNA. 
 
Understanding how instability arises in recombinant coronaviruses, and overcoming 
this, may be necessary before the full potential of coronavirus-based viral vectors 
can be realised. Homologous recombination, a result of template-switching during 
RNA replication, has been demonstrated to occur in several coronaviruses including 
MHV (Makino, et al. 1986, van der Most, et al. 1992), HCoV-OC43 (Lau, et al. 
2011) and IBV (Hughes 2011, Kottier, et al. 1995, Lee and Jackwood 2000) and is 
the most likely explanation for the deletion of heterologous genes from recombinant 
coronaviruses. Recombination may occur due to the presence of similar sequences 
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between the foreign gene and the virus genome, the presence of similar sequences in 
the genome itself, such as TRSs, or the presence of secondary RNA structures within 
the foreign gene or virus genome. 
 
In this study stability was found to increase upon passaging in cell culture at a low 
MOI of 0.01, a result that may be explained by the indirect control of the occurrence 
of recombination events. By infecting cells at a low MOI the number of genomes 
initially present in a single cell will be low and therefore limit the potential for 
recombination events to occur between genomes until further rounds of replication 
have taken place. However, even with passaging at an MOI of 0.05 the stability of an 
MHV Spike-GFP fusion recombinant did not extend beyond P2 before the 
occurrence of deletions within the GFP sequence and the appearance of a mixed 
virus population (Bosch, et al. 2004). Taken together with the data from this study, 
which showed that passaging at a low MOI could only improve stability by a small 
number of passages, this suggests that passaging at a low MOI is not sufficient to 
prevent the deletion of heterologous genes from recombinant coronaviruses, but may 
be beneficial in some circumstances. 
 
Overall this project has demonstrated that IBV does have potential to be used as a 
vaccine vector although further work is required. The data suggests that a successful 
vector would be based on constructs in which Gene 5 has been replaced by the 
heterologous gene, as these were found to be the most stable, achieving 12 passages 
in cell culture whilst still expressing the heterologous protein (Table 5.2). The 
benefits of codon optimization of the heterologous gene were not fully established, 
although there was some evidence from one passaging experiment to suggest that 
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this may result in a modest increase in the stability of the virus (Table 5.2). The 
stability of recombinant coronaviruses expressing heterologous genes remains a 
problem, with no obvious solution as to how to overcome the natural process of 
homologous recombination that appears to lead to the deletion of heterologous 
genes. It remains to be determined how the stability of rIBVs in cell culture 
translates to stability in vivo and this will be the key factor in establishing whether 
IBV can be utilized as a vaccine vector. 
 
The IR and a novel sg mRNA 
 
The analysis of the rIBVs generated for investigation of the use of IBV as a vaccine 
vector led to the identification of a novel sg mRNA for IBV and the closely related 
TCoV, and the suggestion of the existence of a 5
th
 accessory protein for the 
gammacoronaviruses. The novel sg mRNA was associated with a region of the IBV 
and TCoV genome located between the M gene and Gene 5, and referred to variably 
as the IR, ORF 4b or ORF X (Armesto, et al. 2009, Cao, et al. 2008, Gomaa, et al. 
2008, Hewson, et al. 2011). Transcription of the sg mRNA was discovered to be 
initiated from a non-canonical TRS-B, of CAA, located approximately 100nts 
upstream of the AUG of the IR, within the M gene. It was demonstrated that the TRS 
of the IR mRNA was derived in part from this non-canonical TRS-B at positions 6-8, 
while positions 1-5 were derived from the TRS-L. This is unique amongst the 
currently known sg mRNAs of coronaviruses and contradicts the current 
understanding that a mRNA TRS is derived from the TRS-B (van Marle, et al. 1999, 
Zuniga, et al. 2004). 
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The current model of coronavirus sg mRNA transcription can be thought of as a 
three-step process consisting of: 1) pause/stop of the RTC following recognition and 
copying of a TRS-B, (2) base-pairing of the nascent negative-sense RNA to the 
TRS-L and (3) a template switch to allow transcription of the nascent RNA to 
continue to the very 5' end of the genome. The exact mechanisms of coronavirus 
transcription are not yet fully understood but there is increasing evidence to suggest 
that additional factors are involved such as specific sequence elements and RNA-
RNA interactions, the formation of secondary RNA structures such as stem-loops, or 
RNA-protein interactions, (Baric, et al. 1988, Dufour, et al. 2011, Keane, et al. 2012, 
Mateos-Gomez, et al. 2011, Moreno, et al. 2008, Ozdarendeli, et al. 2001, Sola, et 
al. 2011, Sola, et al. 2011, Yang, et al. 2011, Zhang and Lai 1995, Zuniga, et al. 
2010). 
 
The TRS-B is believed to play an important role in the initiation of sg mRNA 
synthesis by acting as a pause/stop signal for the RTC. However, this belief is 
difficult to reconcile with the finding that the IR sg mRNA is transcribed via a TRS-
B of CAA. This 3nt sequence occurs approximately 280 times throughout the Beau-
R genome without generating sg mRNAs and therefore it is proposed that sequence 
recognition of a TRS-B may only have a limited role in the initial steps of sg mRNA 
transcription, i.e. pausing of the RTC. Particularly in the case of the IR sg mRNA, if 
not all sg mRNAs, the suggestion would be that the additional elements such as 
secondary RNA structures, are the dominant factor for initiation of sg mRNA 
synthesis. 
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Further evidence in favour of this possibility was gained from analysis of rIBVs 
BeauR-eGFP IR and BeauR-hRluc IR. In the case of BeauR-eGFP IR and BeauR-
hRluc IR it was discovered that transcription of the reporter gene sg mRNAs was 
mediated by the naturally occurring IR TRS-B, and not the consensus TRS-B 
inserted upstream of the gene sequence, suggesting that simply the presence of a 
TRS-B is not sufficient for initiating transcription. Investigation of the BCoV Gene 5 
sg mRNA also demonstrated the preferential use of a non-canonical TRS-B of 
GGUAGAC despite the presence of a consensus, canonical UCCAAAC sequence 
located 14nts downstream, again suggesting that sequence recognition of a canonical 
TRS-B is not the main factor in initiating the synthesis of sg mRNAs (Ozdarendeli, 
et al. 2001). 
 
Additionally, analysis of the sg mRNAs produced by rIBV BeauR-L-CTTAACAT 
did not demonstrate the presence of any additional, unexpected, sg mRNAs despite 
the presence of a now perfect match between the TRS-L and a CUUAACAU 
sequence beginning at nucleotide 24685 within the M gene of the Beau-R genome. If 
sequence recognition of a TRS was sufficient to initiate transcription then a sg 
mRNA originating from this position would be expected, but this was not the case. 
However, this finding was in contrast to reports concerning SARS-CoV and 
arterivirus EAV, in which mutations in the TRS-L led to the activation of non-
canonical TRS-Bs and the synthesis of novel sg mRNAs (Pasternak, et al. 2003, 
Yount, et al. 2006). These reports suggested that provided a stable TRS-L/TRS-B 
duplex could be formed new sg mRNAs could be generated from sequences that had 
previously not been recognised as a TRS by the RTC. It is possible that the 
mutations introduced in these cases resulted in changes, such as introduction of 
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secondary RNA structures or creation of protein binding sites, that were not 
previously present, and it is these factors that led to the synthesis of sg mRNAs. 
Given the suggestion that the TRS-B is not as important for initiation of sg mRNA 
synthesis as previously thought, the non-canonical IR TRS-B provided a means to 
investigate its role in regulating the levels of sg mRNA transcription of the structural 
and accessory genes. Previous studies have demonstrated that altering the TRS-
L/TRS-B interaction can lead to changes in sg mRNA levels for affected genes 
(Alonso, et al. 2002, Sola, et al. 2005, van Marle, et al. 1999, Yount, et al. 2006, 
Zhang and Lai 1995, Zuniga, et al. 2004). By extending the IR TRS-B to 
CUGAACAA, to match that of Gene 3 and the S gene, it was demonstrated that the 
levels of IR sg mRNA could be increased 6-fold over the natural level (Fig. 7.11), 
thus confirming the importance of the TRS-L/TRS-B interaction in sg mRNA 
synthesis. 
 
The IR sg mRNA contains a putative ORF for expression of an 11kDa protein, with 
the evidence suggesting that this protein is translated during IBV infection (Fig. 6.9), 
therefore resulting in a 5
th
 accessory protein of IBV and related 
gammacoronaviruses. The non-canonical transcription mechanism utilized by the IR, 
and involving incorporation of TRS-L nucleotides into the mRNA TRS, suggests 
that there is potential for other coronaviruses to synthesise sg mRNAs in a similar 
way, via as yet unidentified shortened TRS-Bs. It is possible therefore, that there 
may be other additional proteins produced by coronaviruses that are yet to be 
discovered. 
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Studies of arteriviruses EAV and porcine reproductive and respiratory virus led to 
the discovery of a novel gene that overlaps the arterivirus GP5 structural gene, and 
encodes a potential additional structural protein referred to as ORF5a (Firth, et al. 
2011, Johnson, et al. 2011). Expression of the ORF5a protein is predicted to be from 
the same sg mRNA as GP5, with translation proposed to involve a mechanism of 
leaky ribosomal scanning. These findings, along with the discovery of the IR sg 
mRNA, suggests that there are several mechanisms by which coronaviruses, and the 
closely related arteriviruses, may be able to expand their repertoire of proteins, not 
all of which are fully appreciated at this time. 
 
The discovery of the IR sg mRNA, and the possibility that there may be other 
unidentified sg mRNAs/proteins, also has important implications for the use of IBV, 
or other coronaviruses, as vaccine vectors. It has been shown in several studies that 
replacement of accessory genes results in the most stable recombinant viruses. 
However, if the full complement of proteins is yet to be discovered for a virus, these 
gene replacements may indirectly affect more genes than those intended. While this 
may not alter growth characteristics in cell culture, as demonstrated by the limited 
effects of the deletion of coronavirus accessory proteins (Casais, et al. 2005, de 
Haan, et al. 2002, Hodgson, et al. 2006), effects on in vivo replication may be 
enough to alter the effectiveness of any potential vaccine. 
 
In summary, the data presented in this thesis has demonstrated that IBV has the 
potential to be utilized as a vaccine vector based on the replacement of accessory 
Gene 5 with a heterologous gene. The stability of the 5ab rIBVs in cell culture was 
comparable to, if not better than, similar coronavirus constructs that have been 
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proposed as viral vectors, although in vivo stability was not determined. Important 
discoveries were made with the identification of a novel sg mRNA corresponding to 
the IR of the gammacoronaviruses, and the presence of a potential 11kDa protein 
that would constitute a 5
th
 novel accessory protein of closely related 
gammacoronaviruses. The transcription mechanism involved in synthesis of the IR 
sg mRNA demonstrated the importance of TRS-L/TRS-B interactions in regulating 
the levels of sg mRNAs produced and suggests that current model of coronavirus sg 
mRNA synthesis may not account for the complexity of the interactions occurring 
during virus replication. 
 
8.2 Further Work 
 
IBV as a potential vaccine vector 
The data presented in this thesis demonstrated that the replacement of Gene 5, 
encoding accessory proteins 5a and 5b, resulted in the most stable rIBVs and 
therefore offers the best target for further development of an IBV-based vector 
vaccine. Several follow-up experiments are suggested to explore this possibility 
further. First, BeauR-hRluc 5ab and BeauR-IBVhRluc 5ab should be passaged 
further, in cell culture, to determine if codon optimization does result in a more 
stable rIBV and whether such a process would be beneficial for vaccine design. 
Second, animal experiments are required to demonstrate the stability of the rIBVs in 
vivo, as well as the generation of antibodies against the heterologous protein and an 
effective immune response against IBV. Finally, it will be necessary to demonstrate 
that rIBVs can be generated expressing genes from other avian viruses in place of 
Chapter Eight 
200 
 
Gene 5. These rIBVs should be at least as stable as the 5ab rIBVs tested in this 
study to warrant consideration as a viable vaccine vector candidate. 
 
The IR 
Despite the advances made in this thesis regarding the knowledge of the IR, and the 
associated ORF, much remains unknown. Further work is required not only with 
regards to the IR protein, but also to understand the mechanisms involved in 
coronavirus sg mRNA transcription. Ideally, an antibody against the IR protein is 
required to definitively prove that it is translated during virus infection. Due to the 
failure of the peptide antibody generated in this study an alternative approach, such 
as the generation of a recombinant protein, will be required. A functional antibody 
can subsequently be used to determine the cellular location of the protein during 
infection and possibly any viral, or host, proteins it interacts with. 
 
The unique TRS-B of the IR can be used to further study the mechanisms involved 
in coronavirus sg mRNA transcription. Having demonstrated the role of the TRS in 
determining the levels of sg mRNA transcription, further rIBVs can be generated to 
fully establish the core sequence of the IBV TRS required for achieving the 
maximum level of transcription possible from a gene. It would also be interesting to 
determine whether such a short TRS-B could be introduced for one of the essential 
structural genes, thereby reducing the level of transcription of that gene, and offering 
a mechanism for the molecular attenuation of coronaviruses for vaccine purposes. 
Analysis of the sequence at the site of the IR TRS-B may help in identifying 
particular RNA structures or RNA, or protein, binding sites that are important for 
RTC recognition of a TRS-B. 
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APPENDICES 
 
Appendix 1: Primer Lists 
 
TABLE A1.1: Overlapping PCR Primers 
Primer (F/R) Sequence
a, b
 
A(F) TTTGGCGCGCCGCTAAGTGTGAACCAGACCACTTGCC 
C(R) CCCTTAATTAAGTCGATCTAGATTTAGTATCAGCACCC 
A-eGFP(R) GCTCCTCGCCCTTGCTCACCATCGTCCGTATTTGTTAAG
TTTTTG 
B-eGFP(F) CAAAAACTTAACAAATACGGACGATGGTGAGCAAGGG
CGAGGAGC 
B-eGFP(R) GCTATTGCTCCGCGAAAAGGTTATTACTTGTACAGCTC
GTCC 
C-eGFP(F) GGACGAGCTGTACAAGTAATAACCTTTTCGCGGAGCAA
TAGC 
A-hRluc(R) GTCGTACACCTTGGAAGCCATCGTCCGTATTTGTTAAGT
TTTTG 
B-hRluc(F) CAAAAACTTAACAAATACGGACGATGGCTTCCAAGGTG
TACGAC 
B-hRluc(R) GCTATTGCTCCGCGAAAAGGTTATTACTGCTCGTTCTTC
AGC 
C-hRluc(F) GCTGAAGAACGAGCAGTAATAACCTTTTCGCGGAGCAA
TAGC 
a
 Bold italics denotes added restriction sites 
b
 Underlined sequence denotes sequence derived from reporter genes 
 
 
TABLE A1.2: Reporter Gene Cloning Primers 
Primer (F/R) Sequence
a, b
 
eGFP-IR(F) TTTGCTAGCGGCCAACTTAACAAATACGGACGATGGTG
AGCAAGGGCGAGG 
eGFP-IR(R) AAACCCGGGTTATTACTTGTACAGCTCGTCCATGCC 
hRluc-IR(F) TTTGCTAGCGGCCAACTTAACAAATACGGACGATGGCT
TCCAAGGTGTACG 
hRluc-IR(R) AAACCCGGGTTATTACTGCTCGTTCTTCAGCACGCGC 
a
 Bold italics denotes added restriction sites 
b
 Underlined sequence denotes sequence derived from reporter genes 
 
TABLE A1.3: Site Directed Mutagenesis Primers 
Primer (F/R) Sequence
a
 
TRS-L TG (F) TAGATTTTTAACTGAACAAAACGGAC 
TRS-L TG (R) GTCCGTTTTGTTCAGTTAAAAATCTA 
TRS-L AT (F) TAGATTTTTAACTTAACATAACGGAC 
TRS-L AT (R) GTCCGTTATGTTAAGTTAAAAATCTA 
a
 Nucleotides in bold represent introduced mutations 
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TABLE A1.4: Confirmation PCR Primers 
Primer (F/R) Sequence 
5abS (F) GAGCTATTAACGGTGTTACC 
BG147 (R) AATCTAATCCTTCTCTCAGA 
BG52 (F) GAATGGTGTTCTTTATTG 
BG146 (R) TCTAACACTCTAAGTTGAG 
BG49 (F) TGACGAATTGTCAAAATG 
BG144 (R) AGACAGACACGCAAACACTG 
BG148 (R) ATGTTTTCGTTATCAGGAAC 
 
 
TABLE A1.5: Sequencing and Additional Primers 
Primer (F/R) Sequence 
BG2 (R)  AGTGCCAAACAACCCCTGA 
BG48 (F)  CGCCATACAAGCAAATGC 
BG50 (F)  TAGCGCTCCAACAACTAA 
BG51 (F)  GCAGTTATTGTTAACGAG 
BG54 (F)  ACCACCTAAAGTCGGTTC 
BG56 (F)  CAACAGCGCCCAAAGAAG 
BG69 (F)  GCTTTTGCCACTATTATCTTC 
BG70 (F)  CAAATACGGACGATGAAATG 
BG133 (R)  ATTGCCAGTATTATACTGGC 
BG137 (R)  CTTGCATTTCTGCTGTTATG 
BG140 (R)  TTGAATACGATCAATTTCAC 
BG142 (R)  AGGGATCAAATACTTCTGTG 
BG143 (R)  CAAGAGTACAATTTGTCTCG 
BG145 (R)  CTGTTGCTACACTTTCTAGC 
BG149 (R)  TTCCACTCCTACCACGGTTC 
93/100 (R)  GCTCTAACTCTATACTAGCCT 
eGFP-S (F) CTACCCCGACCACATGAAGC 
eGFP-S (R) TGTTGTAGTTGTACTCCAGC 
hRluc (F) ATGGCTTCCAAGGTGTACGAC 
hRluc (R) TTATTACTGCTCGTTCTTCAGC 
hRluc-S (F) CTTTCACTACTCCTACGAGC 
hRluc-S (R) CAGTTTCCGCATGATCTTGC 
IBVhRluc-S (F) GATTGGGGTGCATGTCTTGC 
IBVhRluc-S (R) TCATAATTTTAGATGGAAGC 
Leader1 (F) CTATTACACTAGCCTTGCGC 
IR (R) GACCACATCCTACAACAACC 
M13 (F) GTAAAACGACGGCCAG 
M13 (R) CAGGAAACAGCTATGAC 
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Appendix 2: Plasmid Maps 
 
pGPTNEB193 
 
 
 
pGPT- IR 
 
 
 
 
pGPT-eGFP 4b 
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Appendix 3: Recombinant IBV genome fragment sequences 
 
BeauR-eGFPΔ5ab 
 
  AscI  24979 
GGCGCGCCGCTAAGTGTGAACCAGACCACTTGCCTAAAGATATATTTGTTTGTACA
CCGGATAGACGTAATATCTACCGTATGGTGCAGAAATATACTGGTGACCAAAGCGG
AAATAAGAAAAGGTTTGCTACGTTTGTCTATGCAAAGCAGTCAGTAGATACTGGCG
AGCTAGAAAGTGTAGCAACAGGAGGAAGTAGTCTTTACACATAAATGTGTGTGTGT
AGAGAGTATTTAAAATTATTCTTTAATAGCGCCTCTGTTTTAAGAGCGCATAAGAG
TATTTATTTTGAGGATACTAATATAAATCCTCTTTGTTTTATACTCTCCTTTCAAG
AGCTATTAACGGTGTTACCTTTCAAGTAGATAATGGAAAAGTCTACTACGAAGGAA
CACCAGTTTTCCAAAAAGGTTGTTGTAGGATGTGGTCCAATTATAAGAAAGAATAA
TTGAACCACCTACTACACTTATTTTTATAAGAGGTACCTTACTTAACAAAAACTTA
ACAAATACGGACGATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGGTGGTGCCCA
TCCTGGTCGAGCTGGACGGCGACGTAAACGGCCACAAGTTCAGCGTGTCCGGCGAG
GGCGAGGGCGATGCCACCTACGGCAAGCTGACCCTGAAGTTCATCTGCACCACCGG
CAAGCTGCCCGTGCCCTGGCCCACCCTCGTGACCACCCTGACCTACGGCGTGCAGT
GCTTCAGCCGCTACCCCGACCACATGAAGCAGCACGACTTCTTCAAGTCCGCCATG
CCCGAAGGCTACGTCCAGGAGCGCACCATCTTCTTCAAGGACGACGGCAACTACAA
GACCCGCGCCGAGGTGAAGTTCGAGGGCGACACCCTGGTGAACCGCATCGAGCTGA
AGGGCATCGACTTCAAGGAGGACGGCAACATCCTGGGGCACAAGCTGGAGTACAAC
TACAACAGCCACAACGTCTATATCATGGCCGACAAGCAGAAGAACGGCATCAAGGT
GAACTTCAAGATCCGCCACAACATCGAGGACGGCAGCGTGCAGCTCGCCGACCACT
ACCAGCAGAACACCCCCATCGGCGACGGCCCCGTGCTGCTGCCCGACAACCACTAC
CTGAGCACCCAGTCCGCCCTGAGCAAAGACCCCAACGAGAAGCGCGATCACATGGT
CCTGCTGGAGTTCGTGACCGCCGCCGGGATCACTCTCGGCATGGACGAGCTGTACA
AGTAATAACCTTTTCGCGGAGCAATAGCAAGAAAAGCTCGAATTTATCTGAGAGAA
GGATTAGATTGTGTTTACTTTCTTAACAAAGCAGGACAAGCAGAGCCTTGTCCCGC
GTGTACCTCTCTAGTATTCCAAGGGAAAACTTGTGAGGAACACATACATAATAATA
ATCTTTTGTCATGGCAAGCGGTAAAGCAGCTGGAAAAACAGACGCCCCAGCGCCAG
TCATTAAACTAGGAGGACCAAAACCACCTAAAGTCGGTTCTTCTGGAAATGCATCT
TGGTTTCAAGCAATAAAAGCCAAGAAGTTAAATACACCTCCGCCCAAGTTTGAAGG
TAGCGGTGTTCCTGATAACGAAAACATTAAGCCAAGCCAGCAACATGGATACTGGA
GACGCCAAGCCAGGTTTAAGCCAGGCAAAGGTGGAAGAAAACCAGTCCCAGATGCT
TGGTACTTTTACTATACTGGAACAGGACCTGCCGCTGACCTGAACTGGGGTGATAC
TCAAGATGGTATAGTGTGGGTTGCTGCTAAGGGTGCTGATACTAAATCTAGATCGA
CTTAATTAA 
   PacI 
 
M-IR-eGFP-5b-N 
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BeauR-hRlucΔ5ab 
 
  AscI  24979 
GGCGCGCCGCTAAGTGTGAACCAGACCACTTGCCTAAAGATATATTTGTTTGTACA
CCGGATAGACGTAATATCTACCGTATGGTGCAGAAATATACTGGTGACCAAAGCGG
AAATAAGAAAAGGTTTGCTACGTTTGTCTATGCAAAGCAGTCAGTAGATACTGGCG
AGCTAGAAAGTGTAGCAACAGGAGGAAGTAGTCTTTACACATAAATGTGTGTGTGT
AGAGAGTATTTAAAATTATTCTTTAATAGCGCCTCTGTTTTAAGAGCGCATAAGAG
TATTTATTTTGAGGATACTAATATAAATCCTCTTTGTTTTATACTCTCCTTTCAAG
AGCTATTAACGGTGTTACCTTTCAAGTAGATAATGGAAAAGTCTACTACGAAGGAA
CACCAGTTTTCCAAAAAGGTTGTTGTAGGATGTGGTCCAATTATAAGAAAGAATAA
TTGAACCACCTACTACACTTATTTTTATAAGAGGTACCTTACTTAACAAAAACTTA
ACAAATACGGACGATGGCTTCCAAGGTGTACGACCCCGAGCAACGCAAACGCATGA
TCACTGGGCCTCAGTGGTGGGCTCGCTGCAAGCAAATGAACGTGCTGGACTCCTTC
ATCAACTACTATGATTCCGAGAAGCACGCCGAGAACGCCGTGATTTTTCTGCATGG
TAACGCTGCCTCCAGCTACCTGTGGAGGCACGTCGTGCCTCACATCGAGCCCGTGG
CTAGATGCATCATCCCTGATCTGATCGGAATGGGTAAGTCCGGCAAGAGCGGGAAT
GGCTCATATCGCCTCCTGGATCACTACAAGTACCTCACCGCTTGGTTCGAGCTGCT
GAACCTTCCAAAGAAAATCATCTTTGTGGGCCACGACTGGGGGGCTTGTCTGGCCT
TTCACTACTCCTACGAGCACCAAGACAAGATCAAGGCCATCGTCCATGCTGAGAGT
GTCGTGGACGTGATCGAGTCCTGGGACGAGTGGCCTGACATCGAGGAGGATATCGC
CCTGATCAAGAGCGAAGAGGGCGAGAAAATGGTGCTTGAGAATAACTTCTTCGTCG
AGACCATGCTCCCAAGCAAGATCATGCGGAAACTGGAGCCTGAGGAGTTCGCTGCC
TACCTGGAGCCATTCAAGGAGAAGGGCGAGGTTAGACGGCCTACCCTCTCCTGGCC
TCGCGAGATCCCTCTCGTTAAGGGAGGCAAGCCCGACGTCGTCCAGATTGTCCGCA
ACTACAACGCCTACCTTCGGGCCAGCGACGATCTGCCTAAGATGTTCATCGAGTCC
GACCCTGGGTTCTTTTCCAACGCTATTGTCGAGGGAGCTAAGAAGTTCCCTAACAC
CGAGTTCGTGAAGGTGAAGGGCCTCCACTTCAGCCAGGAGGACGCTCCAGATGAAA
TGGGTAAGTACATCAAGAGCTTCGTGGAGCGCGTGCTGAAGAACGAGCAGTAATAA
CCTTTTCGCGGAGCAATAGCAAGAAAAGCTCGAATTTATCTGAGAGAAGGATTAGA
TTGTGTTTACTTTCTTAACAAAGCAGGACAAGCAGAGCCTTGTCCCGCGTGTACCT
CTCTAGTATTCCAAGGGAAAACTTGTGAGGAACACATACATAATAATAATCTTTTG
TCATGGCAAGCGGTAAAGCAGCTGGAAAAACAGACGCCCCAGCGCCAGTCATTAAA
CTAGGAGGACCAAAACCACCTAAAGTCGGTTCTTCTGGAAATGCATCTTGGTTTCA
AGCAATAAAAGCCAAGAAGTTAAATACACCTCCGCCCAAGTTTGAAGGTAGCGGTG
TTCCTGATAACGAAAACATTAAGCCAAGCCAGCAACATGGATACTGGAGACGCCAA
GCCAGGTTTAAGCCAGGCAAAGGTGGAAGAAAACCAGTCCCAGATGCTTGGTACTT
TTACTATACTGGAACAGGACCTGCCGCTGACCTGAACTGGGGTGATACTCAAGATG
GTATAGTGTGGGTTGCTGCTAAGGGTGCTGATACTAAATCTAGATCGACTTAATTA
A                                                   PacI 
 
 
M-IR-hRluc-5b-N 
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BeauR-eGFPΔIR 
 
24406 
CATATGGTAGAAAACTTAACAATCCGGAATTAGAAGCAGTTATTGTTAACGAGTTT
CCTAAGAACGGTTGGAATAATAAAAATCCAGCAAATTTTCAAGATGCCCAACGAGA
CAAATTGTACTCTTGACTTTGAACAGTCAGTTCAGCTTTTTAAAGAGTATAATTTA
TTTATAACTGCATTCTTGTTGTTCTTAACCATAATACTTCAGTATGGCTATGCAAC
AAGAAGTAAGGTTATTTATACACTGAAAATGATAGTGTTATGGTGCTTTTGGCCCC
TTAACATTGCAGTAGGTGTAATTTCATGTACATACCCACCAAACACAGGAGGTCTT
GTCGCAGCGATAATACTTACAGTGTTTGCGTGTCTGTCTTTTGTAGGTTATTGGAT
CCAGAGTATTAGACTCTTTAAGCGGTGTAGGTCATGGTGGTCATTTAATCCAGAAT
CTAATGCCGTAGGTTCAATACTCCTAACTAATGGTCAACAATGTAATTTTGCTATA
GAGAGTGTGCCAATGGTGCTTTCTCCAATTATAAAGAATGGTGTTCTTTATTGTGA
GGGTCAGTGGCTTGCTAAGTGTGAACCAGACCACTTGCCTAAAGATATATTTGTTT
GTACACCGGATAGACGTAATATCTACCGTATGGTGCAGAAATATACTGGTGACCAA
AGCGGAAATAAGAAAAGGTTTGCTACGTTTGTCTATGCAAAGCAGTCAGTAGATAC
TGGCGAGCTAGAAAGTGTAGCAACAGGAGGAAGTAGTCTTTACACATAAATGTGTG
TGGCTAGCGGCCAACTTAACAAATACGGACGATGGTGAGCAAGGGCGAGGAGCTGT
TCACCGGGGTGGTGCCCATCCTGGTCGAGCTGGACGGCGACGTAAACGGCCACAAG
TTCAGCGTGTCCGGCGAGGGCGAGGGCGATGCCACCTACGGCAAGCTGACCCTGAA
GTTCATCTGCACCACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCGTGACCACCC
TGACCTACGGCGTGCAGTGCTTCAGCCGCTACCCCGACCACATGAAGCAGCACGAC
TTCTTCAAGTCCGCCATGCCCGAAGGCTACGTCCAGGAGCGCACCATCTTCTTCAA
GGACGACGGCAACTACAAGACCCGCGCCGAGGTGAAGTTCGAGGGCGACACCCTGG
TGAACCGCATCGAGCTGAAGGGCATCGACTTCAAGGAGGACGGCAACATCCTGGGG
CACAAGCTGGAGTACAACTACAACAGCCACAACGTCTATATCATGGCCGACAAGCA
GAAGAACGGCATCAAGGTGAACTTCAAGATCCGCCACAACATCGAGGACGGCAGCG
TGCAGCTCGCCGACCACTACCAGCAGAACACCCCCATCGGCGACGGCCCCGTGCTG
CTGCCCGACAACCACTACCTGAGCACCCAGTCCGCCCTGAGCAAAGACCCCAACGA
GAAGCGCGATCACATGGTCCTGCTGGAGTTCGTGACCGCCGCCGGGATCACTCTCG
GCATGGACGAGCTGTACAAGTAATAACCCGGGATATCACGCGTGGTACCTTACTTA
ACAAAAACTTAACAAATACGGACGATGAAATGGCTGACTAGTTTTGGAAGAGCAGT
TATTTCTTGTTATAAATCCCTACTATTAACTCAACTTAGAGTGTTAGATAGGTTAA
TTTTAGATCACGGACTACTACGCGTTTTAACGTGTAGTAGGCGCGTGCTTTTAGTT
CAATTAGATTTAGTTTATAGGTTGGCGTATACGCCCACCCAATCGCTGGCATGAAT
AATAGTAAAGATAATCCTTTTCGCGGAGCAATAGCAAGAAAAGCTCGAATTTATCT
GAGAGAAGGATTAGATTGTGTTTACTTTCTTAACAAAGCAGGACAAGCAGAGCCTT
GTCCCGCGTGTACCTCTCTAGTATTCCAAGGGAAAACTTGTGAGGAACACATACAT
AATAATAATCTTTTGTCATGGCAAGCGGTAAAGCAGCTGGAAAAACAGACGCCCCA
GCGCCAGTCATTAAACTAGGAGGACCAAAACCACCTAAAGTCGGTTCTTCTGGAAA
TGCATCTTGGTTTCAAGCAATAAAAGCCAAGAAGTTAAATACACCTCCGCCCAAGT
TTGAAGGTAGCGGTGTTCCTGATAACGAAAACATTAAGCCAAGCCAGCAACATGGA
TACTGGAGACGCCAAGCCAGGTTTAAGCCAGGCAAAGGTGGAAGAAAACCAGTCCC
AGATGCTTGGTACTTTTACTATACTGGAACAGGACCTGCCGCTGACCTGAACTGGG
GTGATACTCAAGATGGTATAGTGTGGGTTGCTGCTAAGGGTGCTGATACTAAATCT
AGA 
3c-M-IR-Restriction Sites and TRS-eGFP-Restriction 
Sites-IR-5a-5b-N 
Appendices 
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BeauR-hRlucΔIR 
 
24406 
CATATGGTAGAAAACTTAACAATCCGGAATTAGAAGCAGTTATTGTTAACGAGTTT
CCTAAGAACGGTTGGAATAATAAAAATCCAGCAAATTTTCAAGATGCCCAACGAGA
CAAATTGTACTCTTGACTTTGAACAGTCAGTTCAGCTTTTTAAAGAGTATAATTTA
TTTATAACTGCATTCTTGTTGTTCTTAACCATAATACTTCAGTATGGCTATGCAAC
AAGAAGTAAGGTTATTTATACACTGAAAATGATAGTGTTATGGTGCTTTTGGCCCC
TTAACATTGCAGTAGGTGTAATTTCATGTACATACCCACCAAACACAGGAGGTCTT
GTCGCAGCGATAATACTTACAGTGTTTGCGTGTCTGTCTTTTGTAGGTTATTGGAT
CCAGAGTATTAGACTCTTTAAGCGGTGTAGGTCATGGTGGTCATTTAATCCAGAAT
CTAATGCCGTAGGTTCAATACTCCTAACTAATGGTCAACAATGTAATTTTGCTATA
GAGAGTGTGCCAATGGTGCTTTCTCCAATTATAAAGAATGGTGTTCTTTATTGTGA
GGGTCAGTGGCTTGCTAAGTGTGAACCAGACCACTTGCCTAAAGATATATTTGTTT
GTACACCGGATAGACGTAATATCTACCGTATGGTGCAGAAATATACTGGTGACCAA
AGCGGAAATAAGAAAAGGTTTGCTACGTTTGTCTATGCAAAGCAGTCAGTAGATAC
TGGCGAGCTAGAAAGTGTAGCAACAGGAGGAAGTAGTCTTTACACATAAATGTGTG
TGGCTAGCGGCCAACTTAACAAATACGGACGATGGCTTCCAAGGTGTACGACCCCG
AGCAACGCAAACGCATGATCACTGGGCCTCAGTGGTGGGCTCGCTGCAAGCAAATG
AACGTGCTGGACTCCTTCATCAACTACTATGATTCCGAGAAGCACGCCGAGAACGC
CGTGATTTTTCTGCATGGTAACGCTGCCTCCAGCTACCTGTGGAGGCACGTCGTGC
CTCACATCGAGCCCGTGGCTAGATGCATCATCCCTGATCTGATCGGAATGGGTAAG
TCCGGCAAGAGCGGGAATGGCTCATATCGCCTCCTGGATCACTACAAGTACCTCAC
CGCTTGGTTCGAGCTGCTGAACCTTCCAAAGAAAATCATCTTTGTGGGCCACGACT
GGGGGGCTTGTCTGGCCTTTCACTACTCCTACGAGCACCAAGACAAGATCAAGGCC
ATCGTCCATGCTGAGAGTGTCGTGGACGTGATCGAGTCCTGGGACGAGTGGCCTGA
CATCGAGGAGGATATCGCCCTGATCAAGAGCGAAGAGGGCGAGAAAATGGTGCTTG
AGAATAACTTCTTCGTCGAGACCATGCTCCCAAGCAAGATCATGCGGAAACTGGAG
CCTGAGGAGTTCGCTGCCTACCTGGAGCCATTCAAGGAGAAGGGCGAGGTTAGACG
GCCTACCCTCTCCTGGCCTCGCGAGATCCCTCTCGTTAAGGGAGGCAAGCCCGACG
TCGTCCAGATTGTCCGCAACTACAACGCCTACCTTCGGGCCAGCGACGATCTGCCT
AAGATGTTCATCGAGTCCGACCCTGGGTTCTTTTCCAACGCTATTGTCGAGGGAGC
TAAGAAGTTCCCTAACACCGAGTTCGTGAAGGTGAAGGGCCTCCACTTCAGCCAGG
AGGACGCTCCAGATGAAATGGGTAAGTACATCAAGAGCTTCGTGGAGCGCGTGCTG
AAGAACGAGCAGTAATAACCCGGGATATCACGCGTGGTACCTTACTTAACAAAAAC
TTAACAAATACGGACGATGAAATGGCTGACTAGTTTTGGAAGAGCAGTTATTTCTT
GTTATAAATCCCTACTATTAACTCAACTTAGAGTGTTAGATAGGTTAATTTTAGAT
CACGGACTACTACGCGTTTTAACGTGTAGTAGGCGCGTGCTTTTAGTTCAATTAGA
TTTAGTTTATAGGTTGGCGTATACGCCCACCCAATCGCTGGCATGAATAATAGTAA
AGATAATCCTTTTCGCGGAGCAATAGCAAGAAAAGCTCGAATTTATCTGAGAGAAG
GATTAGATTGTGTTTACTTTCTTAACAAAGCAGGACAAGCAGAGCCTTGTCCCGCG
TGTACCTCTCTAGTATTCCAAGGGAAAACTTGTGAGGAACACATACATAATAATAA
TCTTTTGTCATGGCAAGCGGTAAAGCAGCTGGAAAAACAGACGCCCCAGCGCCAGT
CATTAAACTAGGAGGACCAAAACCACCTAAAGTCGGTTCTTCTGGAAATGCATCTT
GGTTTCAAGCAATAAAAGCCAAGAAGTTAAATACACCTCCGCCCAAGTTTGAAGGT
AGCGGTGTTCCTGATAACGAAAACATTAAGCCAAGCCAGCAACATGGATACTGGAG
ACGCCAAGCCAGGTTTAAGCCAGGCAAAGGTGGAAGAAAACCAGTCCCAGATGCTT
GGTACTTTTACTATACTGGAACAGGACCTGCCGCTGACCTGAACTGGGGTGATACT
CAAGATGGTATAGTGTGGGTTGCTGCTAAGGGTGCTGATACTAAATCTAGA 
3c-M-IR-Restriction Sites and TRS- hRluc-Restriction 
Sites-IR-5a-5b-N 
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BeauR-IBVeGFPΔ5ab 
 
  AscI  24979 
GGCGCGCCGCTAAGTGTGAACCAGACCACTTGCCTAAAGATATATTTGTTTGTACA
CCGGATAGACGTAATATCTACCGTATGGTGCAGAAATATACTGGTGACCAAAGCGG
AAATAAGAAAAGGTTTGCTACGTTTGTCTATGCAAAGCAGTCAGTAGATACTGGCG
AGCTAGAAAGTGTAGCAACAGGAGGAAGTAGTCTTTACACATAAATGTGTGTGTGT
AGAGAGTATTTAAAATTATTCTTTAATAGCGCCTCTGTTTTAAGAGCGCATAAGAG
TATTTATTTTGAGGATACTAATATAAATCCTCTTTGTTTTATACTCTCCTTTCAAG
AGCTATTAACGGTGTTACCTTTCAAGTAGATAATGGAAAAGTCTACTACGAAGGAA
CACCAGTTTTCCAAAAAGGTTGTTGTAGGATGTGGTCCAATTATAAGAAAGAATAA
TTGAACCACCTACTACACTTATTTTTATAAGAGGTACCTTACTTAACAAAAACTTA
ACAAATACGGACGATGGTTTCTAAAGGTGAAGAACTTTTTACTGGTGTTGTTCCAA
TTCTTGTTGAACTTGATGGTGATGTTAATGGTCATAAATTTTCTGTTTCTGGTGAA
GGTGAAGGTGATGCAACTTATGGTAAACTTACTCTTAAATTTATTTGTACTACTGG
TAAACTTCCAGTTCCATGGCCAACTCTTGTTACTACTCTTACTTATGGTGTTCAAT
GTTTTTCTAGATATCCAGATCATATGAAACAACATGATTTTTTTAAATCTGCAATG
CCAGAAGGTTATGTTCAAGAAAGAACTATTTTTTTTAAAGATGATGGTAATTATAA
AACTAGAGCAGAAGTTAAATTTGAAGGTGATACTCTTGTTAATAGAATTGAACTTA
AAGGTATTGATTTTAAAGAAGATGGTAATATTCTTGGTCATAAACTTGAATATAAT
TATAATTCTCATAATGTTTATATTATGGCAGATAAACAAAAAAATGGTATTAAAGT
TAATTTTAAAATTAGACATAATATTGAAGATGGTTCTGTTCAACTTGCAGATCATT
ATCAACAAAATACTCCAATTGGTGATGGTCCAGTTCTTCTTCCAGATAATCATTAT
CTTTCTACTCAATCTGCACTTTCTAAAGATCCAAATGAAAAAAGAGATCATATGGT
TCTTCTTGAATTTGTTACTGCAGCAGGTATTACTCTTGGTATGGATGAACTTTATA
AACCTTTTCGCGGAGCAATAGCAAGAAAAGCTCGAATTTATCTGAGAGAAGGATTA
GATTGTGTTTACTTTCTTAACAAAGCAGGACAAGCAGAGCCTTGTCCCGCGTGTAC
CTCTCTAGTATTCCAAGGGAAAACTTGTGAGGAACACATACATAATAATAATCTTT
TGTCATGGCAAGCGGTAAAGCAGCTGGAAAAACAGACGCCCCAGCGCCAGTCATTA
AACTAGGAGGACCAAAACCACCTAAAGTCGGTTCTTCTGGAAATGCATCTTGGTTT
CAAGCAATAAAAGCCAAGAAGTTAAATACACCTCCGCCCAAGTTTGAAGGTAGCGG
TGTTCCTGATAACGAAAACATTAAGCCAAGCCAGCAACATGGATACTGGAGACGCC
AAGCCAGGTTTAAGCCAGGCAAAGGTGGAAGAAAACCAGTCCCAGATGCTTGGTAC
TTTTACTATACTGGAACAGGACCTGCCGCTGACCTGAACTGGGGTGATACTCAAGA
TGGTATAGTGTGGGTTGCTGCTAAGGGTGCTGATACTAAATCTAGATCGACTTAAT
TAA 
PacI 
 
M-IR-eGFP-5b-N 
 
Appendices 
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BeauR-IBVhRlucΔ5ab 
 
  AscI  24979 
GGCGCGCCGCTAAGTGTGAACCAGACCACTTGCCTAAAGATATATTTGTTTGTACA
CCGGATAGACGTAATATCTACCGTATGGTGCAGAAATATACTGGTGACCAAAGCGG
AAATAAGAAAAGGTTTGCTACGTTTGTCTATGCAAAGCAGTCAGTAGATACTGGCG
AGCTAGAAAGTGTAGCAACAGGAGGAAGTAGTCTTTACACATAAATGTGTGTGTGT
AGAGAGTATTTAAAATTATTCTTTAATAGCGCCTCTGTTTTAAGAGCGCATAAGAG
TATTTATTTTGAGGATACTAATATAAATCCTCTTTGTTTTATACTCTCCTTTCAAG
AGCTATTAACGGTGTTACCTTTCAAGTAGATAATGGAAAAGTCTACTACGAAGGAA
CACCAGTTTTCCAAAAAGGTTGTTGTAGGATGTGGTCCAATTATAAGAAAGAATAA
TTGAACCACCTACTACACTTATTTTTATAAGAGGTACCTTACTTAACAAAAACTTA
ACAAATACGGACGATGGCATCTAAAGTTTATGATCCAGAACAAAGAAAAAGAATGA
TTACTGGTCCACAATGGTGGGCAAGATGTAAACAAATGAATGTTCTTGATTCTTTT
ATTAATTATTATGATTCTGAAAAACATGCAGAAAATGCAGTTATTTTTCTTCATGG
TAATGCAGCATCTTCTTATCTTTGGAGACATGTTGTTCCACATATTGAACCAGTTG
CAAGATGTATTATTCCAGATCTTATTGGTATGGGTAAATCTGGTAAATCTGGTAAT
GGTTCTTATAGACTTCTTGATCATTATAAATATCTTACTGCATGGTTTGAACTTCT
TAATCTTCCAAAAAAAATTATTTTTGTTGGTCATGATTGGGGTGCATGTCTTGCAT
TTCATTATTCTTATGAACATCAAGATAAAATTAAAGCAATTGTTCATGCAGAATCT
GTTGTTGATGTTATTGAATCTTGGGATGAATGGCCAGATATTGAAGAAGATATTGC
ACTTATTAAATCTGAAGAAGGTGAAAAAATGGTTCTTGAAAATAATTTTTTTGTTG
AAACTATGCTTCCATCTAAAATTATGAGAAAACTTGAACCAGAAGAATTTGCAGCA
TATCTTGAACCATTTAAAGAAAAAGGTGAAGTTAGAAGACCAACTCTTTCTTGGCC
AAGAGAAATTCCACTTGTTAAAGGTGGTAAACCAGATGTTGTTCAAATTGTTAGAA
ATTATAATGCATATCTTAGAGCATCTGATGATCTTCCAAAAATGTTTATTGAATCT
GATCCAGGTTTTTTTTCTAATGCAATTGTTGAAGGTGCAAAAAAATTTCCAAATAC
TGAATTTGTTAAAGTTAAAGGTCTTCATTTTTCTCAAGAAGATGCACCAGATGAAA
TGGGTAAATATATTAAATCTTTTGTTGAAAGAGTTCTTAAAAATGAACAATAATAA
CCTTTTCGCGGAGCAATAGCAAGAAAAGCTCGAATTTATCTGAGAGAAGGATTAGA
TTGTGTTTACTTTCTTAACAAAGCAGGACAAGCAGAGCCTTGTCCCGCGTGTACCT
CTCTAGTATTCCAAGGGAAAACTTGTGAGGAACACATACATAATAATAATCTTTTG
TCATGGCAAGCGGTAAAGCAGCTGGAAAAACAGACGCCCCAGCGCCAGTCATTAAA
CTAGGAGGACCAAAACCACCTAAAGTCGGTTCTTCTGGAAATGCATCTTGGTTTCA
AGCAATAAAAGCCAAGAAGTTAAATACACCTCCGCCCAAGTTTGAAGGTAGCGGTG
TTCCTGATAACGAAAACATTAAGCCAAGCCAGCAACATGGATACTGGAGACGCCAA
GCCAGGTTTAAGCCAGGCAAAGGTGGAAGAAAACCAGTCCCAGATGCTTGGTACTT
TTACTATACTGGAACAGGACCTGCCGCTGACCTGAACTGGGGTGATACTCAAGATG
GTATAGTGTGGGTTGCTGCTAAGGGTGCTGATACTAAATCTAGATCGACTTAATTA
A                                                  PacI 
 
 
M-IR-hRluc-5b-N 
Appendices 
210 
 
BeauR-eGFPΔ3ab 
 
  AscI  23361 
GGCGCGCCAGATGTAGTTACGCTTACTTCTTGTCAAGCAAATTATGTAAGTGTAAA
TAAGACCGTCATTACTACATTCGTAGACAATGATGATTTTGATTTTAATGACGAAT
TGTCAAAATGGTGGAATGATACTAAGCATGAGCTACCAGACTTTGACAAATTCAAT
TACACAGTACCTATACTTGACATTGATAGTGAAATTGATCGTATTCAAGGCGTTAT
ACAGGGTCTTAATGACTCTCTAATAGACCTTGAAAAACTTTCAATACTCAAAACTT
ATATTAAGTGGCCTTGGTATGTGTGGTTAGCCATAGCTTTTGCCACTATTATCTTC
ATCTTAATACTAGGATGGGTTTTCTTCATGACTGGTTGTTGTGGTTGTTGTTGTGG
ATGCTTTGGCATTATGCCTCTAATGAGTAAGTGTGGTAAGAAATCTTCTTATTACA
CGACTTTTGATAACGATGTGGTAACTGAACAATACAGACCTAAAAAGTCTGTTTGA
ATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGGTGGTGCCCATCCTGGTCGAGCT
GGACGGCGACGTAAACGGCCACAAGTTCAGCGTGTCCGGCGAGGGCGAGGGCGATG
CCACCTACGGCAAGCTGACCCTGAAGTTCATCTGCACCACCGGCAAGCTGCCCGTG
CCCTGGCCCACCCTCGTGACCACCCTGACCTACGGCGTGCAGTGCTTCAGCCGCTA
CCCCGACCACATGAAGCAGCACGACTTCTTCAAGTCCGCCATGCCCGAAGGCTACG
TCCAGGAGCGCACCATCTTCTTCAAGGACGACGGCAACTACAAGACCCGCGCCGAG
GTGAAGTTCGAGGGCGACACCCTGGTGAACCGCATCGAGCTGAAGGGCATCGACTT
CAAGGAGGACGGCAACATCCTGGGGCACAAGCTGGAGTACAACTACAACAGCCACA
ACGTCTATATCATGGCCGACAAGCAGAAGAACGGCATCAAGGTGAACTTCAAGATC
CGCCACAACATCGAGGACGGCAGCGTGCAGCTCGCCGACCACTACCAGCAGAACAC
CCCCATCGGCGACGGCCCCGTGCTGCTGCCCGACAACCACTACCTGAGCACCCAGT
CCGCCCTGAGCAAAGACCCCAACGAGAAGCGCGATCACATGGTCCTGCTGGAGTTC
GTGACCGCCGCCGGGATCACTCTCGGCATGGACGAGCTGTACAAGTAATAAGTTTT
ACTTAACAAATACGGACGATGATGAATTTATTGAATAAGTCGCTAGAGGAGAATGG
AAGTTTTCTAACAGCGCTTTACATAATTGTAGGATTTTTAGCACTTTATCTTCTAG
GTAGAGCACTTCAAGCATTTGTACAGGCTGCTGATGCTTGTTGTTTATTTTGGTAT
ACATGGGTAGTAATTCCAGGAGCTAAGGGTACAGCCTTTGTATACAAGTATACATA
TGGTAGAAAACTTAACAATCCGGAATTAGAAGCAGTTATTGTTAACGAGTTTCCTA
AGAACGGTTGGAATAATAAAAATCCAGCAAATTTTCAAGATGCCCAACGAGACAAA
TTGTACTCTTGACTTTGAACAGTCAGTTCAGCTTTTTAAAGAGTATAATTTATTTA
TAACTGCATTCTTGTTGTTCTTAACCATAATACTTCAGTATGGCTATGCAACAAGA
AGTAAGGTTATTTATACACTGAAAATGATAGTGTTATGGTGCTTTTGGCCCCTTAA
CATTGCAGTAGGTGTAATTTCATGTACATACTTAATTAA 
                                 PacI 
 
 
 
S–eGFP–TRS plus flanking nucleotides-3C-M  
 
 
Appendices 
211 
 
BeauR-hRlucΔ3ab 
 
 AscI   23361 
GGCGCGCCAGATGTAGTTACGCTTACTTCTTGTCAAGCAAATTATGTAAGTGTAAA
TAAGACCGTCATTACTACATTCGTAGACAATGATGATTTTGATTTTAATGACGAAT
TGTCAAAATGGTGGAATGATACTAAGCATGAGCTACCAGACTTTGACAAATTCAAT
TACACAGTACCTATACTTGACATTGATAGTGAAATTGATCGTATTCAAGGCGTTAT
ACAGGGTCTTAATGACTCTCTAATAGACCTTGAAAAACTTTCAATACTCAAAACTT
ATATTAAGTGGCCTTGGTATGTGTGGTTAGCCATAGCTTTTGCCACTATTATCTTC
ATCTTAATACTAGGATGGGTTTTCTTCATGACTGGTTGTTGTGGTTGTTGTTGTGG
ATGCTTTGGCATTATGCCTCTAATGAGTAAGTGTGGTAAGAAATCTTCTTATTACA
CGACTTTTGATAACGATGTGGTAACTGAACAATACAGACCTAAAAAGTCTGTTTGA
ATGGCTTCCAAGGTGTACGACCCCGAGCAACGCAAACGCATGATCACTGGGCCTCA
GTGGTGGGCTCGCTGCAAGCAAATGAACGTGCTGGACTCCTTCATCAACTACTATG
ATTCCGAGAAGCACGCCGAGAACGCCGTGATTTTTCTGCATGGTAACGCTGCCTCC
AGCTACCTGTGGAGGCACGTCGTGCCTCACATCGAGCCCGTGGCTAGATGCATCAT
CCCTGATCTGATCGGAATGGGTAAGTCCGGCAAGAGCGGGAATGGCTCATATCGCC
TCCTGGATCACTACAAGTACCTCACCGCTTGGTTCGAGCTGCTGAACCTTCCAAAG
AAAATCATCTTTGTGGGCCACGACTGGGGGGCTTGTCTGGCCTTTCACTACTCCTA
CGAGCACCAAGACAAGATCAAGGCCATCGTCCATGCTGAGAGTGTCGTGGACGTGA
TCGAGTCCTGGGACGAGTGGCCTGACATCGAGGAGGATATCGCCCTGATCAAGAGC
GAAGAGGGCGAGAAAATGGTGCTTGAGAATAACTTCTTCGTCGAGACCATGCTCCC
AAGCAAGATCATGCGGAAACTGGAGCCTGAGGAGTTCGCTGCCTACCTGGAGCCAT
TCAAGGAGAAGGGCGAGGTTAGACGGCCTACCCTCTCCTGGCCTCGCGAGATCCCT
CTCGTTAAGGGAGGCAAGCCCGACGTCGTCCAGATTGTCCGCAACTACAACGCCTA
CCTTCGGGCCAGCGACGATCTGCCTAAGATGTTCATCGAGTCCGACCCTGGGTTCT
TTTCCAACGCTATTGTCGAGGGAGCTAAGAAGTTCCCTAACACCGAGTTCGTGAAG
GTGAAGGGCCTCCACTTCAGCCAGGAGGACGCTCCAGATGAAATGGGTAAGTACAT
CAAGAGCTTCGTGGAGCGCGTGCTGAAGAACGAGCAGTAATAAGTTTTACTTAACA
AATACGGACGATGATGAATTTATTGAATAAGTCGCTAGAGGAGAATGGAAGTTTTC
TAACAGCGCTTTACATAATTGTAGGATTTTTAGCACTTTATCTTCTAGGTAGAGCA
CTTCAAGCATTTGTACAGGCTGCTGATGCTTGTTGTTTATTTTGGTATACATGGGT
AGTAATTCCAGGAGCTAAGGGTACAGCCTTTGTATACAAGTATACATATGGTAGAA
AACTTAACAATCCGGAATTAGAAGCAGTTATTGTTAACGAGTTTCCTAAGAACGGT
TGGAATAATAAAAATCCAGCAAATTTTCAAGATGCCCAACGAGACAAATTGTACTC
TTGACTTTGAACAGTCAGTTCAGCTTTTTAAAGAGTATAATTTATTTATAACTGCA
TTCTTGTTGTTCTTAACCATAATACTTCAGTATGGCTATGCAACAAGAAGTAAGGT
TATTTATACACTGAAAATGATAGTGTTATGGTGCTTTTGGCCCCTTAACATTGCAG
TAGGTGTAATTTCATGTACATACTTAATTAA 
                         PacI 
 
 
S–hRluc–TRS plus flanking nucleotides-3C-M  
 
 
 
 
Appendices 
212 
 
BeauR-5a/eGFP 
 
  AscI  24979 
GGCGCGCCGCTAAGTGTGAACCAGACCACTTGCCTAAAGATATATTTGTTTGTACA
CCGGATAGACGTAATATCTACCGTATGGTGCAGAAATATACTGGTGACCAAAGCGG
AAATAAGAAAAGGTTTGCTACGTTTGTCTATGCAAAGCAGTCAGTAGATACTGGCG
AGCTAGAAAGTGTAGCAACAGGAGGAAGTAGTCTTTACACATAAATGTGTGTGTGT
AGAGAGTATTTAAAATTATTCTTTAATAGCGCCTCTGTTTTAAGAGCGCATAAGAG
TATTTATTTTGAGGATACTAATATAAATCCTCTTTGTTTTATACTCTCCTTTCAAG
AGCTATTAACGGTGTTACCTTTCAAGTAGATAATGGAAAAGTCTACTACGAAGGAA
CACCAGTTTTCCAAAAAGGTTGTTGTAGGATGTGGTCCAATTATAAGAAAGAATAA
TTGAACCACCTACTACACTTATTTTTATAAGAGGTACCTTACTTAACAAAAACTTA
ACAAATACGGACGATGAAATGGCTGACTAGTTTTGGAAGAGCAGTTATTTCTTGTT
ATAAATCCCTACTATTAACTCAACTTAGAGTGTTAGATAGGTTAATTTTAGATCAC
GGACTACTACGCGTTTTAACGTGTAGTAGGCGCGTGCTTTTAGTTCAATTAGATTT
AGTTTATAGGTTGGCGTATACGCCCACCCAATCGCTGGCAGTGAGCAAGGGCGAGG
AGCTGTTCACCGGGGTGGTGCCCATCCTGGTCGAGCTGGACGGCGACGTAAACGGC
CACAAGTTCAGCGTGTCCGGCGAGGGCGAGGGCGATGCCACCTACGGCAAGCTGAC
CCTGAAGTTCATCTGCACCACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCGTGA
CCACCCTGACCTACGGCGTGCAGTGCTTCAGCCGCTACCCCGACCACATGAAGCAG
CACGACTTCTTCAAGTCCGCCATGCCCGAAGGCTACGTCCAGGAGCGCACCATCTT
CTTCAAGGACGACGGCAACTACAAGACCCGCGCCGAGGTGAAGTTCGAGGGCGACA
CCCTGGTGAACCGCATCGAGCTGAAGGGCATCGACTTCAAGGAGGACGGCAACATC
CTGGGGCACAAGCTGGAGTACAACTACAACAGCCACAACGTCTATATCATGGCCGA
CAAGCAGAAGAACGGCATCAAGGTGAACTTCAAGATCCGCCACAACATCGAGGACG
GCAGCGTGCAGCTCGCCGACCACTACCAGCAGAACACCCCCATCGGCGACGGCCCC
GTGCTGCTGCCCGACAACCACTACCTGAGCACCCAGTCCGCCCTGAGCAAAGACCC
CAACGAGAAGCGCGATCACATGGTCCTGCTGGAGTTCGTGACCGCCGCCGGGATCA
CTCTCGGCATGGACGAGCTGTACAAGTAATAAATGAATAATAGTAAAGATAATCCT
TTTCGCGGAGCAATAGCAAGAAAAGCTCGAATTTATCTGAGAGAAGGATTAGATTG
TGTTTACTTTCTTAACAAAGCAGGACAAGCAGAGCCTTGTCCCGCGTGTACCTCTC
TAGTATTCCAAGGGAAAACTTGTGAGGAACACATACATAATAATAATCTTTTGTCA
TGGCAAGCGGTAAAGCAGCTGGAAAAACAGACGCCCCAGCGCCAGTCATTAAACTA
GGAGGACCAAAACCACCTAAAGTCGGTTCTTCTGGAAATGCATCTTGGTTTCAAGC
AATAAAAGCCAAGAAGTTAAATACACCTCCGCCCAAGTTTGAAGGTAGCGGTGTTC
CTGATAACGAAAACATTAAGCCAAGCCAGCAACATGGATACTGGAGACGCCAAGCC
AGGTTTAAGCCAGGCAAAGGTGGAAGAAAACCAGTCCCAGATGCTTGGTACTTTTA
CTATACTGGAACAGGACCTGCCGCTGACCTGAACTGGGGTGATACTCAAGATGGTA
TAGTGTGGGTTGCTGCTAAGGGTGCTGATACTAAATCTAGATCGACTTAATTAA 
                                                PacI 
 
 
M-IR-5a/eGFP-5b-N 
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BeauR-eGFPΔ4b  
 
  AscI  24406 
GGCGCGCCCATATGGTAGAAAACTTAACAATCCGGAATTAGAAGCAGTTATTGTTA
ACGAGTTTCCTAAGAACGGTTGGAATAATAAAAATCCAGCAAATTTTCAAGATGCC
CAACGAGACAAATTGTACTCTTGACTTTGAACAGTCAGTTCAGCTTTTTAAAGAGT
ATAATTTATTTATAACTGCATTCTTGTTGTTCTTAACCATAATACTTCAGTATGGC
TATGCAACAAGAAGTAAGGTTATTTATACACTGAAAATGATAGTGTTATGGTGCTT
TTGGCCCCTTAACATTGCAGTAGGTGTAATTTCATGTACATACCCACCAAACACAG
GAGGTCTTGTCGCAGCGATAATACTTACAGTGTTTGCGTGTCTGTCTTTTGTAGGT
TATTGGATCCAGAGTATTAGACTCTTTAAGCGGTGTAGGTCATGGTGGTCATTTAA
TCCAGAATCTAATGCCGTAGGTTCAATACTCCTAACTAATGGTCAACAATGTAATT
TTGCTATAGAGAGTGTGCCAATGGTGCTTTCTCCAATTATAAAGAATGGTGTTCTT
TATTGTGAGGGTCAGTGGCTTGCTAAGTGTGAACCAGACCACTTGCCTAAAGATAT
ATTTGTTTGTACACCGGATAGACGTAATATCTACCGTATGGTGCAGAAATATACTG
GTGACCAAAGCGGAAATAAGAAAAGGTTTGCTACGTTTGTCTATGCAAAGCAGTCA
GTAGATACTGGCGAGCTAGAAAGTGTAGCAACAGGAGGAAGTAGTCTTTACACATA
AATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGGTGGTGCCCATCCTGGTCGAGC
TGGACGGCGACGTAAACGGCCACAAGTTCAGCGTGTCCGGCGAGGGCGAGGGCGAT
GCCACCTACGGCAAGCTGACCCTGAAGTTCATCTGCACCACCGGCAAGCTGCCCGT
GCCCTGGCCCACCCTCGTGACCACCCTGACCTACGGCGTGCAGTGCTTCAGCCGCT
ACCCCGACCACATGAAGCAGCACGACTTCTTCAAGTCCGCCATGCCCGAAGGCTAC
GTCCAGGAGCGCACCATCTTCTTCAAGGACGACGGCAACTACAAGACCCGCGCCGA
GGTGAAGTTCGAGGGCGACACCCTGGTGAACCGCATCGAGCTGAAGGGCATCGACT
TCAAGGAGGACGGCAACATCCTGGGGCACAAGCTGGAGTACAACTACAACAGCCAC
AACGTCTATATCATGGCCGACAAGCAGAAGAACGGCATCAAGGTGAACTTCAAGAT
CCGCCACAACATCGAGGACGGCAGCGTGCAGCTCGCCGACCACTACCAGCAGAACA
CCCCCATCGGCGACGGCCCCGTGCTGCTGCCCGACAACCACTACCTGAGCACCCAG
TCCGCCCTGAGCAAAGACCCCAACGAGAAGCGCGATCACATGGTCCTGCTGGAGTT
CGTGACCGCCGCCGGGATCACTCTCGGCATGGACGAGCTGTACAAGTAATAATTGA
ACCACCTACTACACTTATTTTTATAAGAGGTGTTTTACTTAACAAAAACTTAACAA
ATACGGACGATGAAATGGCTGACTAGTTTTGGAAGAGCAGTTATTTCTTGTTATAA
ATCCCTACTATTAACTCAACTTAGAGTGTTAGATAGGTTAATTTTAGATCACGGAC
TACTACGCGTTTTAACGTGTAGTAGGCGCGTGCTTTTAGTTCAATTAGATTTAGTT
TATAGGTTGGCGTATACGCCCACCCAATCGCTGGCATGAATAATAGTAAAGATAAT
CCTTTTCGCGGAGCAATAGCAAGAAAAGCTCGAATTTATCTGAGAGAAGGATTAGA
TTGTGTTTACTTTCTTAACAAAGCAGGACAAGCAGAGCCTTGTCCCGCGTGTACCT
CTCTAGTATTCCAAGGGAAAACTTGTGAGGAACACATACATAATAATAATCTTTTG
TCATGGCAAGCGGTAAAGCAGCTGGAAAAACAGACGCCCCAGCGCCAGTCATTAAA
CTAGGAGGACCAAAACCACCTAAAGTCGGTTCTTCTGGAAATGCATCTTGGTTTCA
AGCAATAAAAGCCAAGAAGTTAAATACACCTCCGCCCAAGTTTGAAGGTAGCGGTG
TTCCTGATAACGAAAACATTAAGCCAAGCCAGCAACATGGATACTGGAGACGCCAA
GCCAGGTTTAAGCCAGGCAAAGGTGGAAGAAAACCAGTCCCAGATGCTTGGTACTT
TTACTATACTGGAACAGGACCTGCCGCTGACCTGAACTGGGGTGATACTCAAGATG
GTATAGTGTGGGTTGCTGCTAAGGGTGCTGATACTAAATCTAGAGTCGAC 
    SalI 
 
 
3c-M-eGFP-IR-5a-5b-N 
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Appendix 4: Codon optimized reporter gene sequences 
 
 
Codon Optimized eGFP 
 
                   10        20        30        40        50        60 
          ....|....|....|....|....|....|....|....|....|....|....|....| 
pEGFP-C1  ATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGGTGGTGCCCATCCTGGTCGAGCTGGAC 
Emboss    ATGGTTTCTAAAGGTGAAGAACTTTTTACTGGTGTTGTTCCAATTCTTGTTGAACTTGAT 
Manual    ATGGTTTCTAAAGGTGAAGAACTTTTTACTGGTGTTGTTCCAATTCTTGTTGAACTTGAT 
           M  V  S  K  G  E  E  L  F  T  G  V  V  P  I  L  V  E  L  D  
 
                   70        80        90       100       110       120 
          ....|....|....|....|....|....|....|....|....|....|....|....| 
pEGFP-C1  GGCGACGTAAACGGCCACAAGTTCAGCGTGTCCGGCGAGGGCGAGGGCGATGCCACCTAC 
Emboss    GGTGATGTTAATGGTCATAAATTTTCTGTTTCTGGTGAAGGTGAAGGTGATGCAACTTAT 
Manual    GGTGATGTTAATGGTCATAAATTTTCTGTTTCTGGTGAAGGTGAAGGTGATGCAACTTAT 
           G  D  V  N  G  H  K  F  S  V  S  G  E  G  E  G  D  A  T  Y  
 
                  130       140       150       160       170       180 
          ....|....|....|....|....|....|....|....|....|....|....|....| 
pEGFP-C1  GGCAAGCTGACCCTGAAGTTCATCTGCACCACCGGCAAGCTGCCCGTGCCCTGGCCCACC 
Emboss    GGTAAACTTACTCTTAAATTTATTTGTACTACTGGTAAACTTCCAGTTCCATGGCCAACT 
Manual    GGTAAACTTACTCTTAAATTTATTTGTACTACTGGTAAACTTCCAGTTCCATGGCCAACT 
           G  K  L  T  L  K  F  I  C  T  T  G  K  L  P  V  P  W  P  T  
 
                  190       200       210       220       230       240 
          ....|....|....|....|....|....|....|....|....|....|....|....| 
pEGFP-C1  CTCGTGACCACCCTGACCTACGGCGTGCAGTGCTTCAGCCGCTACCCCGACCACATGAAG 
Emboss    CTTGTTACTACTCTTACTTATGGTGTTCAATGTTTTTCTAGATATCCAGATCATATGAAA 
Manual    CTTGTTACTACTCTTACTTATGGTGTTCAATGTTTTTCTAGATATCCAGATCATATGAAA 
           L  V  T  T  L  T  Y  G  V  Q  C  F  S  R  Y  P  D  H  M  K  
 
                  250       260       270       280       290       300 
          ....|....|....|....|....|....|....|....|....|....|....|....| 
pEGFP-C1  CAGCACGACTTCTTCAAGTCCGCCATGCCCGAAGGCTACGTCCAGGAGCGCACCATCTTC 
Emboss    CAACATGATTTTTTTAAATCTGCAATGCCAGAAGGTTATGTTCAAGAAAGAACTATTTTT 
Manual    CAACATGATTTTTTTAAATCTGCAATGCCAGAAGGTTATGTTCAAGAAAGAACTATTTTT 
           Q  H  D  F  F  K  S  A  M  P  E  G  Y  V  Q  E  R  T  I  F  
 
                  310       320       330       340       350       360 
          ....|....|....|....|....|....|....|....|....|....|....|....| 
pEGFP-C1  TTCAAGGACGACGGCAACTACAAGACCCGCGCCGAGGTGAAGTTCGAGGGCGACACCCTG 
Emboss    TTTAAAGATGATGGTAATTATAAAACTAGAGCAGAAGTTAAATTTGAAGGTGATACTCTT 
Manual    TTTAAAGATGATGGTAATTATAAAACTAGAGCAGAAGTTAAATTTGAAGGTGATACTCTT 
           F  K  D  D  G  N  Y  K  T  R  A  E  V  K  F  E  G  D  T  L  
 
                  370       380       390       400       410       420 
          ....|....|....|....|....|....|....|....|....|....|....|....| 
pEGFP-C1  GTGAACCGCATCGAGCTGAAGGGCATCGACTTCAAGGAGGACGGCAACATCCTGGGGCAC 
Emboss    GTTAATAGAATTGAACTTAAAGGTATTGATTTTAAAGAAGATGGTAATATTCTTGGTCAT 
Manual    GTTAATAGAATTGAACTTAAAGGTATTGATTTTAAAGAAGATGGTAATATTCTTGGTCAT 
           V  N  R  I  E  L  K  G  I  D  F  K  E  D  G  N  I  L  G  H  
 
                  430       440       450       460       470       480 
          ....|....|....|....|....|....|....|....|....|....|....|....| 
pEGFP-C1  AAGCTGGAGTACAACTACAACAGCCACAACGTCTATATCATGGCCGACAAGCAGAAGAAC 
Emboss    AAACTTGAATATAATTATAATTCTCATAATGTTTATATTATGGCAGATAAACAAAAAAAT 
Manual    AAACTTGAATATAATTATAATTCTCATAATGTTTATATTATGGCAGATAAACAAAAAAAT 
           K  L  E  Y  N  Y  N  S  H  N  V  Y  I  M  A  D  K  Q  K  N  
 
                  490       500       510       520       530       540 
          ....|....|....|....|....|....|....|....|....|....|....|....| 
pEGFP-C1  GGCATCAAGGTGAACTTCAAGATCCGCCACAACATCGAGGACGGCAGCGTGCAGCTCGCC 
Emboss    GGTATTAAAGTTAATTTTAAAATTAGACATAATATTGAAGATGGTTCTGTTCAACTTGCA 
Manual    GGTATTAAAGTTAATTTTAAAATTAGACATAATATTGAAGATGGTTCTGTTCAACTTGCA 
           G  I  K  V  N  F  K  I  R  H  N  I  E  D  G  S  V  Q  L  A  
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                  550       560       570       580       590       600 
          ....|....|....|....|....|....|....|....|....|....|....|....| 
pEGFP-C1  GACCACTACCAGCAGAACACCCCCATCGGCGACGGCCCCGTGCTGCTGCCCGACAACCAC 
Emboss    GATCATTATCAACAAAATACTCCAATTGGTGATGGTCCAGTTCTTCTTCCAGATAATCAT 
Manual    GATCATTATCAACAAAATACTCCAATTGGTGATGGTCCAGTTCTTCTTCCAGATAATCAT 
           D  H  Y  Q  Q  N  T  P  I  G  D  G  P  V  L  L  P  D  N  H  
 
                  610       620       630       640       650       660 
          ....|....|....|....|....|....|....|....|....|....|....|....| 
pEGFP-C1  TACCTGAGCACCCAGTCCGCCCTGAGCAAAGACCCCAACGAGAAGCGCGATCACATGGTC 
Emboss    TATCTTTCTACTCAATCTGCACTTTCTAAAGATCCAAATGAAAAAAGAGATCATATGGTT 
Manual    TATCTTTCTACTCAATCTGCACTTTCTAAAGATCCAAATGAAAAAAGAGATCATATGGTT 
           Y  L  S  T  Q  S  A  L  S  K  D  P  N  E  K  R  D  H  M  V  
 
                  670       680       690       700       710       
          ....|....|....|....|....|....|....|....|....|....|....|.. 
pEGFP-C1  CTGCTGGAGTTCGTGACCGCCGCCGGGATCACTCTCGGCATGGACGAGCTGTACAAG 
Emboss    CTTCTTGAATTTGTTACTGCAGCAGGTATTACTCTTGGTATGGATGAACTTTATAAA 
Manual    CTTCTTGAATTTGTTACTGCAGCAGGTATTACTCTTGGTATGGATGAACTTTATAAA 
           L  L  E  F  V  T  A  A  G  I  T  L  G  M  D  E  L  Y  K  
 
 
 
 
 
 
Codon Optimized hRluc 
 
                  10        20        30        40        50        60 
         ....|....|....|....|....|....|....|....|....|....|....|....| 
pGL4.75  ATGGCTTCCAAGGTGTACGACCCCGAGCAACGCAAACGCATGATCACTGGGCCTCAGTGG 
Emboss   ATGGCATCTAAAGTTTATGATCCAGAACAAAGAAAAAGAATGATTACTGGTCCACAATGG 
          M  A  S  K  V  Y  D  P  E  Q  R  K  R  M  I  T  G  P  Q  W  
 
                  70        80        90       100       110       120 
         ....|....|....|....|....|....|....|....|....|....|....|....| 
pGL4.75  TGGGCTCGCTGCAAGCAAATGAACGTGCTGGACTCCTTCATCAACTACTATGATTCCGAG 
Emboss   TGGGCAAGATGTAAACAAATGAATGTTCTTGATTCTTTTATTAATTATTATGATTCTGAA 
          W  A  R  C  K  Q  M  N  V  L  D  S  F  I  N  Y  Y  D  S  E  
 
                 130       140       150       160       170       180 
         ....|....|....|....|....|....|....|....|....|....|....|....| 
pGL4.75  AAGCACGCCGAGAACGCCGTGATTTTTCTGCATGGTAACGCTGCCTCCAGCTACCTGTGG 
Emboss   AAACATGCAGAAAATGCAGTTATTTTTCTTCATGGTAATGCAGCATCTTCTTATCTTTGG 
          K  H  A  E  N  A  V  I  F  L  H  G  N  A  A  S  S  Y  L  W  
 
                 190       200       210       220       230       240 
         ....|....|....|....|....|....|....|....|....|....|....|....| 
pGL4.75  AGGCACGTCGTGCCTCACATCGAGCCCGTGGCTAGATGCATCATCCCTGATCTGATCGGA 
Emboss   AGACATGTTGTTCCACATATTGAACCAGTTGCAAGATGTATTATTCCAGATCTTATTGGT 
          R  H  V  V  P  H  I  E  P  V  A  R  C  I  I  P  D  L  I  G  
 
                 250       260       270       280       290       300 
         ....|....|....|....|....|....|....|....|....|....|....|....| 
pGL4.75  ATGGGTAAGTCCGGCAAGAGCGGGAATGGCTCATATCGCCTCCTGGATCACTACAAGTAC 
Emboss   ATGGGTAAATCTGGTAAATCTGGTAATGGTTCTTATAGACTTCTTGATCATTATAAATAT 
          M  G  K  S  G  K  S  G  N  G  S  Y  R  L  L  D  H  Y  K  Y  
 
           310       320       330       340       350       360      
         ....|....|....|....|....|....|....|....|....|....|....|....| 
pGL4.75  CTCACCGCTTGGTTCGAGCTGCTGAACCTTCCAAAGAAAATCATCTTTGTGGGCCACGAC 
Emboss   CTTACTGCATGGTTTGAACTTCTTAATCTTCCAAAAAAAATTATTTTTGTTGGTCATGAT 
          L  T  A  W  F  E  L  L  N  L  P  K  K  I  I  F  V  G  H  D  
 
                 370       380       390       400       410       420 
         ....|....|....|....|....|....|....|....|....|....|....|....| 
pGL4.75  TGGGGGGCTTGTCTGGCCTTTCACTACTCCTACGAGCACCAAGACAAGATCAAGGCCATC 
Emboss   TGGGGTGCATGTCTTGCATTTCATTATTCTTATGAACATCAAGATAAAATTAAAGCAATT 
          W  G  A  C  L  A  F  H  Y  S  Y  E  H  Q  D  K  I  K  A  I  
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                 430       440       450       460       470       480 
         ....|....|....|....|....|....|....|....|....|....|....|....| 
pGL4.75  GTCCATGCTGAGAGTGTCGTGGACGTGATCGAGTCCTGGGACGAGTGGCCTGACATCGAG 
Emboss   GTTCATGCAGAATCTGTTGTTGATGTTATTGAATCTTGGGATGAATGGCCAGATATTGAA 
          V  H  A  E  S  V  V  D  V  I  E  S  W  D  E  W  P  D  I  E  
 
                 490       500       510       520       530       540 
         ....|....|....|....|....|....|....|....|....|....|....|....| 
pGL4.75  GAGGATATCGCCCTGATCAAGAGCGAAGAGGGCGAGAAAATGGTGCTTGAGAATAACTTC 
Emboss   GAAGATATTGCACTTATTAAATCTGAAGAAGGTGAAAAAATGGTTCTTGAAAATAATTTT 
          E  D  I  A  L  I  K  S  E  E  G  E  K  M  V  L  E  N  N  F  
 
                 550       560       570       580       590       600 
         ....|....|....|....|....|....|....|....|....|....|....|....| 
pGL4.75  TTCGTCGAGACCATGCTCCCAAGCAAGATCATGCGGAAACTGGAGCCTGAGGAGTTCGCT 
Emboss   TTTGTTGAAACTATGCTTCCATCTAAAATTATGAGAAAACTTGAACCAGAAGAATTTGCA 
          F  V  E  T  M  L  P  S  K  I  M  R  K  L  E  P  E  E  F  A  
 
                 610       620       630       640       650       660 
         ....|....|....|....|....|....|....|....|....|....|....|....| 
pGL4.75  GCCTACCTGGAGCCATTCAAGGAGAAGGGCGAGGTTAGACGGCCTACCCTCTCCTGGCCT 
Emboss   GCATATCTTGAACCATTTAAAGAAAAAGGTGAAGTTAGAAGACCAACTCTTTCTTGGCCA 
          A  Y  L  E  P  F  K  E  K  G  E  V  R  R  P  T  L  S  W  P  
 
                 670       680       690       700       710       720 
         ....|....|....|....|....|....|....|....|....|....|....|....| 
pGL4.75  CGCGAGATCCCTCTCGTTAAGGGAGGCAAGCCCGACGTCGTCCAGATTGTCCGCAACTAC 
Emboss   AGAGAAATTCCACTTGTTAAAGGTGGTAAACCAGATGTTGTTCAAATTGTTAGAAATTAT 
          R  E  I  P  L  V  K  G  G  K  P  D  V  V  Q  I  V  R  N  Y  
 
                 730       740       750       760       770       780 
         ....|....|....|....|....|....|....|....|....|....|....|....| 
pGL4.75  AACGCCTACCTTCGGGCCAGCGACGATCTGCCTAAGATGTTCATCGAGTCCGACCCTGGG 
Emboss   AATGCATATCTTAGAGCATCTGATGATCTTCCAAAAATGTTTATTGAATCTGATCCAGGT 
          N  A  Y  L  R  A  S  D  D  L  P  K  M  F  I  E  S  D  P  G  
 
                 790       800       810       820       830       840 
         ....|....|....|....|....|....|....|....|....|....|....|....| 
pGL4.75  TTCTTTTCCAACGCTATTGTCGAGGGAGCTAAGAAGTTCCCTAACACCGAGTTCGTGAAG 
Emboss   TTTTTTTCTAATGCAATTGTTGAAGGTGCAAAAAAATTTCCAAATACTGAATTTGTTAAA 
          F  F  S  N  A  I  V  E  G  A  K  K  F  P  N  T  E  F  V  K  
 
                 850       860       870       880       890       900 
         ....|....|....|....|....|....|....|....|....|....|....|....| 
pGL4.75  GTGAAGGGCCTCCACTTCAGCCAGGAGGACGCTCCAGATGAAATGGGTAAGTACATCAAG 
Emboss   GTTAAAGGTCTTCATTTTTCTCAAGAAGATGCACCAGATGAAATGGGTAAATATATTAAA 
          V  K  G  L  H  F  S  Q  E  D  A  P  D  E  M  G  K  Y  I  K  
 
                 910       920       930   
         ....|....|....|....|....|....|... 
pGL4.75  AGCTTCGTGGAGCGCGTGCTGAAGAACGAGCAG 
Emboss   TCTTTTGTTGAAAGAGTTCTTAAAAATGAACAA 
          S  F  V  E  R  V  L  K  N  E  Q  
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Appendix 5: Sample qRT-PCR data 
 
Note to Appendix 5 
This appendix shows sample data from one replicate of the qRT-PCR experiment to 
demonstrate the generation of standard curves, calculation of DNA amounts and 
normalisation of data to 28S housekeeping gene readings. The lower tables provide 
the values from each experiment used for the calculation of fold change values 
following additional normalisation to Gene 3 values to account for changes in the 
replication efficiencies of the rIBVs. 
 
 
 
 
 
 
 
28S Data Replicate 1 IR Gene Data Replicate 1
1 2 3 1 2 3
0.5 13.75 13.78 13.77 100 14.91 14.97 14.94
0.05 14.14 14.11 14.13 10 18.04 17.74 17.89
0.005 15.76 15.76 15.76 1 21.97 21.94 21.955
0.0005 19.75 19.65 19.70 0.1 26.35 26.38 26.365
0.00005 23.73 23.84 23.79 0.01 32.25 32.4 32.325
0.000005 27.3 27.3 27.30 0.001 33.8 33.57 33.685
0.0000005 31.39 31.45 31.42 0.0001 37.79 37.39 37.59
0.00000005 35.02 35.23 35.13 0.00001 38.81 36.47 37.64
18.03 18.09 18.03 18.05 31.21 31.09 31.03 31.11
17.5 17.73 17.56 17.60 29.21 29.16 29.04 29.1366667
17.88 17.78 17.7 17.79 34.64 34.34 34.52 34.5
17.51 17.45 17.5 17.49 28.25 28.32 28.38 28.3166667
18.05 0.00133853 13.385333 31.11 0.011324 113.240027 113240027 8460008.46
17.5966667 0.00175287 17.528713 29.1366667 0.03238476 323.847564 323847564 18475262.1
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